

CITATION REPORT

List of articles citing

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

DOI: 10.1056/nejm199108013250501

New England Journal of Medicine, 1991, 325, 293-302.

Source: <https://exaly.com/paper-pdf/22058257/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2264	Perioperative Care in Left Ventricular Volume Reduction. 1985 , 2, 136-140		
2263	Dilated Cardiomyopathy: Changing Pathophysiological Concepts and Mechanisms of Dysfunction. 1985 , 2, 64-72		
2262	Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks. 1991 , 6, 393-401		
2261	Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. 1991 , 42, 511-39		61
2260	Congestive heart failure in coronary artery disease. 1991 , 91, 409-15		12
2259	Coronary heart disease. 1991 , 303, 1546-7		7
2258	Congestive heart failure in acute myocardial infarction. Treating the spectrum from mild failure to cardiogenic shock. 1991 , 90, 99-100, 105-8, 113		
2257	Coronary heart disease: Author's reply. 1991 , 303, 1546-1547		1
2256	Changing strategies in the management of chronic congestive heart failure. 1991 , 25, 1349-54		1
2255	Oral iron chelation is here: Author's reply. 1991 , 303, 1546-1546		
2254	Oral iron chelation is here. 1991 , 303, 1545-6		
2253	Therapeutic strategies for CHF in the 1990s. 1991 , 26, 127-34, 139-40, 145-6 passim		1
2252	Initial blood pressure response to enalapril in hospitalized patients (Studies of Left Ventricular Dysfunction [SOLVD]). 1991 , 68, 1465-8		19
2251	Inotropic therapy for heart failure--an unfulfilled promise. <i>New England Journal of Medicine</i> , 1991 , 325, 1509-10	59.2	49
2250	ACE inhibitors--a cornerstone of the treatment of heart failure. <i>New England Journal of Medicine</i> , 1991 , 325, 351-3	59.2	128
2249	Treatment of chronic congestive heart failure. <i>New England Journal of Medicine</i> , 1992 , 326, 1220; author reply 1220-1	59.2	1
2248	Oral milrinone in severe chronic heart failure. <i>New England Journal of Medicine</i> , 1992 , 326, 1565; author reply 1567	59.2	2

2247	A noninvasive method of predicting pulmonary-capillary wedge pressure. <i>New England Journal of Medicine</i> , 1992 , 327, 1715-20	59.2	61
2246	Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. <i>New England Journal of Medicine</i> , 1992 , 327, 685-91	59.2	2806
2245	Captopril enhances intracellular calcium handling and beta-adrenergic responsiveness of myocardium from rats with postinfarction failure. 1992 , 71, 797-807		73
2244	Angiotensin converting enzyme inhibitors for hypertension and heart failure?. 1992 , 68, 1-5		3
2243	Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure. 1992 , 86, 1800-9		33
2242	Recent advances in cardiology. 1992 , 68, 327-37		1
2241	Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. 1992 , 86, 431-8		419
2240	Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. 1992 , 86, 1566-74		63
2239	Cardiac disease. 1992 , 2, 207-226		1
2238	Renin system inhibition. Beginning the fourth epoch. 1992 , 85, 362-4		11
2237	Cardiac transplantation: recipient selection, donor procurement, and medical follow-up. A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. 1992 , 86, 1061-79		132
2236	Effects of a nonpeptide vasopressin antagonist (OPC-21268) on cytosolic Ca ²⁺ concentration in vascular and cardiac myocytes. 1992 , 19, 730-3		13
2235	Implications of recent results of long term multifactorial primary prevention of cardiovascular diseases. 1992 , 24, 85-9		6
2234	Chapter 7. Angiotensin / Renin Modulators. 1992 , 59-68		31
2233	Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. <i>New England Journal of Medicine</i> , 1992 , 327, 669-77	59.2	4719
2232	Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). <i>New England Journal of Medicine</i> , 1992 , 327, 678-84	59.2	829
2231	Advances in the treatment of chronic heart failure. 1992 , 304, 1069-70		7
2230	Chagas cardiomyopathy and captopril. 1992 , 13, 966-70		36

2229	Cardiac transplantation: clinical aspects of recipient selection. 1992 , 76, 1196-206	1
2228	Current issues in advanced heart failure. 1992 , 76, 1057-82	1
2227	Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. 1992 , 340, 1173-8	596
2226	Patent Update: Antihypertensive Agents: Recent Advances June through November 1991. 1992 , 2, 305-323	
2225	Vasodilators. A re-evaluation of their role in heart failure. 1992 , 43, 15-36	7
2224	Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure. 1992 , 43, 637-50	9
2223	Noninvasive and invasive strategies for the prevention of sudden death after myocardial infarction. Value, limitations and implications for therapy. 1992 , 44, 336-55	8
2222	Therapeutic use of atrial natriuretic factor. 1992 , 34, 102-5	3
2221	The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure. 1992 , 53, 187-97	8
2220	The J-curve hypothesis. 1992 , 339, 561-2	1
2219	ACE inhibitors for myocardial infarction and unstable angina. 1992 , 340, 1547-8	1
2218	Failure to treat heart failure. 1992 , 339, 278-279	21
2217	ACE inhibitors and heart failure. 1992 , 339, 687-688	3
2216	Treatment of chronic heart failure. 1992 , 340, 92-5	68
2215	New concepts in myocarditis. 1992 , 1, 37-47	7
2214	The push, the pull and the periphery. 1992 , 22, 587-91	
2213	Heart failure: to digitalise or not? The view against. 1992 , 22, 626-30	2
2212	Enalapril and exercise-induced hyperkalemia. A study of patients randomized to double-blind treatment with enalapril or placebo after acute myocardial infarction. 1992 , 37, 401-5	1

2211	The influence of captopril on intrahospital mortality and duration of hospitalization in Nigerians with congestive heart failure. 1992 , 36, 341-3	4
2210	Prevalence and mortality rate of congestive heart failure in the United States. 1992 , 20, 301-6	631
2209	The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. 1992 , 20, 248-54	834
2208	Endothelin and the vascular choir in heart failure. 1992 , 20, 854-7	9
2207	Vasodilator therapy and survival in chronic congestive heart failure. 1992 , 19, 1360-2	4
2206	Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. 1992 , 20, 1056-62	260
2205	The amiodarone odyssey. 1992 , 20, 1063-5	12
2204	Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. 1992 , 20, 1549-55	204
2203	The prevention of heart failure--a new agenda. <i>New England Journal of Medicine</i> , 1992 , 327, 725-7	59.2 93
2202	The myocardial renin-angiotensin system: existence, importance, and clinical implications. 1992 , 123, 1039-45	51
2201	The paradox of beta-adrenergic blockade for the management of congestive heart failure. 1992 , 92, 527-38	96
2200	Dynamic cardiomyoplasty acutely impairs left ventricular diastolic function. 1992 , 104, 1662-1671	28
2199	Changes in drug treatment and case fatality of patients with acute myocardial infarction. Observations from the Newcastle MONICA Project, 1984/1985 to 1988/1990. 1992 , 157, 83-6	6
2198	Comparison of captopril with enalapril in the treatment of heart failure: influence on hemodynamics and measures of renal function. 1992 , 6, 173-80	9
2197	Choice of ACE inhibitor for congestive heart failure. 1992 , 6, 181	
2196	Sudden death in patients with congestive heart failure: future directions. 1992 , 15, 451-70	14
2195	Longevity in patients with high degree atrioventricular block paced in the atrial synchronous or the fixed rate ventricular inhibited mode. 1992 , 15, 304-13	41
2194	Perindopril. 1992 , 10, 446-471	2

2193	Hypertension in the elderly with a special focus on treatment with angiotensin-converting enzyme inhibitors and calcium antagonists. 1992 , 69, 33E-42E	23
2192	Angiotensin-converting enzyme inhibitors as cardioprotective agents. 1992 , 70, 10I-17I	4
2191	A view from Europe. 1992 , 70, 33I-39I	2
2190	Beneficial effects of trandolapril on experimentally induced congestive heart failure in rats. 1992 , 70, 43D-51D	19
2189	Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. 1992 , 70, 359-63	154
2188	Effectiveness of preload reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction. The SOLVD Investigators. 1992 , 69, 1591-5	28
2187	Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). 1992 , 70, 894-900	94
2186	Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. 1992 , 70, 1310-4	43
2185	Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. 1992 , 69, 1458-66	349
2184	Introduction. 1992 , 69, 1-2	33
2183	Left ventricular hypertrophy: an initial response to myocardial injury. 1992 , 69, 3G-7G; discussion 7G-9G	56
2182	Review of randomized trials of digoxin therapy in patients with chronic heart failure. 1992 , 69, 48G-62G; discussion 62G-63G	44
2181	Need for a large randomized trial to evaluate the effects of digitalis on morbidity and mortality in congestive heart failure. 1992 , 69, 64G-70G	55
2180	Recognition and management of asymptomatic patients with left ventricular dysfunction. 1992 , 69, 130G-139G; disc. 139G-140G	9
2179	Management of refractory congestive heart failure. 1992 , 69, 141G-147G; disc. 147G-149G	20
2178	Long-term strategies in the management of heart failure: looking beyond ventricular function and symptoms. 1992 , 69, 150G-154G	13
2177	Heart failure management in the 1990s: the role of lisinopril. Introduction. 1992 , 70, 1C-3C	
2176	Ventricular arrhythmias in heart failure. 1992 , 70, 37C-43C	14

2175	Angiotensin-converting enzyme inhibitors, left ventricular dysfunction, and early heart failure. 1992 , 70, 55C-61C	10
2174	Heart failure in 2001: a prophecy. 1992 , 70, 126C-131C	10
2173	Results of the treatment trial of the studies of left ventricular dysfunction (SOLVD). The SOLVD Investigators. 1992 , 70, 135C-136C	34
2172	Comparison of the first-dose effect of captopril and lisinopril in heart failure. 1992 , 70, 137C-139C	3
2171	Effect of captopril and lisinopril on circadian blood pressure rhythm and renal function in mild-to-moderate heart failure. 1992 , 70, 147C-150C	88
2170	The effect of treatment on survival in congestive heart failure. 1992 , 15, 323-9	11
2169	Aging in the Americas: its impact on cardiovascular health. 1992 , 15, 627-9	1
2168	Sudden cardiac death. 1992 , 17, 693-778	5
2167	First-line pharmacological treatment of hypertension. 1992 , 232, 381-8	2
2166	Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. 1992 , 232, 493-8	37
2165	The cardiac renin-angiotensin system: physiological relevance and pharmacological modulation. 1993 , 71, S25-34	9
2164	Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. 1993 , 45, 247-53	9
2163	Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. 1993 , 44, 485-8	28
2162	A comprehensive algorithm for determining whether a run-in strategy will be a cost-effective design modification in a randomized clinical trial. 1993 , 12, 111-28	24
2161	The NHLBI model: a 25 year history. 1993 , 12, 425-31	23
2160	Sample sizes for event rate equivalence trials using prior information. 1993 , 12, 2009-23	20
2159	Postinfarct heart failure: role of diuretic therapy. 1993 , 7, 863-7	
2158	ACE inhibitors versus diuretics: when to choose which drug?. 1993 , 7, 877-9	1

2157	High or low dose of angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction?. 1993 , 7, 891-2	2
2156	Digoxin--doubts to dampen enthusiasm. 1993 , 7, 897-8	1
2155	The management of heart failure: a matter of definition?. 1993 , 7, 661-9	1
2154	The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. 1993 , 7, 273-82	28
2153	Low-dose combination therapy with metoprolol and captopril for congestive heart failure in mice. 1993 , 7, 795-800	2
2152	Renin profiling for diagnosis, risk assessment, and treatment of hypertension. 1993 , 44, 1163-75	32
2151	OPC-21268: An Orally Effective, Nonpeptide Vasopressin V1 Antagonist. 1993 , 11, 271-282	1
2150	Drugs, surgery, cardioverter defibrillator: a decision based on the clinical problem. 1993 , 16, 519-26	9
2149	Cardiomyopathy Trial. 1993 , 16, 576-581	25
2148	Sudden death in idiopathic dilated cardiomyopathy: role of ventricular arrhythmias. 1993 , 16, 1051-9	27
2147	Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. 1993 , 4, 253-62	216
2146	How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. 1993 , 71, 3C-11C	77
2145	Maximizing benefits of therapies in acute myocardial infarction. 1993 , 72, 145G-155G	5
2144	Captopril and spironolactone therapy for refractory congestive heart failure. 1993 , 71, 29A-33A	23
2143	Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure. 1993 , 72, 21C-24C; discussion 24C-26C	4
2142	Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. 1993 , 71, 602-4	168
2141	Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. 1993 , 71, 1106-7	387
2140	Long-term survival in the Munich Mild Heart Failure Trial (MHFT). 1993 , 71, 1237-9	7

2139	Effectiveness of captopril in reversing renal vasoconstriction after Q-wave acute myocardial infarction. 1993 , 71, 281-6	10
2138	Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. CONSENSUS II Multi-Echo Study Group. 1993 , 72, 1004-9	64
2137	Usefulness of piretanide plus ramipril for systemic hypertension: a multicenter trial. 1993 , 72, 666-71	8
2136	Lessons from recent randomized controlled trials for the management of congestive heart failure. 1993 , 71, 38E-40E	9
2135	Acute and long-term efficacy of perindopril in severe chronic congestive heart failure. 1993 , 71, 48E-56E	9
2134	Acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Results of a long-term open study in 320 patients. 1993 , 71, 61E-68E	6
2133	Eingeladener Kommentar: Transplantevaluation und Therapie mit Prostaglandin E1 bei Patienten mit erhöhtem Lungengefäßwiderstand. 1993 , 25, 362-363	
2132	Inotropic therapy of the failing myocardium. 1993 , 16, 5-14	17
2131	Newer concepts in the medical management of patients with congestive heart failure. 1993 , 16, 380-90	5
2130	Heart failure: drug therapy in the nineties and beyond. 1993 , 16, 459-60	2
2129	Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure. 1993 , 16, 607-12	6
2128	Chairman's introduction. 1993 , 16, 1-4	12
2127	Clinical experience in protecting the failing heart. 1993 , 16, 1125-9	8
2126	Low incidence of stroke in ambulatory patients with heart failure: a prospective study. 1993 , 126, 141-6	93
2125	Acute and long-term effects of flosequinan in patients with chronic cardiac failure. 1993 , 126, 147-54	2
2124	Lisinopril reduces cardiac hypertrophy and mortality in rats with aortocaval fistula. 1993 , 234, 55-60	8
2123	Differentiating systolic from diastolic heart failure: pathophysiologic and therapeutic considerations. 1993 , 95, 645-55	65
2122	Operation for congestive heart failure: transplantation, coronary artery bypass, and cardiomyoplasty. 1993 , 56, 418-24; discussion 424-5	43

2121	The cardiac renin-angiotensin system in heart failure. 1993 , 126, 756-60			30
2120	Intrinsic alterations of diaphragm muscle in experimental cardiomyopathy. 1993 , 126, 770-6			19
2119	Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective. 1993 , 126, 789-93			26
2118	Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. 1993 , 126, 798-806			29
2117	Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure. 1993 , 36, 539-46			
2116	The treatment of heart failure--what next?. 1993 , 35, 557-63			1
2115	Proceedings of the British Pharmacological Society. Clinical Pharmacology Section. 14-16 April 1993. Abstracts. 1993 , 36, 139P-182P			
2114	Effects of lisinopril on electromechanical properties and membrane currents in guinea-pig cardiac preparations. 1993 , 109, 873-9			4
2113	Efficacy and safety of intravenous captopril in congestive heart failure. 1993 , 53, 167-176			8
2112	The incidence and prevalence of congestive heart failure in Rochester, Minnesota. 1993 , 68, 1143-50			127
2111	Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. <i>New England Journal of Medicine</i> , 1993 , 329, 1-7	59.2	695	
2110	Heart Failure and Ventricular Arrhythmias. 1993 , 5, 141-153			1
2109	Phosphodiesterase inhibitors. Do the risks outweigh the benefits?. 1993 , 9, 404-9			6
2108	Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure. 1993 , 3, 556-84			8
2107	Pharmacokinetic drug interactions with ACE inhibitors. 1993 , 25, 20-58			51
2106	Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. 1993 , 25, 274-82			42
2105	Cardiovascular benefits of antihypertensive therapy postacute myocardial infarction. Therapeutic considerations. 1993 , 46 Suppl 2, 48-53			
2104	Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model. 1993 , 3, 387-97			29

2103 Little to Choose Between ACE Inhibitors. **1993**, 1, 4-7

2102 . 1

2101 Survival after the onset of congestive heart failure in Framingham Heart Study subjects. **1993**, 88, 107-15 1433

2100 Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. **1993**, 88, 1602-9 255

2099 Cardiac autonomic control mechanisms in Chagas' heart disease. Therapeutic implications. **1993**, 40, 33-7 16

2098 ACE inhibitors for myocardial infarction and unstable angina. **1993**, 341, 829 7

2097 Congestive heart failure: insights from epidemiology, implications for treatment. **1993**, 68, 1214-8 35

2096 Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. **1993**, 342, 1073-5 371

2095 Activation of neurohumoral systems in postinfarction left ventricular dysfunction. **1993**, 22, 390-8 128

2094 Discordance in degree of right and left ventricular dilation in patients with dilated cardiomyopathy: recognition and clinical implications. **1993**, 21, 649-54 69

2093 Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. **1993**, 21, 655-61 196

2092 Trends in patient selection for heart transplantation. **1993**, 21, 975-81 25

2091 Effect on exercise performance of enalapril therapy initiated early after myocardial infarction. Nordic Enalapril exercise Trial. **1993**, 22, 975-83 5

2090 Toward the quiescent coronary plaque. **1993**, 22, 1228-41 141

2089 Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. **1993**, 22, 3A-5A 119

2088 The epidemiology of heart failure: the Framingham Study. **1993**, 22, 6A-13A 1446

2087 Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. **1993**, 22, 14A-19A 252

2086 Relation of pathophysiologic mechanisms to outcome in heart failure. **1993**, 22, 22A-29A 35

2085	Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. 1993 , 22, 43A-48A	39
2084	Diastolic dysfunction as a cause of heart failure. 1993 , 22, 49A-55A	89
2083	Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. 1993 , 22, 72A-84A	275
2082	Atrial natriuretic peptide in heart failure. 1993 , 22, 86A-92A	62
2081	Calcium channel blockers in heart failure. 1993 , 22, 139A-144A	26
2080	Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. 1993 , 22, 146A-153A	108
2079	Role of converting enzyme inhibitors in the treatment of heart failure. 1993 , 22, 154A-157A	7
2078	Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. 1993 , 22, 158A-161A	21
2077	Exercise rehabilitation in chronic heart failure. 1993 , 22, 172A-177A	45
2076	Current and ongoing randomized trials in heart failure and left ventricular dysfunction. 1993 , 22, 194A-197A	9
2075	Perspective of the pharmaceutical industry on the development of new drugs for heart failure. 1993 , 22, 198A-200A	31
2074	Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction: modification by long-term enalapril treatment. The SOLVD Investigators. 1993 , 22, 1403-10	28
2073	Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. 1993 , 22, 1557-63	71
2072	Natural history of idiopathic dilated cardiomyopathy: effect of referral bias and secular trend. 1993 , 22, 1921-6	45
2071	24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. 1993 , 22, 21-31	238
2070	Viral myocarditis: Changing concepts in pathogenesis and implications in diagnosis and treatment. 1993 , 2, 247-257	7
2069	Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 1993 , 342, 1441-6	1024
2068	Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. 1993 , 341, 1105-9	285

2067	Effects of captopril on myocardial protection during cardioplegia. 1993 , 42, 225-30		16
2066	The effect of early converting enzyme inhibition on neurohumoral activation in acute myocardial infarction. 1993 , 42, 37-45		6
2065	Heart failure. Unfinished business--a possible role for vasodilators. 1993 , 40, 1-6		2
2064	Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. <i>New England Journal of Medicine</i> , 1993 , 329, 149-55	59.2	394
2063	Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects. 1993 , 53, 843-51		4
2062	Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction. 1993 , 69, 512-5		25
2061	Starting treatment with angiotensin converting enzyme inhibitors in heart failure: how, where, and how much?. 1993 , 69, 282-3		
2060	Cardioreparation and the concept of modulating cardiovascular structure and function. 1993 , 2, 6-21		29
2059	Combination treatment with captopril and the thyroid hormone analogue 3,5-diiodothyropropionic acid. A new approach to improving left ventricular performance in heart failure. 1993 , 88, 1289-98		52
2058	Cardiovascular health and disease in women. <i>New England Journal of Medicine</i> , 1993 , 329, 247-56	59.2	574
2057	A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. 1993 , 14, 403-9		26
2056	The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. 1993 , 2, 86-100		76
2055	Overview: Recent Advances in Angiotensin II Receptor Antagonists. 1993 , 3, 581-596		5
2054	Age and the cardiovascular system. <i>New England Journal of Medicine</i> , 1993 , 328, 1279-80	59.2	4
2053	Digoxin in heart failure. <i>New England Journal of Medicine</i> , 1993 , 329, 51-3	59.2	32
2052	The search for the ideal positive inotropic agent. <i>New England Journal of Medicine</i> , 1993 , 329, 201-2	59.2	61
2051	Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. <i>New England Journal of Medicine</i> , 1993 , 329, 1819-20	59.2	1
2050	Calcium antagonists or beta-blockers in chronic ischaemic left ventricular dysfunction?. 1993 , 14 Suppl F, 26-8		3

2049	Ischaemic heart failure: is prevention in sight?. 1993 , 70, 5-7	2
2048	Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. 1993 , 21, 921-4	74
2047	Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). 1993 , 88, 492-501	86
2046	Medical advances in the treatment of congestive heart failure. 1993 , 88, 2941-52	81
2045	1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee.. 1993 , 22, 392-403	160
2044	Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. 1993 , 72, 312-8	123
2043	Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. 1993 , 87, 1969-73	373
2042	Angiotensin converting enzyme inhibitors in heart failure: how good are they?. 1993 , 69, 373-5	14
2041	Beta blockers and the failing heart: is it time for a U-turn?. 1993 , 70, 8-12	11
2040	Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. SOLVD Investigators. 1993 , 88, 481-91	68
2039	Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. 1993 , 72, 1245-54	328
2038	Myocardial hypertrophy, angiotensin, and ACE inhibitors. 1993 , 44, 875-81	7
2037	Effects of enalapril on ventricular volumes and neurohumoral status after inferior wall myocardial infarction. 1993 , 305, 216-21	4
2036	Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. 1993 , 27, 731-5	45
2035	Heart failure, ventricular remodelling and the renin-angiotensin system: insights from recently completed clinical trials. 1993 , 14 Suppl C, 14-7	9
2034	Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. 1993 , 88, 2277-83	259
2033	Heart Failure: Its Progression and Its Therapy. 1993 , 28, 75-84	
2032	Antithrombotic Therapy in Atrial Fibrillation-To the Editor. 1993 , 104, 1939-1940	

2031	Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. 1993 , 33, 1023-38	62
2030	Memorandum from a Who/Isa Meeting. 1993 , 15, 1363-1395	17
2029	Management of dilated cardiomyopathy. 1993 , 28, 45-8, 51-3	
2028	Pharmacology and Mechanisms of Action of Nitroglycerin and Long-Acting Nitrates. 1993 , 1-48	1
2027	Advanced congestive heart failure. 1993 , 94, 97-116	14
2026	Neurohormonal systems during progression of heart failure: a review. 1993 , 83, 21-9	18
2025	What to try while congestive heart failure patients are still ambulatory. 1993 , 94, 66-8, 71, 75-8 passim	2
2024	Pharmacologic Management of Heart Failure: Neurohormonal Agents. 1993 , 5, 599-608	1
2023	Do Beta-Blockers have a Role in Patients with Congestive Heart Failure?. 1994 , 12, 133-142	17
2022	Do Digitalis Glycosides Still Have a Role in Congestive Heart Failure?. 1994 , 12, 51-62	4
2021	Use of Angiotensin-Converting Enzyme Inhibitors in Heart Failure. 1994 , 10, 156-163	1
2020	Hypertension: not solely a blood pressure problem. 1994 , 95, 79-86	1
2019	Government intervention in cardiovascular disease--help or hindrance? A Swedish viewpoint. 1994 , 85 Suppl 1, 90-5	1
2018	Approach to Ischemic Heart Disease, Coronary Care, and Severe Heart Failure (Including Cardiogenic Shock). 1994 , 10, 145-160	2
2017	Clinical aspects of cardiomyopathy in dialysis patients. 1994 , 12, 267-76	16
2016	Patient characteristics in cases of chronic severe heart failure with different degrees of left ventricular systolic dysfunction. 1994 , 85, 137-44	18
2015	Improving patient care: consequences for resource allocation. 1994 , 84, 420-6	2
2014	Patients with suspected acute myocardial infarction and acute heart failure: does it matter whether an infarction was developed or not?. 1994 , 84, 126-34	

2013	Role of Vasodilator Therapy in Congestive Heart Failure: Effects on Mortality. 1994 , 12, 87-99	
2012	Inotropic agents in development. 1994 , 3, 457-468	7
2011	Quality of life and cardiovascular medication. 1994 , 15, 126-147	5
2010	A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. 1994 , 90, 1765-73	753
2009	Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure. 1994 , 71, 261-7	28
2008	Use of 'Xapril' in patients with chronic heart failure. A paradigm or epitaph for our times?. 1994 , 90, 1550-1	11
2007	Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. 1994 , 23, 258-68	150
2006	Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants. 1994 , 70, 329-43	8
2005	Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. 1994 , 89, 345-54	335
2004	Prevention and regression of coronary atherosclerosis. Is it safe and efficacious therapy?. 1994 , 105, 718-26	11
2003	Prognosis in congestive heart failure. 1994 , 45, 341-50	43
2002	Efficacy and dosage of enalapril in congenital and acquired heart disease. 1994 , 70, 35-9	52
2001	Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. 1994 , 90, 2126-46	689
2000	N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. 1994 , 89, 1934-42	218
1999	Activation of angiotensinogen and angiotensin-converting enzyme gene expression in the left ventricle of senescent rats. 1994 , 90, 1328-33	58
1998	Corcoran Lecture. Angiotensin-converting enzyme inhibition and the heart. 1994 , 23, 813-8	48
1997	Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. 1994 , 89, 1632-42	223
1996	An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. 1994 , 90, 2051-5	46

1995	Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition. 1994 , 90, 2457-67	108
1994	Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. A novel aspect of endothelium dysfunction. 1994 , 75, 454-61	26
1993	Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. 1994 , 72, 226-30	92
1992	Cardiac failure in an elderly population. 1994 , 4, 199-211	
1991	Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. 1994 , 72, 528-33	52
1990	Beta-blocker treatment for chronic heart failure. The frog prince. 1994 , 90, 2153-6	19
1989	Tissue angiotensin system in cardiovascular medicine. A paradigm shift?. 1994 , 89, 493-8	240
1988	Evidence of inadequate investigation and treatment of patients with heart failure. 1994 , 71, 584-7	123
1987	Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. 1994 , 90, 2748-56	30
1986	Angiotensin-converting enzyme in human skeletal muscle. A simple in vitro assay of activity in needle biopsy specimens. 1994 , 54, 105-11	53
1985	Long-term clinical effect of nilvadipine in patients with chronic heart failure: a double-blind placebo-controlled study. 1994 , 9, 249-53	1
1984	Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. 1994 , 9, 113-20	29
1983	The effects of afterload reduction on myocardial carbon 11-labeled acetate kinetics and noninvasively estimated mechanical efficiency in patients with dilated cardiomyopathy. 1994 , 1, 3-16	39
1982	Pharmacotherapy of congestive heart failure. Currently used and experimental drugs. 1994 , 16, 234-42	5
1981	Evidence for cardiovascular remodeling in a patient with Bartter's syndrome. 1994 , 72, 874-7	5
1980	Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. 1994 , 46, 191-6	95
1979	Peripheral factors in the management of congestive heart failure. 1994 , 8, 75-82	7
1978	Therapeutic management of dilated cardiomyopathy. 1994 , 8, 83-8	2

1977	Alcoholic cardiomyopathy. 1994 , 8, 89-94	18
1976	When to start an ACE inhibitor and in whom. 1994 , 8, 111-4	2
1975	Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure. 1994 , 8, 685-92	14
1974	Neurohormones in patients with ischemic left ventricular dysfunction. 1994 , 8 Suppl 2, 313-7	4
1973	Risk stratification after myocardial infarction: role of electrical instability, ischemia, and left ventricular function. 1994 , 8 Suppl 2, 335-43	8
1972	Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II Study. Danish Study Group on Verapamil in Myocardial Infarction. 1994 , 8, 823-8	4
1971	Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril. 1994 , 8, 829-36	6
1970	Infarct-related heart failure: the choice of ACE inhibitor does not matter. 1994 , 8, 433-6	10
1969	High incidence of renal artery stenosis in patients with coronary artery disease. 1994 , 32, 8-10	136
1968	Prognosis during one year of follow-up after acute myocardial infarction with emphasis on morbidity. 1994 , 17, 15-20	24
1967	New evidence for improved survival in chronic heart failure. 1994 , 17, 55-8	3
1966	Acronyms for heart failure trials. 1994 , 17, 576-8	
1965	Is there a role for positive inotropic agents in congestive heart failure: focus on mortality. 1994 , 17, 641-7	12
1964	Effects of lisinopril on cardiac contractility and ionic currents. 1994 , 25, 825-32	5
1963	Patient perception of a long-term clinical trial: experience using a close-out questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial. SOLVD Close-out Working Group. 1994 , 15, 284-93	50
1962	Cardiogenic shock complicating coronary artery disease: diagnosis, treatment, and management. 1994 , 19, 693-742	
1961	Current approaches in the treatment of hypertension. 1994 , 19, 399-469	3
1960	Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease. 1994 , 73, 1191-6	8

1959	Beta blockade in congestive heart failure--the need for a definitive study. 1994 , 73, 597-9	5
1958	Physiology and clinical implications of variability of cardiovascular parameters with focus on heart rate and blood pressure. 1994 , 73, 3C-9C	93
1957	Role of neurohormones in ventricular adaptation and failure. 1994 , 73, 36C-39C	3
1956	Has the problem of heart failure been solved?. 1994 , 73, 40C-43C	
1955	The TRAndolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. The Trace Study Group. 1994 , 73, 44C-50C	60
1954	Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. 1994 , 73, 881-6	68
1953	Measurement of left ventricular ejection fraction by acoustic quantification and comparison with radionuclide angiography. 1994 , 74, 1052-6	58
1952	Beneficial effects of a single dose of quinapril on left ventricular performance in chronic mitral regurgitation. 1994 , 73, 785-91	17
1951	Single-chamber ventricular pacing is not associated with worsening heart failure in sick sinus syndrome. 1994 , 73, 693-7	20
1950	Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) and RADIANCE (Randomized Assessment of Digoxin on Inhibitors of the angiotensin Converting Enzyme) trials. 1994 , 37, 49-58	20
1949	Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. 1994 , 24, 1310-20	252
1948	Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. 1994 , 24, 1321-7	80
1947	Does heart transplantation confer additional benefit over medical therapy to patients who have waited > 6 months for heart transplantation?. 1994 , 24, 1547-51	17
1946	Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. 1994 , 23, 1410-20	190
1945	Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. 1994 , 23, 393-400	130
1944	Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. 1994 , 24, 67-73	122
1943	Convocation address. Cardiovascular medicine. 1994 , 23, 1266-8	
1942	Beta-blockers in heart failure: promising or proved?. 1994 , 23, 814-21	65

1941	Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. 1994 , 43, 151-63	17
1940	Effect of captopril on lymphocytic beta-adrenergic receptors in normal and hypoxic conditions. 1994 , 44, 137-43	5
1939	Plasma renin activity in chagasic patients with and without congestive heart failure. 1994 , 47, 5-11	16
1938	Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure. 1994 , 43, 299-304	18
1937	Antiarrhythmic effect of converting enzyme inhibitors in congestive heart failure. 1994 , 43, 315-8	16
1936	Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain. 1994 , 44, 203-15	4
1935	Idiopathic dilated cardiomyopathy. <i>New England Journal of Medicine</i> , 1994 , 331, 1564-75	59.2 712
1934	Cardiac Renin-Angiotensin System in Cardiac Hypertrophy and Failure. 1994 , 91-99	2
1933	Heart rate variability: a measure of cardiac autonomic tone. 1994 , 127, 1376-81	503
1932	Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. 1994 , 127, 1388-401	90
1931	The impact of left ventricular dysfunction on outcomes with the implantable defibrillator. 1994 , 127, 1159-63	5
1930	Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. 1994 , 128, 1328-32	26
1929	Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. 1994 , 128, 358-64	39
1928	Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. 1994 , 128, 997-1009	22
1927	First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study. The Enalapril-Captopril Investigators. 1994 , 128, 551-6	10
1926	Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure. 1994 , 128, 557-63	15
1925	Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. 1994 , 128, 564-74	141
1924	Incidence of hospitalization for digitalis toxicity among elderly Americans. 1994 , 96, 426-31	29

1923	Dynamic descending thoracic aortomyoplasty: comparison with intraaortic balloon pump in a model of heart failure. 1994 , 58, 366-70; discussion 371	18
1922	Effect of coronary artery bypass graft surgery on survival. 1994 , 344, 1222-1224	5
1921	Digoxin in eurhythmic heart failure: PROVED or "not proven"?. 1994 , 343, 128-9	13
1920	Myocardial infarction: ACE inhibitors for all? For ever?. 1994 , 344, 279-81	17
1919	Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). 1994 , 344, 493-8	754
1918	Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and diastolic blood flow. 1994 , 37, 273-8	10
1917	Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. 1994 , 38, 117-23	12
1916	Natural history of incidentally discovered, asymptomatic idiopathic dilated cardiomyopathy. 1994 , 74, 737-9	35
1915	Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era. A prospective trial. 1994 , 90, 1747-56	105
1914	Prescribing cardiovascular drugs for elderly patients. 1994 , 4, 93-100	2
1913	Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. 1994 , 47 Suppl 4, 1-13	17
1912	Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. 1994 , 48, 227-52	21
1911	Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension. 1994 , 6, 155-82	6
1910	Specific precautions may be required when treating elderly patients with CHF. 1994 , 4, 7-10	
1909	Enalapril: pharmacoeconomic and QOL data support use in heart failure and hypertension. 1994 , 4, 1-4	
1908	Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. 1994 , 90, 2056-69	388
1907	Sudden cardiac death in heart failure. The role of abnormal repolarization. 1994 , 90, 2534-9	355
1906	Echocardiography should be performed in all elderly patients with congestive heart failure. 1994 , 42, 1300-2	38

1905	Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. 1994 , 28, 146-58	49
1904	Metabolic tissue characterization in the failing heart by positron emission tomography. 1994 , 15 Suppl D, 14-9	25
1903	An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. 1994 , 15, 1616-20	145
1902	Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure. 1994 , 34, 1116-20	55
1901	Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. 1994 , 15, 303-10	114
1900	Clinical significance and management of ventricular arrhythmias in heart failure. 1994 , 15 Suppl D, 155-63	11
1899	Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Düsseldorf, Munich, Germany. 1994 , 15 Suppl D, 113-22	31
1898	Toward a duty to report clinical trials accurately: the clinical alert and beyond. 1994 , 22, 327-38	8
1897	Exercise peak VO ₂ determination in chronic heart failure: is it still of value?. 1994 , 15, 495-502	61
1896	Congestive heart failure. 1994 , 96, 167-172	5
1895	Lisinopril overdose and management with intravenous angiotensin II. 1994 , 28, 1165-8	30
1894	Hypertension: are beta-blockers and diuretics appropriate first-line therapies?. 1994 , 28, 617-25	6
1893	Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. 1994 , 105, 1360-4	35
1892	Oral enoximone as a substitute for intravenous catecholamine support in end-stage congestive heart failure. 1994 , 15, 242-6	11
1891	Quality of life on enalapril after acute myocardial infarction. 1994 , 15, 1135-9	21
1890	A new paradigm for blood pressure management. 1994 , 29, 47, 51-2, 55 passim	5
1889	Health care delivery for chronic congestive heart failure in the United Kingdom. 1994 , 9 Suppl 1, S12-5	1
1888	Optimizing the treatment of heart failure. 1994 , 9 Suppl 1, S21-7	2

1887	Practical challenges. 1994 , 9, S16-S20	2
1886	Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. 1994 , 84, 20-8	180
1885	Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group. 1995 , 35, 673-80	14
1884	Calcium antagonist use in congestive heart failure: still a bridge too far?. 1995 , 35, 443-53	5
1883	Effects of captopril and isosorbide dinitrate on hemorheological parameters in patients with chronic congestive heart failure due to coronary heart disease. 1995 , 15, 335-346	1
1882	Heart Failure: Management of Patients with Left-Ventricular Systolic Dysfunction: Quick Reference Guide for Clinicians. 1995 , 3, 67-92	0
1881	Heart failure syndrome. Rationale for current drug treatment. 1995 , 16 Suppl F, 2-3	3
1880	Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease. 1995 , 107, 162-8	50
1879	Attitudes of physicians in the treatment of congestive heart failure in older adults. 1995 , 43, 943-4	3
1878	Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction. 1995 , 29, 664-669	20
1877	Potential role of angiotensin converting enzyme inhibitors in treatment of atherosclerosis. 1995 , 16 Suppl K, 49-54	13
1876	Treatment of ventricular arrhythmias in older adults. 1995 , 43, 688-95	9
1875	Comparison of the effects of cilazapril and captopril versus placebo on exercise testing in chronic heart failure patients: a double-blind, randomized, multicenter trial. The Cilazapril-Captopril Multicenter Group. 1995 , 86 Suppl 1, 34-40	5
1874	Continuing advances in hypertension: the Joint National Committee's fifth report. 1995 , 310 Suppl 1, S48-52	8
1873	Contemporary management of patients with heart failure. 1995 , 79, 1171-90	5
1872	Noninvasive assessment of left ventricular mass, chamber volume, and contractile function. 1995 , 20, 364-440	27
1871	Molecular cardiomyoplasty: potential cardiac gene therapy for chronic heart failure. 1995 , 109, 918-23; discussion 923-4	27
1870	Clinical and left ventricular function outcomes up to five years after dynamic cardiomyoplasty. 1995 , 109, 353-62; discussion 362-3	53

1869	Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias. 1995 , 37, 307-46	60
1868	Effects of enalapril on heart rate variability in patients with congestive heart failure. 1995 , 76, 1045-8	33
1867	Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure. 1995 , 76, 1253-8	20
1866	The hibernating myocardium: implications for management of congestive heart failure. 1995 , 75, 17A-25A	77
1865	Progression of mild untreated heart failure during six months follow-up and clinical and neurohumoral effects of ibopamine and digoxin as monotherapy. DIMT Study Group. Dutch Ibopamine Multicenter Trial. 1995 , 75, 796-800	29
1864	Angiotensin-converting enzyme inhibitors and calcium antagonists after acute myocardial infarction. 1995 , 75, 4E-9E	7
1863	Calcium antagonists and left ventricular dysfunction. 1995 , 75, 71E-76E	7
1862	Disparate effects of antihypertensive drugs on large artery distensibility and compliance in hypertension. 1995 , 76, 46E-49E	12
1861	Fundamental role of angiotensin-converting enzyme inhibitors in the management of congestive heart failure. 1995 , 75, 3F-6F	11
1860	Safety and efficacy study of delapril versus enalapril in patients with congestive heart failure. 1995 , 75, 44F-49F	4
1859	Angiotensin-converting enzyme inhibitors in the clinical setting of chronic congestive heart failure. 1995 , 75, 50F-55F	6
1858	Neurohumoral variability in left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. 1995 , 75, 354-9	9
1857	Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). 1995 , 75, 1023-7	95
1856	Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. 1995 , 75, 1151-7	91
1855	Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. SOLVD Investigators. 1995 , 75, 1244-9	40
1854	The cardiovascular clinical nurse specialist as case manager during endovascular revascularization of renal artery stenosis. 1995 , 13, 14-20	3
1853	Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group. 1995 , 9, 234-42	77
1852	Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group. 1995 , 9, 243-52	105

1851	Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency. 1995 , 9, 328-31	55
1850	Heart failure: a growing public health problem. 1995 , 237, 135-41	156
1849	Nephrotoxicity of ACE-inhibitors: Age and chronic renal failure increase the risk. 1995 , 5, 71-77	1
1848	Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors. 1995 , 1, 251-257	5
1847	Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials. 1995 , 9, 89-102	18
1846	"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. 1995 , 9, 145-9	156
1845	New concepts regarding events that lead to end-stage heart disease. 1995 , 9 Suppl 3, 489-92	4
1844	ACE inhibitors and calcium antagonists in the treatment of congestive heart failure. 1995 , 9 Suppl 3, 503-7	5
1843	Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. 1995 , 9 Suppl 3, 509-23	28
1842	Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Ramipril Study Group. 1995 , 9, 589-94	16
1841	Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial. 1995 , 9, 693-700	33
1840	Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. 1995 , 49, 95-102	15
1839	Effect of captopril on myocardial beta-adrenoceptor density and Gi alpha-proteins in patients with mild to moderate heart failure due to dilated cardiomyopathy. 1995 , 47, 389-94	10
1838	Latissimus dorsi dynamic cardiomyoplasty: role of combined ICD implantation. 1995 , 10, 295-7	8
1837	Pacing in dilated cardiomyopathy. 1995 , 18, 1341-5	1
1836	Pharmacology and Clinical Use of the New ACE-Inhibitor Moexipril. 1995 , 13, 211-229	21
1835	In-hospital complications among survivors of admission for congestive heart failure, chronic obstructive pulmonary disease, or diabetes mellitus. 1995 , 10, 307-14	17
1834	Choosing antihypertensive therapy. 1995 , 10, 700-2	2

1833	Tissue angiotensin generation and regulation of vascular tone. 1995 , 65, 193-213	20
1832	An empirical evaluation of the placebo run-in. 1995 , 16, 41-50	21
1831	Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin. 1995 , 290, 55-9	12
1830	Isoniazid preventive therapy for pulmonary tuberculosis sequelae: which patients up to which age?. 1995 , 76, 394-400	6
1829	Scientific insights from clinical studies of converting-enzyme inhibitors in the failing heart. 1995 , 5, 37-44	9
1828	Heart failure: lessons learned over the past 25 years. 1995 , 18, 123-30	2
1827	Neuroendocrine changes in heart failure and their clinical relevance. 1995 , 18, 440-5	39
1826	Clinical efficacy of ibopamine in patients with chronic heart failure. 1995 , 18, 122-31	1
1825	Effects of ACE inhibition on the hypertrophied heart-implications for reversal and prognosis: An updated review. 1995 , 18, I-12-I-22	
1824	The effects of ACE inhibition on ischemic cardiac events: Pump failure, reinfarction, hospitalization for angina, and ventricular tachyarrhythmias. 1995 , 18, I-26-I-33	0
1823	Maintaining long-term control of blood pressure: the role of improved compliance. 1995 , 18, III 12-6	45
1822	Strategies for pharmacologic modulation of the heart failure phenotype. 1995 , 18, IV28-35	
1821	Cell death in the failing heart: role of an unnatural growth response to overload. 1995 , 18, IV36-44	24
1820	Clinical trials: specific problems associated with the use of a placebo-control group. 1995 , 73, 421-4	8
1819	Is cardiomyoplasty an alternative to cardiac transplantation?. 1995 , 162, 343-4	
1818	Congestive cardiac failure and arrhythmias. 1995 , 162, 44-7	0
1817	Section Review: Cardiovascular & Renal: Changing insights in the drug treatment of congestive heart failure. 1995 , 4, 1045-1056	3
1816	Angiotensin-Converting Enzyme Inhibitors Post-Myocardial Infarction. 1995 , 13, 379-390	9

1815	Beta-1-selectivity is not essential to achieve therapeutic efficacy with beta-blockade therapy for idiopathic dilated cardiomyopathy. 1995 , 86, 217-23	4
1814	Successful treatment of hyponatremia with angiotensin-converting enzyme inhibitors in patients with congestive heart failure. 1995 , 86, 477-80	12
1813	Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. 1995 , 269, E426-37	38
1812	Identifying the patient with heart failure. 1995 , 23, 139-53	7
1811	Arterial Thrombosis for the Clinician. 1995 , 13, 295-310	2
1810	Medical Therapy and Prognosis in Chronic Heart Failure. 1995 , 13, 5-26	7
1809	New Medical Therapies for Advanced Left Ventricular Dysfunction. 1995 , 13, 27-34	3
1808	Quantifying Cardiovascular Risk in Hypertension. 1995 , 13, 519-527	
1807	Clinical pharmacokinetics and efficacy of renin inhibitors. 1995 , 29, 6-14	31
1806	Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease?. 1995 , 18, 708-14	174
1805	Combining salicylate and enalapril in patients with coronary artery disease and heart failure. 1995 , 73, 227-36	45
1804	Left ventricular volumes, ejection fraction, and plasma proatrial natriuretic factor (1-98) after withdrawal of enalapril treatment initiated early after myocardial infarction. CONSENSUS II Multi-Echo Study Group. 1995 , 73, 506-10	5
1803	ACE inhibitors in heart failure. What dose?. 1995 , 71, 65-6	9
1802	ACE inhibitors after myocardial infarction: patient selection or treatment for all?. 1995 , 73, 397-400	11
1801	The Emerging Role of the Food and Drug Administration in Pharmacoeconomic Evaluation during the Drug Development Process. 1995 , 29, 1105-1111	1
1800	Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure. 1995 , 273, 1450	1036
1799	The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies. 1995 , 274, 620	491
1798	Rationale for Treatment of Patients With Chronic Heart Failure With Adrenergic Blockade. 1995 , 274, 1462	49

1797	Plasma proatrial natriuretic factor (1-98) concentration after myocardial infarction: relation to indices of cardiac and renal function. 1995 , 73, 511-6	20
1796	Long-term prognostic significance of M mode echocardiography in young men after myocardial infarction. 1995 , 74, 124-30	12
1795	Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol. 1995 , 74, 140-8	11
1794	Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. 1995 , 74, 502-7	49
1793	An audit of echocardiograms in acute left ventricular failure. 1995 , 71, 738-40	
1792	A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients. 1995 , 46, 811-7	6
1791	Heart Hypertrophy and Failure. 1995 ,	
1790	Diuretics. 1995 ,	2
1789	The angiotensin converting enzyme gene in cardiovascular disease. 1995 , 74, 207-8	6
1788	Coronary artery disease, valvular heart disease, bradycardia, and heart failure. 1995 , 71, 346-53	
1787	Effects of captopril and enalapril on renal function in elderly patients with chronic heart failure. 1995 , 71, 287-92	7
1786	Investigation in general practice of patients with suspected heart failure. How should the essential echocardiographic service be delivered?. 1995 , 74, 335-6	12
1785	Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. 1995 , 74, 584-91	60
1784	Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients. Influence of ACE inhibition. 1995 , 8, 40-7	22
1783	The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. 1995 , 8, 909-14	31
1782	Cardioprotective potential of antihypertensives. 1995 , 8, 49S-52S	2
1781	Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). 1995 , 8, 1147-53	27
1780	Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. 1995 , 17, 1005-30	15

1779	Long-term therapy of patients with heart failure. Drug therapy: from trial results to clinical practice. 1995 , 20, 69-78	1
1778	Left ventricular volume in thrombolysed patients with acute anterior myocardial infarction: the effect of captopril and xamoterol. 1995 , 51, 137-42	9
1777	Tissue angiotensin I-converting enzyme activity in aging hamsters with and without cardiomyopathy. 1995 , 78, 163-70	6
1776	Cardiomyoplasty: a summing up. 1995 , 19, 199-203	1
1775	Similia similibus obscurantur: the pharmacological clinical activity bias I. A prototype model to correct a disease-drug interaction leading to misestimations of drug-attributable side effects. 1995 , 9, 583-92	2
1774	Recovery of left ventricular function in acute nonischemic congestive cardiomyopathy. 1995 , 129, 24-30	12
1773	Escalating nitrate dose overcomes early attenuation of hemodynamic effect caused by nitrate tolerance in patients with heart failure. 1995 , 130, 798-805	8
1772	Peripartum cardiomyopathy. 1995 , 130, 860-70	185
1771	Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. 1995 , 130, 1089-93	59
1770	Angiotensin-converting enzyme inhibitors and beta-blockers in long-term treatment of dilated cardiomyopathy. 1995 , 129, 754-61	14
1769	Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). 1995 , 130, 494-500	63
1768	Sensitive method for quantitation of angiotensin-converting enzyme (ACE) activity in tissue. 1995 , 50, 1445-50	61
1767	Myocarditis and idiopathic dilated cardiomyopathy. 1995 , 99, 309-14	79
1766	Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. 1995 , 99, 629-35	95
1765	Prognosis of idiopathic dilated cardiomyopathy. 1995 , 1, 337-45	8
1764	Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. 1995 , 1, 371-80	69
1763	Treatment with enalapril fails to prevent impaired cardiopulmonary baroreflex control in dogs with left ventricular dysfunction. 1995 , 1, 381-9	7
1762	Transition from asymptomatic left ventricular dysfunction to congestive heart failure. 1995 , 1, 409-19	7

1761	Clinical Uses of Diuretics. 1995 , 443-505	0
1760	Enalapril improves heart failure induced by monocrotaline without reducing pulmonary hypertension in rats: roles of preserved myocardial creatine kinase and lactate dehydrogenase isoenzymes. 1995 , 47, 225-33	16
1759	Effects of intravenous magnesium sulphate in suspected acute myocardial infarction on acute arrhythmias and long-term outcome. 1995 , 49, 143-51	11
1758	The Interdisciplinary Heart Failure and Transplant Program Münster: a 5-year experience. 1995 , 50, 7-17	15
1757	Improvement in exercise capacity of candidates awaiting heart transplantation. 1995 , 25, 163-70	143
1756	Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. 1995 , 25, 1154-61	429
1755	Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. 1995 , 25, 1445-50	26
1754	Angiotensin-converting enzyme inhibitors after myocardial infarction: indications and timing. 1995 , 25, 42S-46S	19
1753	Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction. 1995 , 25, 47S-51S	8
1752	Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. 1995 , 26, 93-101	38
1751	Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. 1995 , 26, 1251-6	61
1750	Adverse consequences of high sympathetic nervous activity in the failing human heart. 1995 , 26, 1257-63	544
1749	Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. 1995 , 26, 1417-23	177
1748	Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. 1995 , 26, 438-45	165
1747	Physician use of beta-adrenergic blocking therapy: a changing perspective. 1995 , 26, 547-52	52
1746	Cardiac failure: a revised paradigm. 1995 , 1, 261-6	18
1745	Statistical issues and analysis of mortality and morbidity randomized clinical trials in congestive heart failure. 1995 , 1, 303-9	
1744	Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure. 1995 , 1, 117-25	1

1743	Interobserver discordance in the classification of mechanisms of death in studies of heart failure. 1995 , 1, 127-32		36
1742	Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. 1995 , 1, 201-6		172
1741	Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: comparison with clinical evaluation, ejection fraction, and exercise capacity. 1995 , 1, 207-16		30
1740	Vesnarinone: a new inotropic agent for treating congestive heart failure. 1995 , 1, 249-57		18
1739	A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. <i>New England Journal of Medicine</i> , 1995 , 333, 1190-5	59.2	1790
1738	ACE inhibitors. Drug interactions of clinical significance. 1995 , 12, 334-47		25
1737	The management of ventricular arrhythmias in older patients after CAST. 1995 , 6, 112-24		5
1736	Left ventricular hypertrophy. Prevalence in older patients and management. 1995 , 6, 301-11		3
1735	Digoxin in the treatment of patients with chronic heart failure. Its place in therapy. 1995 , 7, 1-9		2
1734	Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. 1995 , 49, 440-66		39
1733	Risk and management of hypertension-related left ventricular hypertrophy. 1995 , 50, 959-70		3
1732	Clinical and economic factors in the treatment of congestive heart failure. 1995 , 7, 119-27		26
1731	Current management of acute myocardial infarction. 1995 , 41, 366-433		
1730	Angiotensin converting enzyme gene polymorphism and the course of angiographically defined coronary artery disease. 1995 , 114, 133-5		11
1729	Do we need more anti-hypertensive drugs: lessons from the new biology. 1995 , 345, 1555-7		9
1728	Is mortality rate what it is all about in congestive heart failure?. 1995 , 346, 1501-1502		1
1727	Inpatient general medicine is evidence based. 1995 , 346, 407-410		285
1726	Continuous ambulatory peritoneal dialysis for patients with severe left ventricular systolic dysfunction and end-stage renal disease. 1995 , 25, 761-8		19

1725	Justifying echocardiography in patients with heart failure. 1996 , 9, 582-4	1
1724	Ventricular Remodeling After Orthotopic Cardiac Transplantation. 1996 , 71, 735-742	2
1723	Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. 1996 , 76, 232-7	109
1722	[Cost-effectiveness analysis of the treatment with enalapril of chronic heart failure in Spain]. 1996 , 10, 135-42	4
1721	Spirals, paradigms, and the progression of heart failure. 1996 , 2, 1-4	8
1720	Clinical epidemiology of heart failure: experience in a rural hospital. 1996 , 2, 25-9	4
1719	Impact of advances in therapy for heart failure on secular trends in mortality. 1996 , 2, 31-2	3
1718	Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. 1996 , 2, 47-54	178
1717	Effects of long-term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure. 1996 , 2, 301-10	3
1716	Pathophysiologic and therapeutic implications of sleep apnea in congestive heart failure. 1996 , 2, 223-40	63
1715	Prognosis in congestive heart failure. 1996 , 2, S225-9	12
1714	The use of ACE inhibitors after myocardial infarction. 1996 , 2, S231-7	2
1713	Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. 1996 , 27, 345-52	272
1712	Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). 1996 , 27, 642-9	74
1711	Survival after myocardial infarction in rats: captopril versus losartan. 1996 , 27, 714-9	81
1710	Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. 1996 , 27, 650-7	234
1709	Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. 1996 , 27, 1192-7	54
1708	Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). 1996 , 27, 1201-6	976

1707	The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. 1996 , 28, 162-7	128
1706	Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). 1996 , 28, 114-21	63
1705	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. 1996 , 27, 1007-19	188
1704	A comparative review of the adverse effects of calcium antagonists. 1996 , 15, 91-106	38
1703	Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. 1996 , 131, 177-85	36
1702	Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise. 1996 , 131, 999-1006	8
1701	Successful heart failure therapy is effective antiarrhythmia therapy. 1996 , 131, 1048-50	1
1700	Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. 1996 , 131, 350-5	122
1699	Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group. 1996 , 132, 71-7	7
1698	Links between hypertension and myocardial infarction. 1996 , 132, 213-221	19
1697	The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. 1996 , 132, 229-234	30
1696	Utilization of echocardiography by internists and cardiologists: a comparative study. 1996 , 101, 584-91	16
1695	The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. 1996 , 83, 143-52	16
1694	Women and Mexican Americans receive fewer cardiovascular drugs following myocardial infarction than men and non-Hispanic whites: the Corpus Christi Heart Project, 1988-1990. 1996 , 49, 279-87	35
1693	Calcium antagonists and cardiovascular prognosis: a homogeneous group?. 1996 , 9, 99-109	2
1692	Cardiac function, metabolism and perfusion in Duchenne and Becker muscular dystrophy. 1996 , 6, 237-46	31
1691	Acute hemodynamic and long-term clinical effects of isradipine in patients with coronary artery disease and chronic heart failure. A double-blind, placebo-controlled study. 1996 , 53, 37-43	4
1690	Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy. 1996 , 56, 283-8	26

1689 [Current status of treatment of chronic cardiac insufficiency]. **1996**, 17, 135-43

1688 Dynamic cardiomyoplasty in South America. **1996**, 61, 408-12 44

1687 Regional effects of aortomyoplasty in acute ischemia. **1996**, 61, 426-9 7

1686 Prediction of outcome after revascularization in patients with poor left ventricular function. **1996**, 61, 1428-34 37

1685 Basic mechanisms in heart failure: the cytokine hypothesis. **1996**, 2, 243-9 338

1684 Clinical pharmacology and clinical trials in Japan. **1996**, 74, 479-86 8

1683 Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. **1996**, 348, 7-12 1115

1682 Value of digoxin in heart failure and sinus rhythm: new features of an old drug?. **1996**, 28, 813-9 32

1681 Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. **1996**, 28, 1083-91 113

1680 Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?. **1996**, 28, 1323-7 68

1679 Effects of enalapril on cardiac function, exercise capacity, and biochemical factors in patients with chronic heart failure. **1996**, 57, 622-629

1678 Guidelines for the treatment of hypertension: a commentary. **1996**, 57, 3-15 6

1677 Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure. **1996**, 59, 686-98 4

1676 Fish oil and other nutritional adjuvants for treatment of congestive heart failure. **1996**, 46, 400-6 7

1675 Cardiomyopathies in infants and children. **1996**, 6, 137-144

1674 The management of chronic heart failure. *New England Journal of Medicine*, **1996**, 335, 490-8 59.2 264

1673 The Progression From Hypertension to Congestive Heart Failure. **1996**, 275, 1557 1137

1672 Anthracycline-induced cardiotoxicity. **1996**, 125, 47-58 526

1671	The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. <i>New England Journal of Medicine</i> , 1996 , 334, 1349-55	59.2	3610
1670	ACE inhibitors and the kidney. A risk-benefit assessment. 1996 , 15, 200-11		50
1669	Quality of life in older patients with congestive heart failure. Effects of ACE inhibitors. 1996 , 8, 23-8		4
1668	Optimal treatment of angina in older patients. 1996 , 8, 349-57		5
1667	Optimal dosage of ACE inhibitors in older patients. 1996 , 9, 262-73		8
1666	The clinical potential of endothelin receptor antagonists in cardiovascular medicine. 1996 , 51, 12-27		58
1665	Current guidelines for the treatment of congestive heart failure. 1996 , 51, 89-98		14
1664	Novel drugs and current therapeutic approaches in the treatment of heart failure. 1996 , 51, 347-58		12
1663	Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction. 1996 , 52, 564-88		19
1662	Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. <i>Studies of Left Ventricular Dysfunction</i> . 1996 , 9, 156-67		14
1661	The pharmacoeconomics of ACE inhibitors in chronic heart failure. 1996 , 9, 188-97		34
1660	Formulary management of ACE inhibitors. 1996 , 10, 594-613		10
1659	Effects of Angiotensin-Converting Enzyme Inhibitors on the Heart and Vessels in Clinical and Experimental Hypertension. 1996 , 12, 226-243		6
1658	Brief report: acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis. 1996 , 5, 360-2		22
1657	Hypertension and Coronary Artery Disease in the Elderly. 1996 , 12, 41-56		5
1656	Pathophysiology of Coronary Artery Disease. 1996 , 12, 1-21		6
1655	Management of Postmyocardial Infarction in the Elderly Patient. 1996 , 12, 169-180		3
1654	References / Subject Index. 1996 , 38, 145-168		

- 1653 The Role of Digoxin in the Treatment of Chronic Congestive Heart Failure. **1996**, 1, 259-264
- 1652 Management of Heart Failure Caused Primarily by Left Ventricular Systolic Dysfunction. **1996**, 9, 17-22
- 1651 The impact of angiotensin converting enzyme inhibitors on the arterial wall. **1996**, 1, 109-113 6
- 1650 Acute filling pattern changes of the failing left ventricle after captopril as related to ventricular structure. **1996**, 87, 153-60 2
- 1649 Current controversies with ACE inhibitor treatment in heart failure. **1996**, 87 Suppl 1, 23-8 11
- 1648 Prognostic value of echocardiography in 190 patients with chronic congestive heart failure. A comparison with New York Heart Association functional classes and radionuclide ventriculography. **1996**, 87, 250-6 14
- 1647 Age and gender differences in left ventricular function among patients with stable angina and a matched control group. A report from the Angina Prognosis Study in Stockholm. **1996**, 87, 287-93 7
- 1646 The Economics of Cardiac Failure. **1996**, 89, 9-12 1
- 1645 Cost-effectiveness in clinical cardiology. Part 1: Coronary artery disease and congestive heart failure. **1996**, 109, 1359-69 7
- 1644 Cardiovascular diseases in women: an equal opportunity killer. **1996**, NS36, 360-9 2
- 1643 Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands. **1996**, 17, 731-40 25
- 1642 A cardiologist's perspective on evolving concepts in the management of congestive heart failure. **1996**, 36, 973-84 5
- 1641 Implementation of discharge plans for chronically ill elders discharged home. **1996**, 21, 30-40 27
- 1640 Prolongation of the life span of cardiomyopathic hamster by the adrenergic beta 1-selective partial agonist denopamine. **1996**, 72, 325-33 5
- 1639 Angiotensin II receptor antagonists: the prototype losartan. **1996**, 30, 625-36 23
- 1638 Refractory congestive heart failure: overview and application of extracorporeal ultrafiltration. **1996**, 3, 166-73 18
- 1637 Myocardial infarction: when and how should we initiate treatment with ACE inhibitors? GISSI-3 Investigators. **1996**, 87 Suppl 1, 16-22 3
- 1636 Thrombosis in Ischemic Heart Disease. **1996**, 156, 1382 58

1635	The effect of nifedipine on ventriculoarterial coupling in old myocardial infarction. 1996 , 60, 35-42	3
1634	What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction?. 1996 , 30, 986-93	8
1633	Evolving concepts regarding selection of patients for cardiac transplantation. Assessing risks and benefits. 1996 , 109, 223-32	13
1632	The diagnosis and management of cardiac failure. 1996 , 41, 72-5	
1631	Pharmacologic treatment of congestive heart failure. 1996 , 19, 271-7	11
1630	Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group. 1996 , 19, 543-8	9
1629	Comparison of time domain and spectral turbulence analysis of the signal-averaged electrocardiogram for the prediction of prognosis in idiopathic dilated cardiomyopathy. 1996 , 19, 800-8	7
1628	Endogenous cardiac vasoactive factors modulate endothelin production by cardiac fibroblasts in culture. 1996 , 5, 95-102	1
1627	Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. 1996 , 17, 77-97	106
1626	The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. 1996 , 17, 304-15	26
1625	Effects of the angiotensin-II antagonist (ANG-II-A) BIBR 277 on hemodynamics and ventricular function after CPR in pigs. 1996 , 22, S93-S93	
1624	Heart transplant candidates at high risk can be identified at the time of initial evaluation. 1996 , 9, 38-45	17
1623	A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. 1996 , 26, 89-95	17
1622	Rationale, background, and design of the randomized angiotensin receptor antagonist-angiotensin-converting enzyme inhibitor study (RAAS). 1996 , 78, 1129-31	19
1621	Lack of association between insertion/deletion polymorphism of the angiotensin-converting enzyme gene and end-stage heart failure due to ischemic or idiopathic dilate cardiomyopathy in the Chinese. 1996 , 77, 1008-10	36
1620	Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. 1996 , 77, 1017-20	362
1619	Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. 1996 , 77, 832-8	120
1618	Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. 1996 , 77, 843-50	228

1617	Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. 1996 , 77, 1191-6	10
1616	Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. 1996 , 77, 1197-201	19
1615	The renin-angiotensin system in left ventricular remodeling. 1996 , 77, 8C-16C	47
1614	Nitrates in the treatment of congestive heart failure. 1996 , 77, 41C-51C	41
1613	Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction. 1996 , 77, 16D-21D	25
1612	Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. 1996 , 78, 890-5	280
1611	Technological advances in implantable cardioverter-defibrillators before the year 2000 and beyond. 1996 , 78, 108-15	5
1610	The endothelin system and its potential as a therapeutic target in cardiovascular disease. 1996 , 72, 109-48	136
1609	Angiotensin-converting enzyme inhibition after acute myocardial infarction with special reference to the Fourth International Study of Infarct Survival (ISIS-4). 1996 , 39, 201-6	3
1608	Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. 1996 , 10, 85-7	20
1607	Angiotensin II Modulation of Insulin-like Growth Factor I Expression in the Cardiovascular System. 1996 , 6, 187-93	6
1606	Purification and assay methods for angiotensin-converting enzyme. 1996 , 743, 105-22	28
1605	Congestive heart failure in the elderly requiring hospital admission. 1996 , 23, 225-38	15
1604	Angiotensin II type 1 receptor induced signal-transduction pathways as new targets for pharmacological treatment of the renin-angiotensin system. 1996 , 91 Suppl 2, 91-6	3
1603	Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril. 1996 , 10, 75-9	4
1602	Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process?. 1996 , 10 Suppl 2, 623-9	9
1601	Angiotensin-converting enzyme inhibitors and coronary artery disease. 1996 , 10 Suppl 2, 631-7	5
1600	Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. 1996 , 10 Suppl 2, 639-47	9

1599	Role of myocardial viability in the improvement of cardiac function after revascularization. 1996 , 1, 105-113	
1598	Prevention of ventricular remodeling after myocardial infarction and in congestive heart failure. 1996 , 1, 115-129	20
1597	Regression of established ventricular remodeling: A therapeutic goal in ventricular dysfunction?. 1996 , 1, 131-137	
1596	Beta blockers in heart failure. 1996 , 1, 5-13	6
1595	Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. 1996 , 157, 251-8	12
1594	Heart Failure: Management of Patients With Left-Ventricular Systolic Dysfunction. 1996 , 8, 85-95	
1593	Dynamic cardiomyoplasty in the treatment of dilated cardiomyopathy: current results and perspectives. 1996 , 11, 207-16	17
1592	Beneficial Effects of Captopril and Metoprolol Treatment in Idiopathic Dilated Cardiomyopathy. 1996 , 1, 393-399	
1591	Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene Associates with Increased Risk for Late Potentials in Patients with Myocardial Infarction. 1996 , 1, 405-410	
1590	Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction. 1996 , 3, 150-6	53
1589	Diagnosis and management of heart failure in the elderly. 1996 , 72, 577-80	10
1588	The renin-angiotensin system and cardiac remodelling after acute myocardial infarction. 1996 , 76, 68-72	
1587	Is there a link between the circulating renin-angiotensin system and coronary disease? A buoyant view. 1996 , 76, 18-22	10
1586	Inhibition of the renin-angiotensin system after acute myocardial infarction--treat first, select later?. 1996 , 76, 73-8	4
1585	Cardiovascular disease and genetics of the renin-angiotensin system. 1996 , 76, 13-7	8
1584	The renin-angiotensin system and the heart: a historical review. 1996 , 76, 7-12	10
1583	Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.. 1996 , 75, 576-581	36
1582	Inhibitors of the renin-angiotensin system in established cardiac failure. 1996 , 76, 83-91	2

1581	Beta-adrenergic blockers and survival in heart failure. <i>New England Journal of Medicine</i> , 1996 , 334, 1396-399.2	88
1580	ACE inhibitors unmask incoordinate diastolic wall motion in restrictive left ventricular disease. 1996 , 76, 326-31	31
1579	Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. 1996 , 76, 218-22	51
1578	The renin-angiotensin system and the heart: beyond 2000. 1996 , 76, 98-103	5
1577	Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure. 1996 , 75, 159-64	10
1576	Refractory Heart Failure: A Therapeutic Approach. 1996 , 11, 121-148	4
1575	Adverse effects of the angiotensin-converting enzyme inhibitors. 1996 , 30, 55-61	66
1574	Carvedilol in patients with chronic heart failure. <i>New England Journal of Medicine</i> , 1996 , 335, 1318; author reply 1319-20	59.2 21
1573	Prediction of heart failure - an art aided by technology. <i>New England Journal of Medicine</i> , 1997 , 336, 1381-2	11
1572	Digoxin in patients with heart failure. <i>New England Journal of Medicine</i> , 1997 , 337, 129; author reply 130-1	59.2 4
1571	Amlodipine in chronic heart failure. <i>New England Journal of Medicine</i> , 1997 , 336, 1023; author reply 1024	59.2 6
1570	Hypercoagulability in heart failure. 1997 , 23, 543-5	52
1569	The Multicenter Automatic Defibrillator Implantation Trial. 1997 , 2, 229-238	1
1568	The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice. 1997 , 73, 409-11	11
1567	Towards a comprehensive telecardiology monitoring centre for community-based services. 1997 , 3 Suppl 1, 60-2	16
1566	The management of congestive heart failure. 1997 , 73, 194-200	8
1565	Effect of enalapril maleate on cerebral blood flow in patients with chronic heart failure. 1997 , 48, 707-13	25
1564	Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure. 1997 , 78, 230-6	130

1563	Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. <i>New England Journal of Medicine</i> , 1997 , 337, 1569-75	59.2	779
1562	Hypertension and heart failure: the link continues. 1997 , 112, 9-10		1
1561	Angiotensin-I-converting enzyme DD genotype is a risk factor of coronary artery disease. 1997 , 57, 127-32		15
1560	Discrepancies between meta-analyses and subsequent large randomized, controlled trials. <i>New England Journal of Medicine</i> , 1997 , 337, 536-42	59.2	1038
1559	Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials. 1997 , 6, 475-87		7
1558	Opening Speech of the Prague Conference. 1997 , 3, 83-84		2
1557	Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results. 1997 , 48, 103-14		15
1556	Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? An antagonist viewpoint. 1997 , 31, 893-6		1
1555	Effects of enalapril on the exercise capacity and neurohumoral factors during exercise in patients with chronic heart failure. 1997 , 88, 6-13		3
1554	Beta-blocker use in systolic heart failure and dilated cardiomyopathy. 1997 , 37, 7-19		19
1553	Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. 2000 , CD002188		5
1552	Factors contributing to the hospitalization of patients with congestive heart failure. 1997 , 87, 643-8		167
1551	Treatment of congestive heart failure in older persons. 1997 , 45, 1252-7		19
1550	Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. 1997 , 15, 339-48		45
1549	Determinants of perceived health in patients with left ventricular dysfunction: a structural modeling analysis. 1997 , 59, 193-200		27
1548	Angiotensin converting enzyme inhibitor/calcium antagonist combination. 1997 , 15, S109-S117		8
1547	Treatment with verapamil and trandolapril in patients with congestive heart failure and myocardial infarction. The Danish Verapamil Infarction Trial (DAVIT Study Group). 1997 , 15, S119-22		1
1546	Protective effect of captopril on ischemic myocardium. 1997 , 61, 161-9		14

1545	Angiotensin-converting enzyme inhibitor up-regulates cardiac beta-receptors in cultured neonatal rat myocytes. 1997 , 61, 170-9	7
1544	Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction. 1997 , 61, 308-14	19
1543	Arrhythmias and sudden death in heart failure. 1997 , 61, 727-40	28
1542	Chapter 28 Mode of action of angiotensin converting enzyme inhibitors. 1997 , 8, 547-560	1
1541	Current concepts in the treatment of congestive heart failure. 1997 , 88 Suppl 2, 2-6	8
1540	The endothelium in coronary artery disease. 1997 , 88 Suppl 3, 3-19	34
1539	Factors associated with antihypertensive prescribing. 1997 , 31, 154-9	7
1538	The antiatherogenic potential of blocking the renin-angiotensin system. 1997 , 6, 1651-8	1
1537	A Survey of Heart Failure in General Practice. 1997 , 3, 85-89	9
1536	Simplified echocardiography in the diagnosis of heart failure. 1997 , 31, 9-16	34
1535	An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure. 1997 , 13, 583-92	4
1534	Publication bias in clinical trials and economic analyses. 1997 , 12, 10-6	29
1533	More scope for ACE inhibitor use in left ventricular systolic dysfunction. 1997 , 10, 5-8	
1532	Current status of diuretics, beta-blockers, alpha-blockers, and alpha-beta-blockers in the treatment of hypertension. 1997 , 81, 1305-17	9
1531	Hypertension and coronary artery disease. 1997 , 81, 1147-63	2
1530	Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists. 1997 , 81, 1319-33	10
1529	Risk factors for early anthracycline clinical cardiotoxicity in children: the pediatric oncology group experience. 1997 , 8, 83-90	15
1528	IMPACT OF ASTHMA THERAPY ON CARDIOVASCULAR DISORDERS IN THE ELDERLY. 1997 , 17, 627-644	3

- 1527 Betabloqueantes en la insuficiencia cardíaca: ¿deben incluirse siempre en la estrategia terapéutica? Argumentos a favor. **1997**, 50, 300-303
- 1526 Betabloqueantes en la insuficiencia cardíaca: ¿deben incluirse siempre en la estrategia terapéutica? Argumentos en contra. **1997**, 50, 304-307
- 1525 Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure. **1997**, 54, 103-16 13
- 1524 Antiarrhythmic therapies for the prevention of sudden cardiac death. **1997**, 54, 235-52 21
- 1523 Levosimendan, a novel Ca²⁺ sensitizer, activates the glibenclamide-sensitive K⁺ channel in rat arterial myocytes. **1997**, 333, 249-59 205
- 1522 The mysterious angiotensin-converting enzyme inhibitors. **1997**, 3, 161-3 1
- 1521 Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure. **1997**, 3, 165-71 8
- 1520 The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. **1997**, 3, 249-54 290
- 1519 Effects of angiotensin-converting enzyme inhibitor on plasma B-type natriuretic peptide levels in patients with acute myocardial infarction. **1997**, 3, 287-93 12
- 1518 Angiotensin-converting enzyme inhibitors in heart failure: physicians' prescribing behavior. **1997**, 3, 295-302 14
- 1517 Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. **1997**, 3, 91-6 15
- 1516 The Effect of Drug Therapy on Quality of Life in Heart Failure. **1997**, 2, 93-106 1
- 1515 Do ACE inhibitors provide protection for the heart in the clinical setting of acute myocardial infarction?. **1997**, 54 Suppl 5, 48-58 6
- 1514 Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?. **1997**, 54 Suppl 5, 59-70 28
- 1513 Endothelial dysfunction and atherothrombotic occlusive disease. **1997**, 54 Suppl 3, 41-9; discussion 49-50 11
- 1512 Optimal treatment of heart failure in the elderly. **1997**, 10, 435-43 1
- 1511 The generalisability of pharmacoeconomic studies. **1997**, 11, 503-14 32
- 1510 Changing mortality from coronary heart disease among smokers and nonsmokers over a 20-year interval. **1997**, 26, 441-6 10

1509	The place of angiotensin-converting enzyme inhibition after acute myocardial infarction. 1997 , 134, S25-30	3
1508	Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?. 1997 , 134, S31-47	11
1507	Treatment with verapamil and trandolapril in patients with congestive heart failure and angina pectoris or myocardial infarction. The DAVIT Study Group. Danish Verapamil Infarction Trial. 1997 , 134, S48-52	8
1506	Blood pressure and cardiovascular morbidity and mortality rates in the elderly. 1997 , 134, 758-63	72
1505	Prediction of pulmonary capillary wedge pressure and assessment of stroke volume by noninvasive impedance cardiography. 1997 , 134, 450-5	20
1504	Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. 1997 , 134, 37-43	26
1503	Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. 1997 , 134, 188-95	72
1502	Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. 1997 , 133, 550-7	31
1501	Quantitative measures of regional asynergy add independent prognostic information to left ventricular ejection fraction in patients with prior myocardial infarction. 1997 , 133, 640-7	8
1500	Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. 1997 , 133, 703-12	422
1499	Effects of nisoldipine and/or enalapril on left ventricular function and exercise capacity in patients with recent anterior myocardial infarction and mild cardiac dysfunction. 1997 , 133, 268-72	3
1498	Effects of amlodipine in patients with chronic heart failure. 1997 , 134, 872-8	6
1497	Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. 1997 , 134, 889-900	64
1496	Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. 1997 , 134, 901-9	37
1495	The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. 1997 , 134, 961-6	35
1494	Sarcoidosis in a pregnant woman. 1997 , 9, 78-86	8
1493	Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. 1997 , 10, 272S-279S	11
1492	The progression from hypertension to heart failure. 1997 , 10, 280S-288S	16

1491	Treatment of congestive heart failure: experience with fosinopril. 1997 , 10, 289S-298S	5
1490	Focus on congestive heart failure. 1997 , 1, 32-3	
1489	Angiotensin converting enzyme inhibitors after myocardial infarction: what do the trials tell us?. 1997 , 1, 186-192	
1488	Incidence of cough induced by imidapril in patients with hypertension with enalapril-associated cough. 1997 , 58, 601-608	6
1487	Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: a multicenter, double-masked study. 1997 , 58, 331-342	7
1486	Evolving costs of long-term left ventricular assist device implantation. 1997 , 64, 1312-9	34
1485	Quality of life with an implanted left ventricular assist device. 1997 , 64, 1764-9	77
1484	Signalment, survival, and prognostic factors in Doberman pinschers with end-stage cardiomyopathy. 1997 , 11, 323-6	88
1483	Citalopram toxicity. 1997 , 350, 518-9	60
1482	Digoxin for patients with heart failure in sinus rhythm. 1997 , 350, 519	
1481	Bayesian interim statistical analysis of randomised trials: the case against. 1997 , 349, 1168-9	2
1480	Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). 1997 , 349, 747-52	1357
1479	Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. 1997 , 350, 829-33	492
1478	Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. 1997 , 349, 1493-7	130
1477	Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. 1997 , 349, 375-380	598
1476	Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. 1997 , 29, 147-52	108
1475	Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. 1997 , 29, 1060-6	329
1474	Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. 1997 , 29, 1468-73	25

1473	Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents: a review of potential benefits and possible adverse reactions. 1997 , 29, 1414-21	48
1472	Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. 1997 , 30, 35-41	103
1471	Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. 1997 , 30, 518-26	172
1470	Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. 1997 , 30, 576-84	121
1469	Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. 1997 , 30, 725-32	428
1468	Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. 1997 , 30, 1002-8	290
1467	Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. 1997 , 30, 983-91	89
1466	Stress-induced left ventricular outflow tract obstruction: a potential cause of dyspnea in the elderly. 1997 , 30, 1301-7	68
1465	Primary prevention of sudden cardiac death in heart failure: will the solution be shocking?. 1997 , 30, 1589-97	162
1464	Implantable left ventricular assist devices provide an excellent outpatient bridge to transplantation and recovery. 1997 , 30, 1773-7	96
1463	Angiotensin converting enzyme inhibition improves baroreflex-induced noradrenaline spillover responses in rabbits with heart failure. 1997 , 66, 87-93	5
1462	Predictors of sudden death and death from pump failure in congestive heart failure are different. Analysis of 24 h Holter monitoring, clinical variables, blood chemistry, exercise test and radionuclide angiography. 1997 , 58, 151-62	20
1461	Effects of digoxin on time domain measures of heart rate variability in patients with stable chronic cardiac failure: withdrawal and comparison group studies. 1997 , 59, 29-36	9
1460	Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?. 1997 , 59, 7-10	84
1459	Clinical course of Chagas' heart disease: a comparison with dilated cardiomyopathy. 1997 , 60, 187-93	137
1458	Should general practitioners use the electrocardiogram to select patients with suspected heart failure for echocardiography?. 1997 , 62, 31-6	42
1457	Angiotensin II type-I receptor antagonists in the treatment of heart failure. 1997 , 62 Suppl 1, S13-7	4
1456	Sympathetic inhibition with clonidine improves autonomic balance in congestive heart failure. 1997 , 59, 139-44	12

1455	Effects of enalapril on left ventricular function and exercise performance after a first acute myocardial infarction. The EDEN Study Investigators. 1997 , 59, 257-65	4
1454	Older patients and advances in cardiology. 1997 , 350, 1779-80	2
1453	The relationship between hospital length of stay and rate of death in heart failure. 1997 , 26, 177-86	19
1452	Calcium channel blockers: association with myocardial infarction, mortality, and cancer. 1997 , 19, 1255-68; discussion 1253-4	5
1451	The clinical significance of neurohormonal activation. 1997 , 19 Suppl A, 53-73	4
1450	Safety of calcium antagonists in patients with congestive heart failure. 1997 , 19 Suppl A, 92-113	7
1449	Infarct-related artery patency and long-term effects on left ventricular remodelling. 1997 , 88 Suppl 1, 26-35; discussion 36	3
1448	Interactions between ACE Inhibitors and Diuretics. 1997 , 321-334	2
1447	Current perspective on the use of angiotensin-converting enzyme inhibitors in the management of coronary (atherosclerotic) artery disease. 1997 , 31, 1499-506	12
1446	Selecting antihypertensive drug therapy: the JNC-V controversy. 1997 , 3, 42-6	
1445	[Medical treatment of heart failure at a tertiary hospital of Sã Paulo]. 1997 , 69, 375-9	2
1444	Lisinopril Use in a Large Military Medical Center. 1997 , 162, 113-117	
1443	Reducing the burden of chronic heart failure. 1997 , 167, 61-2	6
1442	Potential Role of Angiotensin-Converting Enzyme Inhibition in Myocardial Ischemia and Current Clinical Trials. 1997 , 20, II-58	4
1441	[Drug treatment for stable coronary artery disease at primary and tertiary medical centers]. 1997 , 69, 165-8	
1440	Heart Failure in Women. 1997 , 9, 511-519	18
1439	Pharmaceutical Companies and Managed Care in the UK. 1997 , 1, 100-102	1
1438	Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. 1997 , 126, 1-12	130

1437	Evaluating the association between drug use and outcome--should the information from observational studies affect therapeutic use?. 1997 , 88 Suppl 3, 63-7	3
1436	The place of amiodarone: an overview of the four recent large controlled trials. 1997 , 27, 582-90	3
1435	Heart failure--outlooks and strategies for treatment. 1997 , 27, 485-91	
1434	Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Management Committee on behalf of the High Blood Pressure Research Council of Australia. 1997 , 24, 188-92	39
1433	Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure. 1997 , 11, 83-9	5
1432	Design of the cardiac insufficiency bisoprolol study II (OBIS II). 1997 , 11, 138-142	26
1431	Classification of sudden and arrhythmic death. 1997 , 20, 2545-52	35
1430	Use of left ventricular ejection fraction or wall-motion score index in predicting arrhythmic death in patients following an acute myocardial infarction. The TRACE Study Group. 1997 , 20, 2553-9	21
1429	Acute hemodynamic improvement by pacing in patients with severe congestive heart failure. 1997 , 20, 313-24	72
1428	CV-11974: A Nonpeptide Angiotensin II Type 1 Receptor Antagonist. 1997 , 15, 59-74	4
1427	Congestive heart failure and arrhythmias: therapeutic modalities. 1997 , 8, 89-97	10
1426	The GISSI Story (1983-1996): A Comprehensive Review. 1997 , 10, 3-28	3
1425	Nonsustained Ventricular Tachycardia. 1997 , 2, 79-91	
1424	Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. 1997 , 51, 164-72	146
1423	Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. 1997 , 40, 85-93	9
1422	Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. 1997 , 79, 794-8	67
1421	Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure. 1997 , 79, 909-13	61
1420	Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. 1997 , 79, 1118-20	74

1419	Relation of daily activity levels in patients with chronic heart failure to long-term prognosis. 1997 , 79, 1364-9	117
1418	Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 1997 , 79, 1645-50	369
1417	Response of symptomatic myocardial ischemia in ischemic cardiomyopathy to intensive vasodilator therapy. 1997 , 80, 212-4	1
1416	Association between diuretic use, clinical response, and death in acute heart failure. 1997 , 80, 519-22	41
1415	Effect of ramipril on mitral regurgitation secondary to mitral valve prolapse. 1997 , 80, 655-8	33
1414	Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. 1997 , 80, 110A-117A	54
1413	Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. 1997 , 80, 1101-4	61
1412	Short- and long-term reproducibility of heart rate variability in patients with long-standing type I diabetes mellitus. 1997 , 80, 1198-202	44
1411	Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. 1997 , 80, 14H-27H	33
1410	Economics of treating heart failure. 1997 , 80, 33H-38H	30
1409	Symposium summary remarks. 1997 , 80, 89H-90H	
1408	The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. 1997 , 80, 9J-14J	43
1407	Overview of the treatment of heart failure. 1997 , 80, 2L-6L	19
1406	Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. 1997 , 80, 46L-54L	29
1405	Peripartum cardiomyopathy: a longitudinal echocardiographic study. 1997 , 177, 1129-32	64
1404	A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. 1997 , 79, 58-63	266
1403	Categorization of abnormal left ventricular function: comparison between radionuclide angiographic and echocardiographic technique in postinfarction patients. 1997 , 79, 108-11	3
1402	Enalapril reduces QTc dispersion in mild congestive heart failure secondary to coronary artery disease. 1997 , 79, 328-33	39

1401	Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significance. 1997 , 18, 557-60; discussion 561-7	32
1400	When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?. 1997 , 18, 613-20; discussion 661-6	44
1399	Catheter ablation of ventricular tachycardia in Chagasic Cardiomyopathy. 1997 , 20, 169-74	11
1398	The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil). 1997 , 20, 320-6	40
1397	Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. 1997 , 20, 441-5	24
1396	Reverse remodeling in heart failure with intensification of vasodilator therapy. 1997 , 20, 697-702	32
1395	Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigations of Arrhythmia and Mortality ON Dofetilide. 1997 , 20, 704-10	84
1394	Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. 1997 , 20, 949-54	61
1393	Classification of heart failure in population based research: an assessment of six heart failure scores. 1997 , 13, 491-502	79
1392	Effect of ramipril on heart rate variability in digitalis-treated patients with chronic heart failure. 1997 , 11, 531-6	5
1391	Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors. 1997 , 4, 167-175	3
1390	Role of Amiodarone in Heart Failure. 1997 , 2, 3-10	1
1389	Asymptomatic Left Ventricular Dysfunction. 1997 , 2, 11-22	6
1388	Arrhythmias Associated with Dilated Cardiomyopathy. 1997 , 1, 223-228	
1387	[Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany]. 1997 , 92, 499-504	
1386	Does digoxin still have a role in congestive heart failure?. 1997 , 64, 833-7	2
1385	Effects of the AT1-selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs. 1997 , 35, 61-8	14
1384	Medical treatment of heart failure: the Canadian Cardiovascular Society's Consensus Conference revisited. 1997 , 10, 711-6	1

1383	Sudden death in heart failure. 1997 , 1, 249-260	3
1382	Is there a role for warfarin or aspirin therapy in heart failure?. 1997 , 1, 271-276	3
1381	Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. 1997 , 12, 523-30	100
1380	Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure. Effect of physician specialty and patient characteristics. 1997 , 12, 563-6	54
1379	Heart failure and angiotensin-converting enzyme inhibitors. Is there a need for specialty care?. 1997 , 12, 581-2	4
1378	Angiotensin-converting enzyme (ACE) inhibitors and angioedema. 1997 , 136, 153-158	12
1377	Inhibition of pulmonary endothelial angiotensin converting enzyme activity by trandolaprilat in vivo. 1997 , 41, 22-30	3
1376	Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. 1998 , 63, 79-86	56
1375	Dopamine Beta-Hydroxylase Inhibition: A Potential Therapy for the Treatment of Congestive Heart Failure. 1998 , 2, 195-201	2
1374	Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. 1998 , 21, 103-8	77
1373	Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. 1998 , 21, 261-8	18
1372	Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction. 1998 , 21, 807-11	11
1371	Effects of dichloroacetate in patients with congestive heart failure. 1998 , 21, 888-92	52
1370	The effects of an angiotensin-converting inhibitor (enalapril) on patients with mild cardiac failure--evaluating cardiac function based on the relationship between daily walking pace and heart rate. 1998 , 21, 893-8	3
1369	The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure. 1998 , 21, 899-904	7
1368	Decrease with age in frequency of the homozygous deletional angiotensin-converting enzyme genotype in hypertensive patients. 1998 , 25, 928-31	2
1367	Effects of long-term treatment with trandolapril on sarcoplasmic reticulum function of cardiac muscle in rats with chronic heart failure following myocardial infarction. 1998 , 123, 326-34	18
1366	A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators. 1998 , 9, 864-91	37

- 1365 Nitrates in Left Ventricular Dysfunction and Congestive Heart Failure. **1998**, 81, 54A-56A
- 1364 Design of a randomized, placebo-controlled multicenter trial on the long-term effects of intermittent transdermal nitroglycerin on left ventricular remodeling after acute myocardial infarction. Transdermal Nitroglycerin Investigators Group. **1998**, 81, 719-24 7
- 1363 Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. **1998**, 81, 1178-81 46
- 1362 William Howard Frishman, MD: a conversation with the editor. Interview by William Clifford Roberts. **1998**, 81, 1323-38
- 1361 Relation between severity of coronary artery disease, left ventricular function and myocardial infarction, and influence of the ACE I/D gene polymorphism. **1998**, 82, 160-5 20
- 1360 Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. **1998**, 82, 25H-30H 70
- 1359 Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. **1998**, 82, 881-7 70
- 1358 Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. **1998**, 82, 1299-301, A10 43
- 1357 Peripartum cardiomyopathy: a comprehensive review. **1998**, 178, 409-14 83
- 1356 Coronary artery bypass surgery as treatment for ischemic heart failure: the predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. **1998**, 115, 791-9 83
- 1355 Are symptoms the most important target for therapy in chronic heart failure?. **1998**, 41, 59-64 8
- 1354 Treatment guidelines in heart failure. **1998**, 41, 65-72 17
- 1353 Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure. **1998**, 41, 225-36 15
- 1352 Impaired endothelium-dependent relaxation in large, but not small arteries in rats after coronary ligation. **1998**, 355, 167-74 2
- 1351 Modeling the cellular basis of altered excitation-contraction coupling in heart failure. **1998**, 69, 497-514 30
- 1350 6 The patient under chronic medication. **1998**, 12, 405-418
- 1349 Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and angiotensin-converting enzyme inhibitor. **1998**, 31, 93-9 18
- 1348 Latissimus Dorsi Cardiomyoplasty. **1998**, 7, 57-60

1347 Abstract. **1998**, 7, 25

1346 Abstract. **1998**, 7, 25

1345 Abstract. **1998**, 7, 25-26

1344 Abstract. **1998**, 7, 26

1343 Abstract. **1998**, 7, 26

1342 Estimation of the dissociation constants for pulmonary endothelial angiotensin converting enzyme reactions withtrandolaprilat and enalaprilat in vivo. **1998**, 44, 80-86 2

1341 Beta-blocker treatment in heart failure. Role of heart rate reduction. **1998**, 93 Suppl 1, 148-55 11

1340 [The renin-angiotensin system in cardiovascular diseases]. **1998**, 93, 416-25 4

1339 [Heart failure: diagnosis and therapy]. **1998**, 93, 555-6

1338 Sudden cardiac death in patients with congestive heart failure: toward a unified rational treatment approach. **1998**, 5, 80-5

1337 Evolving therapeutic concepts and imaging in ischemic cardiomyopathy. **1998**, 5, 598-608 5

1336 Repeatability of automatic left ventricular cavity volume measurements from myocardial perfusion SPECT. **1998**, 5, 477-83 48

1335 Peptidyl human heart chymase inhibitors. 1. Synthesis and inhibitory activity of difluoromethylene ketone derivatives bearing P' binding subsites. **1998**, 8, 913-8 21

1334 Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failure. **1998**, 45, 559-66 2

1333 Heart failure. Symposium proceedings. 21-24 April 1998. **1998**, 46, 360-2

1332 Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine. **1998**, 63, 175-8 11

1331 Percent achieved of predicted peak exercise oxygen uptake and kinetics of recovery of oxygen uptake after exercise for risk stratification in chronic heart failure. **1998**, 64, 117-24 25

1330 Valsartan in heart failure patients previously untreated with an ACE inhibitor. **1998**, 65, 239-46 68

- 1329 La r adaptation des insuffisants cardiaques chroniques. Un concept r ent. **1998**, 41, 67-75
- 1328 Left-ventricular dysfunction. **1998**, 351, 371-372
- 1327 Assessment of heart failure with plasma natriuretic peptides. **1998**, 351, 444; author reply 445 3
- 1326 Time to focus on the more typical heart-failure patients. **1998**, 352, 3-4 63
- 1325 Biochemical detection of left-ventricular systolic dysfunction. **1998**, 351, 9-13 853
- 1324 Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. **1998**, 352, 13-6 135
- 1323 Successes and failures of current treatment of heart failure. **1998**, 352 Suppl 1, SI19-28 71
- 1322 15 years of heart-failure trials: what have we learned?. **1998**, 352 Suppl 1, SI29-33 37
- 1321 Organisation of the care of patients with heart failure. **1998**, 352 Suppl 1, SI15-8 24
- 1320 The molecular and cellular pathophysiology of heart failure. **1998**, 27, 3-19; quiz 20-1 44
- 1319 Postmarketing drug surveillance: an epidemiologic approach. **1998**, 20 Suppl C, C32-9 7
- 1318 New developments in cardiovascular adrenergic receptor pharmacology: molecular mechanisms and clinical relevance. **1998**, 12, 80-95 23
- 1317 Regulation of myocardial extracellular matrix components by mechanical and chemical growth factors. **1998**, 7, 145-51 21
- 1316 Antihypertensive drug treatment and fibrinolytic function. **1998**, 11, 378-84 27
- 1315 Paradoxical hypertension after reversal of heart failure in patients treated with intensive vasodilator therapy. **1998**, 11, 1041-7 2
- 1314 The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. **1998**, 11, 1433-41 16
- 1313 Cardiovascular disease prevention research at the National Heart, Lung, and Blood Institute. **1998**, 14, 317-30 4
- 1312 Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. **1998**, 31, 419-25 188

1311	Differential effect of acute baroreceptor unloading on cardiac and systemic sympathetic tone in congestive heart failure. 1998 , 31, 583-7	56
1310	Anticoagulation in dilated cardiomyopathy. 1998 , 31, 745-8	81
1309	Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. 1998 , 31, 749-53	184
1308	Increased oxidative stress in patients with congestive heart failure. 1998 , 31, 1352-6	454
1307	Functional Effects of Endogenous Bradykinin in Congestive Heart Failure. 1998 , 31, 1679-1686	51
1306	Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. 1998 , 32, 360-7	63
1305	Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. 1998 , 32, 438-43	42
1304	Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. <i>Studies of Left Ventricular Dysfunction</i> . 1998 , 32, 695-703	745
1303	Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. <i>Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme</i> . 1998 , 32, 686-92	35
1302	Effects of angiotensin II on expression of the gap junction channel protein connexin43 in neonatal rat ventricular myocytes. 1998 , 32, 800-7	80
1301	Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. 1998 , 32, 921-6	211
1300	Etiology and response to drug treatment in heart failure. 1998 , 32, 1167-72	85
1299	Administration of an intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: comparison with cine magnetic resonance imaging. 1998 , 32, 1426-32	189
1298	Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. 1998 , 32, 1228-37	136
1297	Effect of cilazapril on ventricular remodeling assessed by Doppler-echocardiographic assessment and cardiac gene expression. 1998 , 12, 57-70	18
1296	Oxidative stress and the pathogenesis of heart failure. 1998 , 16, 665-75, viii-ix	41
1295	Sleep apnea in congestive heart failure. 1998 , 19, 99-113	100
1294	Chronic heart failure and morphine treatment. 1998 , 73, 194	1

1293	Health of older women. 1998 , 82, 127-44	21
1292	Carvedilol. <i>New England Journal of Medicine</i> , 1998 , 339, 1759-65	59.2 208
1291	Pathogenesis of sodium and water retention in cardiac failure. 1998 , 20, 773-81	20
1290	Sympathetic Control of Circulation in Hypertension and Congestive Heart Failure. 1998 , 7, 40-45	6
1289	Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure. 1998 , 7, 1897-914	19
1288	How do GPs use clinical information in their judgements of heart failure? A clinical judgement analysis study. 1998 , 16, 95-100	34
1287	Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. 1998 , 83, 1182-91	400
1286	Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. 1998 , 136, 672-80	13
1285	Serial exercise testing and prognosis in selected patients considered for cardiac transplantation. 1998 , 135, 221-9	33
1284	Myocardial infarction, ventricular remodeling, and angiotensin-converting enzyme inhibition: where we stand today. 1998 , 136, 931-3	3
1283	Acute hemodynamic effects of endogenous adenosine in patients with chronic heart failure. 1998 , 136, 37-42	10
1282	Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?. 1998 , 136, 43-8	50
1281	Clinical definition and epidemiology of advanced heart failure. 1998 , 135, S204-15	113
1280	Current medical therapy for advanced heart failure. 1998 , 135, S231-48	38
1279	Current and novel pharmacologic approaches in advanced heart failure. 1998 , 135, S249-63	18
1278	Optimizing therapy for complex or refractory heart failure: a management algorithm. 1998 , 135, S293-309	76
1277	JNC V revisited: standard of care or individualized treatment for hypertension?. 1998 , 135, S8-15	0
1276	Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-1995. 1998 , 135, 367-72	33

1275	Restoring function in failing hearts: the effects of beta blockers. 1998 , 104, 163-9	22
1274	Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. 1998 , 105, 275-315	77
1273	Calcium antagonists and cancer. Is there really a link?. 1998 , 18, 1-7	7
1272	Choosing the most appropriate treatment for stable angina. Safety considerations. 1998 , 19, 23-44	33
1271	Amlodipine in ischaemic left ventricular dysfunction with mild to moderate heart failure. 1998 , 16, 289-96	1
1270	ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. 1998 , 139, 153-9	64
1269	Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. 1998 , 140, 199-270	422
1268	Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure. 1998 , 4, 185-91	26
1267	Strategies for patient recruitment into clinical trials. 1998 , 4, 235-6	2
1266	Beta-blockade and amiodarone therapy: twin brothers from different parents. 1998 , 4, 289-94	1
1265	AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns. 1998 , 4, 311-23	15
1264	Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action. 1998 , 4, 325-32	6
1263	Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. 1998 , 4, 115-9	25
1262	The brain is a possible target for an angiotensin-converting enzyme inhibitor in the treatment of chronic heart failure. 1998 , 4, 139-44	14
1261	Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. 1998 , 4, 3-8	33
1260	Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers. 1998 , 16, 711-25, ix	8
1259	[Trends of morbidity and mortality in chronic heart failure in Catalonia]. 1998 , 51, 972-6	18
1258	The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study. 1998 , 12, 423-8	8

1257	Calcium sensitising agents in heart failure. 1998 , 12, 191-204	28
1256	Treatment Expectations in Congestive Heart Failure. 1998 , 4, 41-49	2
1255	Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. 1998 , 98, 1735-41	46
1254	Evidence-based pharmacotherapy: review of basic concepts and applications in clinical practice. 1998 , 32, 1193-200	11
1253	A congestive heart failure project with measured improvements in care. 1998 , 21, 472-86	24
1252	Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. 1998 , 98, 757-65	90
1251	Carvedilol in the treatment of hypertension--a review of the clinical data base. 1998 , 47, 67-80	5
1250	Social support, social disability and their role as predictors of depression among patients with congestive heart failure. 1998 , 26, 87-95	43
1249	Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II. 1998 , 82, 503-12	30
1248	Mechanical circulatory support and cardiac transplantation. 1998 , 97, 2079-90	119
1247	Anesthesia for Heart Transplantation. 1998 , 2, 131-139	1
1246	Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. 1998 , 98, 2282-9	757
1245	Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. 1998 , 83, 743-51	107
1244	Local angiotensin II generation in the rat heart: role of renin uptake. 1998 , 82, 13-20	91
1243	Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts. 1998 , 97, 55-65	152
1242	Mechanism of beta-adrenergic receptor upregulation induced by ACE inhibition in cultured neonatal rat cardiac myocytes: roles of bradykinin and protein kinase C. 1998 , 97, 2268-73	31
1241	Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. 1998 , 97, 2316-22	353
1240	Quality of life in chronic heart failure: cilazapril and captopril versus placebo. Cilazapril-Captopril Multicentre Group. 1998 , 79, 593-8	8

1239	Differences in tissue angiotensin II-forming pathways by species and organs in vitro. 1998 , 32, 514-20	120
1238	Angiotensin II type 1 receptor A1166C gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme gene polymorphism on the risk of these diseases. 1998 , 19, 1657-65	40
1237	Recent advances. <i>Cardiology</i> . 1998 , 316, 911-5	2
1236	Anti-aldosterone therapy in the treatment of heart failure: new thoughts on an old hormone. 1998 , 7, 753-9	4
1235	Endothelial dysfunction: implications for therapy of cardiovascular diseases. 1998 , 32, 459-70	27
1234	Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. 1998 , 31, 925-8	41
1233	Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). 1998 , 98, 1510-6	919
1232	Evidence into practice, experimentation and quasi experimentation: are the methods up to the task?. 1998 , 52, 75-81	15
1231	Chronic heart failure in the United States: a manifestation of coronary artery disease. 1998 , 97, 282-9	640
1230	Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. 1998 , 98, 2849-54	53
1229	Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II. 1998 , 80, 134-40	17
1228	Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. 1998 , 97, 2202-12	522
1227	Implantable left ventricular assist devices. <i>New England Journal of Medicine</i> , 1998 , 339, 1522-33	59.2 395
1226	Angiotensin-converting enzyme inhibitors. 1998 , 97, 1411-20	554
1225	Overview of studies of exercise training in chronic heart failure: the need for a prospective randomized multicentre European trial. 1998 , 19, 830-41	52
1224	Quality of care for two common illnesses in teaching and nonteaching hospitals. 1998 , 17, 194-205	62
1223	Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. 1998 , 98, 1636-43	78
1222	Multiple Risk Factors in Cardiovascular Disease. 1998 ,	

1221	Myocardial contractile efficiency and oxygen cost of contractility are preserved during transition from compensated hypertrophy to failure in rats with salt-sensitive hypertension. 1998 , 31, 949-60	31
1220	Amlodipine monotherapy, angiotensin-converting enzyme inhibition, and combination therapy with pacing-induced heart failure. 1998 , 31, 755-65	15
1219	Quality improvement in the diagnosis and treatment of heart failure by participating Indiana and Kentucky hospitals. 1998 , 21, 461-71	2
1218	Pharmacologic Management of Chronic Heart Failure: A Review. 1998 , 2, 168-190	2
1217	Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. 1998 , 98, 2141-7	233
1216	Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial. 1998 , 97, 2017-24	42
1215	Clinical insights into the pathogenesis of primary pulmonary hypertension. 1998 , 114, 237S-241S	44
1214	Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. 1998 , 19, 1808-13	31
1213	Hypertension-induced congestive heart failure. 1998 , 47, 5-7	4
1212	Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure. 1998 , 39, 617-24	32
1211	Calcium channel blockers in heart failure. 1998 , 89 Suppl 1, 38-46	40
1210	Pathophysiology of the Renin-Angiotensin System in Heart Failure. 1998 , 305-322	
1209	Treatment of Heart Failure. 1998 , 343-368	
1208	Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure?. 1998 , 19, 842-6	120
1207	Innovations in the pharmacologic management of heart failure. 1998 , 9, 172-91; quiz 327-8	6
1206	Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. 1998 , 129, 286-93	192
1205	Long-term effects on cardiac output and peripheral resistance in patients treated with enalapril after acute myocardial infarction. CONSENSUS II Multi-Echo Study Group. Cooperative New Scandinavian Enalapril Survival Study. 1998 , 89, 291-6	2
1204	Angiotensin II type 1-receptor antagonist candesartan cilexetil prevents left ventricular dysfunction in myocardial infarcted rats. 1998 , 78, 45-54	19

1203	Risk stratification in chronic heart failure. 1998 , 19, 696-710	149
1202	Preventing disability in older people with chronic disease: what is a doctor to do?. 1998 , 46, 1314-6	2
1201	Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers. 1998 , 38, 477-91	6
1200	Evaluating the use of angiotensin-converting enzyme inhibitors for older nursing home residents with chronic heart failure. 1998 , 46, 1550-4	29
1199	Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. 1998 , 16, 761-9	59
1198	Hormonal and cardiorenal responses to acute saline loading in mild congestive heart failure--the effect of angiotensin converting enzyme inhibition. 1998 , 62, 29-35	4
1197	Baroreceptor sensitivity during the compensatory phase of left ventricular overloading. 1998 , 62, 773-8	1
1196	Recent advances. General medicine. 1998 , 317, 792-5	
1195	North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. 1998 , 316, 1369-75	53
1194	Cardiovascular ageing and heart failure. 1998 , 169, 480-4	8
1193	The endothelin system:a novel therapeutic target in cardiovascular disease. 1998 , 3, 95-112	3
1192	Management and outcomes of congestive heart failure: a prospective study of hospitalised patients. 1998 , 168, 115-8	35
1191	Current Concepts in the Management of Heart Failure. 1998 , 14, 228-239	
1190	Evaluation of ACE Inhibitor Therapy for Congestive Heart Failure in an Outpatient Setting. 1998 , 14, 7-11	1
1189	Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure. 1998 , 84, 1234-41	71
1188	Structure and in vitro function of human subcutaneous small arteries in mild heart failure. 1998 , 274, C1298-305	6
1187	Human neuropeptide Y potentiates alpha1-adrenergic blood pressure responses in vivo. 1998 , 275, H760-6	7
1186	[Heart failure at a large tertiary hospital of Sã Paulo]. 1998 , 71, 15-20	15

1185	Molecular beta-adrenergic signaling abnormalities in failing rabbit hearts after infarction. 1999 , 276, H1853-60	31
1184	Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. 1999 , 277, H2167-75	14
1183	Use of medical resources and quality of life of patients with chronic heart failure: a prospective survey in a large Italian community hospital. 1999 , 1, 411-7	22
1182	ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure. 1999 , 277, H1609-17	13
1181	Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. 1999 , 1, 385-93	10
1180	Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. 1999 , 276, H53-62	36
1179	NO modulates myocardial O ₂ consumption in the nonhuman primate: an additional mechanism of action of amlodipine. 1999 , 276, H2069-75	10
1178	Guidelines for hypertension in the elderly--1999 revised version. Ministry of Health and Welfare of Japan. 1999 , 22, 231-59	18
1177	Abstracts from the Evidence Supported Medicine Union/NHS Executive West Midlands Conference, 17-18 March 1999, Birmingham. 1999 , 3, 11-64	
1176	Correspondence. 1999 , 60, 70-71	2
1175	Cardiovascular Problems in Peritoneal Dialysis Patients: A Short Overview. 1999 , 19, 150-158	1
1174	9. Therapy for cardiac failure: treatments old and new. 1999 , 171, 265-271	1
1173	Tailored therapy to hemodynamic goals for advanced heart failure. 1999 , 1, 251-7	111
1172	Diabetes mellitus and congestive heart failure. Further knowledge needed. 1999 , 20, 789-95	119
1171	Drug-induced agranulocytosis in older people. A case series of 25 patients. 1999 , 28, 325-6	9
1170	New Treatment Strategies in Patients with Impaired Left Ventricular Systolic Function. Part II: Treatment of Moderate to Severe Cardiac Dysfunction. 1999 , 317, 312-317	
1169	Effects of imidapril on NOS expression and myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats. 1999 , 44, 518-26	41
1168	CE Credit: Endothelial Dysfunction and the Promise of ACE Inhibitors. 1999 , 99, 44	

1167	High prevalence and persistence of sleep apnoea in patients referred for acute left ventricular failure and medically treated over 2 months. 1999 , 20, 1201-9	115
1166	beta-Blockers in congestive heart failure. 1999 , 8, 1795-1805	3
1165	The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The united kingdom heart failure evaluation and assessment of risk trial (UK-HEART). 1999 , 20, 1335-41	72
1164	AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. 1999 , 20, 997-1008	63
1163	The merit of beta(1)-blockade in heart failure. 1999 , 20, 1761-3	1
1162	Age-related differences in management of heart disease: a study of cardiac medication use in an older cohort. Pacemaker Selection in the Elderly (PASE) Investigators. 1999 , 47, 145-50	24
1161	Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. 1999 , 91 Suppl 1, 19-22	25
1160	Racial differences in the outcome of left ventricular dysfunction. <i>New England Journal of Medicine</i> , 1999 , 340, 609-16	59.2 291
1159	Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. 1999 , 33, 961-8	63
1158	State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. 1999 , 34, 987-96	113
1157	Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice. 1999 , 84, 752-62	92
1156	Failure of women's hearts. 1999 , 99, 2334-41	119
1155	Trends in antihypertensive drug advertising, 1985-1996. 1999 , 99, 2055-7	54
1154	The renin-angiotensin system in essential hypertension: associations with cardiovascular risk. 1999 , 8, 70-8	15
1153	Clinical assessment of indication for ACE-inhibitor treatment early after acute myocardial infarction. 1999 , 33, 137-42	1
1152	Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. 1999 , 100, 1298-304	178
1151	Major beta blocker mortality trials in chronic heart failure: a critical review. 1999 , 82 Suppl 4, IV14-22	31
1150	Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. 1999 , 100, 1056-64	735

1149 Salt and Water Homeostasis. **1999**, 24, 27-66

1148 Role of angiotensin receptor blockers in heart failure: not yet RESOLVD. **1999**, 100, 1032-4 20

1147 Angiotensin induces inflammatory activation of human vascular smooth muscle cells. **1999**, 19, 1623-9 395

1146 TNF-alpha and heart failure. The difference between proof of principle and hypothesis testing. **1999**, 99, 3213-4 28

1145 Mechanisms and models in heart failure: A combinatorial approach. **1999**, 100, 999-1008 625

1144 Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. **1999**, 100, 2093-9 178

1143 Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. **1999**, 100, 1311-5 291

1142 Increase in Plasma Angiotensin II Levels After Chemical Blockade of AT1 Receptor Blockers, But Not With Antisense Oligodeoxynucleotide Directed at AT1 Receptor mRNA: A Major Benefit of Gene Therapy. **1999**, 4, 135-136 2

1141 Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. **1999**, 20, 1182-90 84

1140 DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. **1999**, 33, 1164-8 88

1139 Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. **1999**, 19, 2119-26 57

1138 Design Issues in Noninferiority/Equivalence Trials. **1999**, 33, 1205-1218 53

1137 Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. **1999**, 99, 2652-7 63

1136 New developments in the treatment of cardiac failure. **1999**, 81, 276-7 1

1135 Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus. **1999**, 16, 358-72 17

1134 Reappearance of the J-shaped curve. **1999**, 34, 1179-80 5

1133 Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays. **1999**, 82, 584-8 18

1132 ACE inhibitors and heart failure in hospital: any difference between cardiologists and general physicians?. **1999**, 75, 219-2 15

1131	The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. 1999 , 1, 7-18	93
1130	Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. 1999 , 47, 179-87	10
1129	The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. 1999 , 245, 435-43	10
1128	The health care costs of heart failure in Sweden. 1999 , 246, 275-84	126
1127	A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke. 1999 , 246, 549-59	14
1126	Renal response to captopril reflects state of local renin system in healthy humans. 1999 , 56, 635-41	25
1125	Comprehensive multidisciplinary programs for the management of patients with congestive heart failure. 1999 , 14, 130-5	115
1124	Knowledge, patterns of care, and outcomes of care for generalists and specialists. 1999 , 14, 499-511	167
1123	A random effects model for multivariate failure time data from multicenter clinical trials. 1999 , 55, 182-9	7
1122	Uncovering a multitude of sins: medication management in the home post acute hospitalisation among the chronically ill. 1999 , 29, 220-7	44
1121	Dilated cardiomyopathy: changing pathophysiological concepts and mechanisms of dysfunction. 1999 , 14, 64-74	14
1120	Perioperative care in left ventricular volume reduction. 1999 , 14, 136-40	0
1119	Improvement of exercise capacity of rats with chronic heart failure by long-term treatment with trandolapril. 1999 , 126, 1585-92	12
1118	The Value of Questionnaires in Assessing Physical Activity, Fitness, and Quality of Life. 1999 , 3, 305-311	2
1117	Cardiac Remodeling: From Concepts to Therapeutics. 1999 , 4, 7-20	1
1116	Workshop on Diagnosis and Treatment of Cardiac Maladaptive Remodeling. 1999 , 4, 97-100	
1115	Blacks were at greater risk of progression of heart failure and death from all causes than whites. 1999 , 3, 49	
1114	The diagnosis and treatment of asymptomatic left ventricular dysfunction. 1999 , 3, 31-33	

1113	Sudden death in dilated cardiomyopathy. 1999 , 22, 267-72	18
1112	The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy. 1999 , 22, 397-402	17
1111	Cardioprotective effect of orally administered angiotensin-converting enzyme inhibitor against ischemia. Reperfusion injury in the isolated rat heart. 1999 , 47, 425-31	2
1110	[Drug therapy for prognostic improvement after acute myocardial infarct]. 1999 , 24, 389-97	2
1109	Long-acting calcium channel antagonist pranidipine prevents ventricular remodeling after myocardial infarction in rats. 1999 , 14, 111-9	8
1108	Sympathetic activation in heart failure: A target of therapeutic approaches. 1999 , 88, S005-11	1
1107	Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation. 1999 , 94, 128-35	4
1106	Symptomatic systolic ventricular failure. 1999 , 1, 20-8	
1105	Review of the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). 1999 , 1, 29-30	1
1104	Current issues regarding beta-adrenergic blockade in patients with congestive heart failure: patient selection, nonselective versus selective blockade, management of adverse effects, and indications for withdrawal of therapy. 1999 , 1, 47-54	1
1103	Refractory heart failure. 1999 , 1, 67-81	3
1102	Hypertensive cardiovascular disease in African Americans. 1999 , 1, 521-8	26
1101	The renin-angiotensin system antagonism in the treatment of hypertension. 1999 , 1, 275-7	1
1100	Endothelin in heart failure. 1999 , 1, 62-8	5
1099	Underutilization of ACE inhibitors in heart failure. 1999 , 19, 1296-307	19
1098	The role of organic nitrates in the treatment of heart failure. 1999 , 41, 255-64	15
1097	Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. 1999 , 41, 265-300	27
1096	Beta blocker treatment in heart failure. 1999 , 41, 301-21	34

1095	Late results of Senning operation. 1999 , 117, 488-95	87
1094	End-point interpretation in clinical trials: the case for discipline. 1999 , 20, 40-9; discussion 50-1	53
1093	Detecting selection bias in randomized clinical trials. 1999 , 20, 319-27	131
1092	Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. 1999 , 83, 43-7	92
1091	Prognostic utility of myocardial viability assessment. 1999 , 83, 696-702, A7	31
1090	Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. 1999 , 83, 740-4	39
1089	Has the survival of the heart failure population changed? Lessons from trials. 1999 , 83, 112D-119D	54
1088	Potential benefit of biventricular pacing in patients with congestive heart failure and ventricular tachyarrhythmia. 1999 , 83, 143D-150D	120
1087	Cost effectiveness of carvedilol for heart failure. 1999 , 83, 890-6	64
1086	Gender differences and practice implications of risk factors for frequent hospitalization for heart failure in an urban center serving predominantly African-American patients. 1999 , 83, 1350-5	28
1085	Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts. 1999 , 83, 92H-98H	23
1084	White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). 1999 , 84, 252-7	73
1083	Comparison of echocardiography and radionuclide angiography as predictors of mortality in patients with left ventricular dysfunction (studies of left ventricular dysfunction). 1999 , 84, 299-303	25
1082	Amlodipine therapy in congestive heart failure: hemodynamic and neurohormonal effects at rest and after treadmill exercise. 1999 , 84, 3L-15L	8
1081	Cardiac angiotensin-converting enzyme activity in myocardial infarction. 1999 , 84, 774-8	10
1080	Beta-blocker therapy in heart failure: pathophysiology and clinical results. 1999 , 24, 421-60	4
1079	Shock: A comparative physiologic approach to mechanisms and therapy. 1999 , 18, 1-14	3
1078	Incorporating economic analysis in evidence-based guidelines for mental health: the profile approach. 1999 , 2, 13-19	5

1077	The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. <i>New England Journal of Medicine</i> , 1999 , 341, 709-17 ²	6637
1076	Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing. 1999 , 15, 535-50	26
1075	Health-related quality of life in elderly patients with heart failure. 1999 , 33, 278-85	72
1074	Costs associated with symptomatic systolic heart failure. 1999 , 16, 399-407	10
1073	1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. 1999 , 21, 1009-60	410
1072	Summary of randomized trials of angiotensin converting enzyme inhibitors. 1999 , 21, 835-45	16
1071	Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why?. 1999 , 21, 553-62	10
1070	Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. 1999 , 99, 2626-32	1052
1069	Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. 1999 , 33, 1447-52	106
1068	Cost of hospitalizations for heart failure: sodium retention versus other decompensating factors. 1999 , 28, 102-9	22
1067	Factors influencing patient compliance with therapeutic regimens in chronic heart failure: A critical incident technique analysis. 1999 , 28, 334-41	80
1066	The diagnosis and treatment of asymptomatic left ventricular dysfunction. 1999 , 3, 31-33	
1065	Prognostic factors in acute cardiogenic pulmonary edema. 1999 , 17, 329-32	24
1064	Prognostic indices in heart transplant candidates after the first hospitalization triggered by the need for intravenous pharmacologic circulatory support. 1999 , 18, 654-63	14
1063	Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?. 1999 , 12, 195S-203S	18
1062	Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. 1999 , 12, 1071-6	72
1061	Angiotensin II and connective tissue: homeostasis and reciprocal regulation. 1999 , 82, 1-17	34
1060	The prognostic implications of outpatient diuretic dose in heart failure. 1999 , 71, 219-25	20

1059	A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines. 1999 , 47, 37-52	31
1058	Outstanding issues in use of disease-modifying agents in rheumatoid arthritis. 1999 , 353, 257-8	11
1057	Shifts in mortality curves. 1999 , 354, 2169	
1056	Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. 1999 , 354, 9-12	138
1055	Shifts in mortality curves: saving or extending lives?. 1999 , 354, 1378-81	38
1054	Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). 1999 , 353, 2001-2007	3766
1053	Current and novel pharmacologic approaches in advanced heart failure. 1999 , 28, 227-42	1
1052	Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. 1999 , 33, 640-6	108
1051	Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. 1999 , 33, 916-23	116
1050	Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. 1999 , 33, 951-8	206
1049	Delapril versus enalapril in patients with congestive heart failure. 1999 , 60, 446-457	2
1048	Generic drugs: the Canadian perspective. 1999 , 31, 16S-18S	2
1047	The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. 1999 , 67, 723-30	281
1046	Selección y evaluación de pacientes candidatos a trasplante cardíaco. 1999 , 52, 604-616	1
1045	Unstable angina. Introduction. 1999 , 17, xiii-xvii	1
1044	The adverse health effects of tobacco and tobacco-related products. 1999 , 26, 463-98	25
1043	[Practice guidelines of the Spanish Society of Cardiology. Recommendations for the use of antithrombotic treatment in cardiology]. 1999 , 52, 801-20	19
1042	Heart failure. 1999 , 17, 123-35	27

1041	Heart failure treatments: issues of safety versus issues of quality of life. 1999 , 20, 1-7	1
1040	Drug Use Patterns in a Very Elderly Population. 1999 , 17, 389-398	24
1039	Insights from the study of heart rate variability. 1999 , 50, 249-61	402
1038	Drug-induced heart failure. 1999 , 33, 1152-62	84
1037	Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. 1999 , 33, 1163-73	46
1036	Does heart failure confer a hypercoagulable state? Virchow's triad revisited. 1999 , 33, 1424-6	278
1035	Antiadrenergic effect of chronic amiodarone therapy in human heart failure. 1999 , 33, 1553-9	28
1034	Prediction of hospital readmission for heart failure: development of a simple risk score based on administrative data. 1999 , 33, 1560-6	181
1033	Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. 1999 , 33, 1948-55	1083
1032	Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. 1999 , 33, 1926-34	104
1031	Determinant of microvolt-level T-wave alternans in patients with dilated cardiomyopathy. 1999 , 34, 374-80	84
1030	EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. 1999 , 34, 876-84	9
1029	Clinical profiles of four large pedigrees with familial dilated cardiomyopathy: preliminary recommendations for clinical practice. 1999 , 34, 837-47	47
1028	Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. 1999 , 34, 983-8	100
1027	Neuroendocrine activation in heart failure is modified by endurance exercise training. 1999 , 34, 1170-5	150
1026	Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure. 1999 , 34, 2072-7	27
1025	Angiotensin-converting enzyme inhibitors and cytokines in heart failure: dose and effect?. 1999 , 34, 2068-71	10
1024	Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis. 1999 , 145, 309-14	52

1023	Blacks were at greater risk of progression of heart failure and death from all causes than whites. 1999 , 3, 49	
1022	Heart failure disease management: a critical review. 1999 , 5, 64-75	159
1021	Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. 1999 , 5, 155-60	124
1020	Beneficial effects of long-term treatment with enalapril on cardiac function and heart rate variability in patients with old myocardial infarction. 1999 , 5, 292-9	6
1019	Vasopressin: a therapeutic target in congestive heart failure?. 1999 , 5, 347-56	44
1018	Variations in family physicians' and cardiologists' care for patients with heart failure. 1999 , 138, 826-34	48
1017	ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. 1999 , 138, 843-8	18
1016	Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). 1999 , 138, 849-55	126
1015	Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. 1999 , 138, 1126-32	196
1014	Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. 1999 , 138, 254-60	41
1013	Effect of exercise training on heart rate variability in healthy older adults. 1999 , 138, 567-76	110
1012	Cardiac troponins in congestive heart failure. 1999 , 138, 646-53	97
1011	Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. 1999 , 138, 654-62	43
1010	Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. 1999 , 137, 658-65	61
1009	Contemporary issues in heart failure. 1999 , 138, 5-8	5
1008	Heart failure: A case for subspecialized care management. 1999 , 138, 14-6	3
1007	Insights into the contemporary epidemiology and outpatient management of congestive heart failure. 1999 , 138, 87-94	119
1006	Assimilating new therapeutic interventions into clinical practice: how does hypertension compare with other therapeutic areas?. 1999 , 138, 256-60	11

1005	Quality of care for patients hospitalized with heart failure at academic medical centers. 1999 , 137, 1028-34	43
1004	Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. 1999 , 137, 1035-43	37
1003	Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. 1999 , 137, 1094-9	36
1002	Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors. 1999 , 137, S25-S34	23
1001	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data. 1999 , 137, S115-9	11
1000	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective. 1999 , 137, S120-2	2
999	Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. 1999 , 137, 79-92	38
998	Diuretic treatment and diuretic resistance in heart failure. 1999 , 106, 90-6	141
997	Clinical outcomes in heart failure: report from a community hospital-based registry. 1999 , 107, 549-55	66
996	Left ventricular end-systolic wall stress is a potent prognostic variable in patients with dilated cardiomyopathy. 1999 , 63, 196-200	13
995	Improved survival of idiopathic dilated cardiomyopathy in the 1990s. 1999 , 63, 333-8	14
994	Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. 1999 , 318, 234-7	34
993	Randomised controlled trials in cardiovascular medicine: past achievements, future challenges. 1999 , 319, 564-8	23
992	The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. 1999 , 111, 406-16	130
991	Influence of aetiology on the effects of treatment in heart failure. 1999 , 6, 131-9	3
990	Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. 1999 , 159, 257-61	174
989	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. 1999 , 17, 151-183	467
988	Is the prognosis of heart failure improving?. 1999 , 1, 229-41	129

987	Effective management of complex heart failure. 1999 , 105, 17-24	4
986	Treatment of arrhythmias in heart failure. 1999 , 1, 133-7	2
985	Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. 1999 , 1, 73-9	11
984	Beta-blockers for advanced heart failure--how far can you go?. 1999 , 1, 259-62	3
983	1999 World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension. 1999 , 8, 9-43	42
982	Primary care physicians: champions of or an impediment to optimal care of the patient with heart failure?. 1999 , 1, 11-5	20
981	Sudden death in heart failure: vascular or electrical?. 1999 , 1, 41-5	57
980	Heart failure: why and how to define it?. 1999 , 1, 7-10	18
979	Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. 1999 , 99, 2658-64	175
978	Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction. 1999 , 47, 302-8	32
977	Underutilization of ACE inhibitors in older persons. 1999 , 47, 1385-6	1
976	Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. 1999 , 318, 368-72	122
975	Non-compliance and knowledge of prescribed medication in elderly patients with heart failure. 1999 , 1, 145-9	152
974	Effects of aerobic exercise training on indices of ventricular repolarization in patients with chronic heart failure. 1999 , 116, 83-7	50
973	Phosphodiesterase III inhibitors for heart failure. 2000 ,	
972	Beta blockade in patients with congestive heart failure. Why, who, and how. 2000 , 108, 103-6, 109-10, 116-8	1
971	Chapter 7. Advances in the understanding and treatment of congestive heart failure (HF). 2000 , 35, 63-72	
970	Evaluation of brain natriuretic peptide in the diagnosis of heart failure. 2000 , 93, 19-25	53

969	A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. 2000 , 2, 423-9	34
968	Hemodynamic and hormonal effects of the angiotensin II antagonist, candesartan cilexetil, in patients with congestive heart failure. 2000 , 93, 175-82	9
967	Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. 2000 , 2, 439-46	39
966	Feasibility and accuracy of left ventricular volumes and ejection fraction determination by fundamental, tissue harmonic, and intravenous contrast imaging in difficult-to-image patients. 2000 , 13, 216-24	75
965	Clinical characteristics and prognosis of hospitalized patients with congestive heart failure--a study in Fukuoka, Japan. 2000 , 64, 953-9	69
964	Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. 2000 , 64, 365-9	51
963	Effect of beta-blocker therapy on severe ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. 2000 , 64, 87-92	6
962	Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure?. 2000 , 160, 1409-13	38
961	Drug Therapy of Heart Failure in the Elderly. 2000 , 30, 274-278	0
960	Optimising direct access ECHO referral in suspected heart failure. 2000 , 45, 43-4	9
959	Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. 2000 , 320, 220-4	61
958	Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. 2000 , 321, 1113-6	17
957	That was the year that was: an evidence-based clinical geriatrics update 1998-1999. 2000 , 48, 1717-25	1
956	Cardiovascular pharmacology: new drugs and new indications. 2000 , 13, 5-13	1
955	Soundbites and snapshots: what is a day?. 2000 , 28, 2169-70	1
954	Cost-effectiveness of noninvasive ventilation for acute chronic obstructive pulmonary disease: cashing in too quickly. 2000 , 28, 2170-1	2
953	Treatment of Edematous Disorders with Diuretics. 2000 , 319, 25-37	6
952	Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. 2001 , CD003333	8

951	Antiperoxynitrite strategies for the experimental therapy of shock. 2000 , 28, 2156-7	8
950	Continuous monitoring of cardiac output: how many assumptions are valid?. 2000 , 28, 2168-9	3
949	A new score to detect neonatal nosocomial infection: "a rule of 14". 2000 , 28, 2166-7	4
948	Interaction of oxyradicals, antioxidants, and nitric oxide during sepsis. 2000 , 28, 2161-2	46
947	Advances in mechanical bridge to heart transplantation. 2000 , 5, 126-133	1
946	Update on recent clinical trials in congestive heart failure. 2000 , 15, 293-303	11
945	Mannitol: a therapeutic alternative in the treatment of acute hyponatremia?. 2000 , 28, 2152-3	4
944	Exogenous surfactant and furosemide: is more better?. 2000 , 28, 2153-4	0
943	Endotoxin cross tolerance: another inflammatory preconditioning stimulus?. 2000 , 28, 2164-5	6
942	Measuring Health Outcomes for Older People Using the Sage Database. 2000 , 19, 67-86	5
941	Mechanical ventilators and respiratory centers. 2000 , 28, 2154-6	3
940	Tumor necrosis factor-alpha and the development of multiple organ failure. 2000 , 28, 2158-9	2
939	Can synthetic high-octane fuel avoid an energy crisis? Support for the use of dopexamine. 2000 , 28, 2159-60	
938	Diminished oxygen extraction and hypoxia in the presence of normal delivery of oxygen by the microvasculature. 2000 , 28, 2163-4	2
937	Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. 2000 , 18, 1121-8	114
936	Angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure in general practice in north Cumbria. 2000 , 2, 201-7	9
935	Reduction of hospital days by biventricular pacing. 2000 , 2, 399-406	40
934	Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure. 2000 , 2, 107-12	8

933	Use of an angular transformation for ratio estimation in cost-effectiveness analysis. 2000 , 19, 2989-3003	29
932	Therapy of heart failure. 2000 , 57, 1418-25	30
931	Second line pharmacological management of paroxysmal and persistent atrial fibrillation in france: a cost analysis. 2000 , 3, 407-16	19
930	Racial differences in the utilization of oral anticoagulant therapy in heart failure: a study of elderly hospitalized patients. 2000 , 15, 134-7	16
929	Failure of evidence-based medicine in the treatment of hypertension in older patients. 2000 , 15, 702-9	21
928	The rational use of beta-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy. 2000 , 49, 1-9	16
927	Towards a blood test for heart failure: the potential use of circulating natriuretic peptides. 2000 , 50, 15-20	12
926	Drugs used in secondary prevention after myocardial infarction: case presentation. 2000 , 50, 405-17	3
925	Role of neuropeptides in heart failure: preliminary information or knowledge?. 2000 , 30, 561-2	2
924	Debate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?. 2000 , 1, 98-101	6
923	Automated quantitative determination of the new renin inhibitor CGP 60536 by high-performance liquid chromatography. 2000 , 738, 129-36	9
922	Chymase-dependent angiotensin II formation in human blood vessels. 2000 , 14, 373-6	6
921	Recent advances in the management of chronic heart failure. 2000 , 30, 475-82	2
920	Systolic heart failure: practical implementation of standard guidelines. 2000 , 3, 1-12	2
919	Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review. 2000 , 12, 91-111	24
918	Predicting long-term functional results after myocardial revascularization in ischemic cardiomyopathy. 2000 , 120, 478-89	58
917	Heart failure in women. 2000 , 15, 121-33	29
916	Evolution and pathophysiology of chronic systolic heart failure. 2000 , 20, 349S-358S	12

- 915 beta-blocker therapy: a standard of care for heart failure. **2000**, 20, 359S-367S 6
- 914 The role of the renin-angiotensin-aldosterone system in the management of heart failure. **2000**, 20, 368S-378S 5
- 913 Practical issues in the treatment of patients with heart failure. **2000**, 20, 385S-391S 1
- 912 Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors. **2000**, 20, 698-710 16
- 911 Advances in the treatment of congestive heart failure: new approaches for an old disease. **2000**, 20, 787-804 22
- 910 The role of angiotensin receptor blockers in heart failure. **2000**, 6, 103-109
- 909 Difficult cases in heart failure: beneficial effects of aldosterone blockade in heart failure. **2000**, 6, 115-117
- 908 Differential effects of direct antagonism of All compared to ACE inhibitors on serum potassium levels and azotemia in patients with severe congestive heart failure. **2000**, 6, 193-196 6
- 907 Beta blockers with ACE inhibitors in mild heart failure. **2000**, 6, 215-219
- 906 Possible interaction between aspirin and ACE inhibitors: update on unresolved controversy. **2000**, 6, 313-318 4
- 905 The AHF SCENE II Preceptorship Program: rationale and design of an educational program to optimize management of advanced heart failure. **2000**, 6, 319-324 1
- 904 Results of revascularization in patients with severe left ventricular dysfunction. **2000**, 119, 550-7 63
- 903 Myocyte contractile dysfunction with hypertrophy and failure: relevance to cardiac surgery. **2000**, 119, 388-400 9
- 902 Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. **2000**, 85, 187-92 67
- 901 Effect of angiotensin-converting enzyme inhibitor (enalapril or imidapril) on ventilation during exercise in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. **2000**, 85, 658-60, A10 6
- 900 Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure. **2000**, 85, 977-80 7
- 899 Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. **2000**, 397, 113-20 14
- 898 Post-hospitalization management of high-risk coronary patients. **2000**, 85, 13B-20B 116

897	Effect of quinapril initiated during progressive remodeling in asymptomatic patients with healed myocardial infarction. 2000 , 86, 139-44	11
896	Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. 2000 , 86, 519-23	27
895	Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. 2000 , 86, 644-8	19
894	Profiling risk from arrhythmic or hemodynamic death. 2000 , 86, 126K-132K	9
893	Matching cardiac rhythm management technology to patient needs: pacing/ablation/implantable cardioverter defibrillators. 2000 , 86, 58K-70K	1
892	Other primary prevention trials-what is clinically and economically necessary?. 2000 , 4 Suppl 1, 109-15	3
891	The control of adrenergic function in heart failure: therapeutic intervention. 2000 , 5, 101-14	30
890	Use of myocardial perfusion imaging to assess viability. 2000 , 7, 72-80	3
889	Accuracy of the automated assessment of left ventricular function with gated perfusion SPECT in the presence of perfusion defects and left ventricular dysfunction: correlation with equilibrium radionuclide ventriculography and echocardiography. 2000 , 7, 301-11	51
888	Effect of altering the left ventricular pressure on epicardial activation time in dogs with and without pacing-induced heart failure. 2000 , 4, 561-8	2
887	Psychosocial factors as predictors of functional status at 1 year in patients with left ventricular dysfunction. 2000 , 23, 290-300	65
886	Inhibition of angiotensin-converting enzyme protects endothelial cell against hypoxia/reoxygenation injury. 2000 , 11, 257-66	16
885	Impact of left ventricular size on pharmacologic reverse remodeling in heart failure. 2000 , 23, 355-8	12
884	Can we prevent congestive heart failure? Excerpts from a symposium. 2000 , 23, IV1-3	
883	Overview of the relationship between ischemia and congestive heart failure. 2000 , 23, IV4-8	25
882	Class effects and evidence-based medicine. 2000 , 23, IV15-9	18
881	New and emerging pharmacologic strategies in the management of chronic heart failure. 2000 , 23, 724-30	7
880	Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure. 2000 , 23, 909-14	20

879	The economic burden of heart failure. 2000 , 23, 1116-10	160
878	Endothelial function as a therapeutic target in coronary artery disease. 2000 , 2, 303-7	7
877	The myocardial matrix and the development and progression of ventricular remodeling. 2000 , 2, 112-9	29
876	Diastolic heart failure in the community. 2000 , 2, 461-9	16
875	Management of heart failure. 2000 , 2, 221-4	1
874	Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. 2000 , 2, 258-62	48
873	Vasopeptidase inhibition: a new direction in cardiovascular treatment. 2000 , 2, 384-91	7
872	HOPE gives reason for hope. Heart Outcomes Prevention Evaluation. 2000 , 2, 59-61	1
871	Sarcoidosis and the Heart. 2000 , 2, 385-398	14
870	Idiopathic Cardiomyopathy. 2000 , 2, 421-430	1
869	Cost of treating heart failure in an Irish teaching hospital. 2000 , 169, 241-4	7
868	Augmented responses of angiotensin I and II in patients with ischemic heart disease: relation to left ventricular function. 2000 , 41, 269-78	
867	Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. 2000 , 23, 25-31	30
866	Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. 2000 , 2, 407-12	29
865	Effects of carvedilol in heart failure due to dilated cardiomyopathy. Results of a double-blind randomized placebo-controlled study (CARIBE study). 2000 , 74, 233-42	4
864	'ACE inhibitors are better than AT(1) receptor blockers (ARBs)' - controversies in heart failure. 2000 , 2, 237-40	2
863	Reviewers List. 2000 , 160, 3503	
862	Management of Adult Heart Failure: Bolus versus Continuous Infusion Loop Diuretics, A Review of the Literature. 2000 , 35, 832-836	2

861	Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure. 2000 , 279, H3012-9	15
860	Effects of cardiotrophin-1 on hemodynamics and endocrine function of the heart. 2000 , 279, H388-96	24
859	The problem of ventricular dysrhythmias and sudden death mortality in heart failure: the impact of current therapy. 2000 , 93, 56-69	6
858	Quality, Equity and Partnership—West Midlands Partnership for Developing Quality/NHS Executive Conference, 15–16 March 2000, Birmingham. 2000 , 4, 1-68	
857	Pharmacologic Regulation of the Renin–Angiotensin System: Physiologic and Pathologic Effects. 2000 , 16, 138-146	1
856	Inhibition of arterial thrombogenesis by quinapril but not losartan. 2000 , 5, 121-7	7
855	Evaluating quality of care for patients with heart failure. 2000 , 101, E122-40	101
854	The HOPE Study (Heart Outcomes Prevention Evaluation). 2000 , 1, 18-20	74
853	Why we need new strategies in CHF management. 2000 , 1 Suppl 1, 12-6	0
852	The HF epidemic: the need for new treatment strategies. 2000 , 1, S32-4	
851	Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. 2000 , 101, 385-91	261
850	Clinical trials in cardiovascular medicine: are we looking for statistical significance or clinical relevance?. 2000 , 84, 129-33	2
849	Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. 2000 , 102, 1990-5	50
848	ACE Inhibition versus Angiotensin-II Antagonism in Heart Failure. 2000 , 8, 195-203	2
847	Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. 2000 , 36, 523-30	36
846	Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. 2000 , 36, 127-31	77
845	Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. 2000 , 21, 53-7	177
844	Drug treatment in heart failure. 2000 , 320, 1188-92	33

843	Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. 2000 , 2, 447-54		25
842	Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE)--rationale, study design and study protocol. 2000 , 2, 431-7		48
841	Spirolactone for heart failure: spiraling out of control. 2000 , 118, 1522-3		1
840	Spirolactone in patients with heart failure. <i>New England Journal of Medicine</i> , 2000 , 342, 132; author reply 133-4	59.2	17
839	Underlying causes and survival in patients with heart failure. <i>New England Journal of Medicine</i> , 2000 , 342, 1120-2	59.2	16
838	A narrow QRS does not predict a normal left ventricular function in Chagas' disease. 2000 , 23, 2014-7		16
837	beta-blockers in heart failure: recently completed and ongoing clinical trials. 2000 , 9, 415-28		1
836	New advances in the pharmacological management of chronic heart failure. 2000 , 1, 261-9		
835	Anesthesia for left ventricular assist device placement. 2000 , 14, 316-326		36
834	Reversal of heart failure remodeling in women. 2000 , 9, 513-9		1
833	A regression-based method for estimating mean treatment cost in the presence of right-censoring. 2000 , 1, 299-313		46
832	Recruitable ACE and tissue repair in the infarcted heart. 2000 , 1, 295-303		26
831	Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. 2000 , 102, 61-6		512
830	Progress in heart failure Management? Lessons from the real world. 2000 , 102, 1076-8		82
829	Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. 2000 , 102, 1126-31		436
828	Measurement of the renin-angiotensin system in heart failure. 2000 , 1, 210-26		2
827	Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. 2000 , 102, 611-6		255
826	Influence of beta-blockers on mortality in chronic heart failure. 2000 , 34, 1440-51		7

825	Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure. 2000 , 1, 147-50	15
824	Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. 2000 , 86, 139-43	117
823	Neurohumoral blockade in CHF management. 2000 , 1 Suppl 1, 24-30	17
822	Surgery for heart failure: options and outcomes. 2000 , 15, 287-93	3
821	beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. 2000 , 86, 807-15	82
820	Ongoing Clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction. 2000 , 1, 131-6	1
819	The importance of early intervention in CHF--signs and symptom relief. 2000 , 1 Suppl 1, 17-23	1
818	Angiotensin blockade inhibits SIF DNA binding activities via STAT3 after myocardial infarction. 2000 , 32, 23-33	11
817	Bradykinin regulates captopril-induced upregulation of beta-adrenergic receptor in cultured neonatal rat cardiomyocytes. 2000 , 32, 153-9	6
816	Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the antiarrhythmics versus implantable defibrillators (AVID) study registry. 2000 , 139, 804-13	23
815	Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. 2000 , 139, 587-95	39
814	Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. 2000 , 139, 609-17	97
813	Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. 2000 , 139, 624-31	53
812	Challenges in the conduct and interpretation of phase II (pilot) randomized trials. 2000 , 139, S136-42	16
811	The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. 2000 , 139, S143-54	10
810	Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited. 2000 , 139, 78-84	152
809	Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. 2000 , 109, 371-7	47
808	Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. 2000 , 109, 489-92	23

807	Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. 2000 , 109, 605-13	195
806	HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation. 2000 , 355, 246-7	15
805	Current medical therapy for advanced heart failure. 2000 , 29, 16-32	29
804	Does gender bias exist in the medical management of heart failure?. 2000 , 75, 65-9	30
803	Idiopathic dilated cardiomyopathy in an Omani population of the Arabian Peninsula: prevalence, clinical profile and natural history. 2000 , 75, 147-58; discussion 158-9	60
802	Left ventricular remodelling and dysfunction. Can the process be prevented?. 2000 , 72, 143-50	22
801	Applied physiology: understanding cardiac failure. 2000 , 10, 284-288	
800	Cardiac protection: evolving role of angiotensin receptor blockers. 2000 , 139, S15-22	16
799	Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. 2000 , 139, 952-61	48
798	Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. 2000 , 140, 361-6	37
797	Combined treatment with losartan and an ACE inhibitor in mild to moderate heart failure: results of a double-blind, randomized, placebo-controlled trial. 2000 , 140, e25	8
796	Characteristics of patients referred for cardiac transplantation: implications for the donor organ shortage. 2000 , 140, 857-61	5
795	The congestion score: a simple tool for a complicated disease?. 2000 , 140, 824-6	9
794	Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. 2000 , 140, 840-7	245
793	Reporting the study populations of clinical trials. Clear transmission or static on the line?. 2000 , 53, 973-9	35
792	Vital epidemiologic clues in heart failure. 2000 , 53, 229-35	84
791	Treating high-risk hypertensive patients. 2000 , 13, 68S-73S	3
790	Heart failure: future treatment approaches. 2000 , 13, 74S-78S	2

789	Fibrinolytic function in diuretic-induced volume depletion. 2000 , 13, 359-63	18
788	Intérêt clinique du BNP (brain natriuretic peptide) dans l'insuffisance cardiaque : revue de la littérature et expérience personnelle. 2000 , 15, 161-168	
787	Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. 2000 , 36, S24-30	52
786	Prognostic value of serum cytokines in patients with congestive heart failure. 2000 , 19, 419-25	102
785	Sudden death in heart failure patients: effects of optimized medical therapy. 2000 , 19, S32-7	1
784	Sudden cardiac death syndrome and pump dysfunction: the link. 2000 , 19, S27-31	3
783	Postoperative drug therapy to extend survival after coronary artery bypass grafting. 2000 , 69, 1315-6	8
782	Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. 2000 , 355, 1126-30	1111
781	Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. 2000 , 355, 1575-81	1159
780	Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. 2000 , 355, 1582-7	1486
779	Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. 2000 , 356, 615-20	319
778	Comparison of losartan and captopril in ELITE II. 2000 , 356, 851; author reply 852-3	5
777	Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. 2000 , 356, 1757-9	45
776	La insuficiencia cardíaca congestiva en atención primaria (I).. 2000 , 26, 5-13	5
775	Diuretic therapy in elderly heart failure patients with and without left ventricular systolic dysfunction. 2000 , 16, 289-300	16
774	Losartan: a review of its use, with special focus on elderly patients. 2000 , 16, 227-50	34
773	Optimising management of patients with advanced heart failure: the importance of preventing progression. 2000 , 16, 87-106	2
772	Heart rate as a determinant of cardiac function. 2000 ,	

771	[Prevention of sudden death in patients awaiting heart transplantation]. 2000 , 53, 736-45	1
770	Valsartan: a novel angiotensin type 1 receptor antagonist. 2000 , 1, 337-50	27
769	The fixed combination of verapamil SR/trandolapril. 2000 , 1, 515-35	3
768	Angiotensin antagonists. 2000 , 20, 211-34	5
767	ACE inhibitors after myocardial infarction. Clinical and economic considerations. 2000 , 17, 237-43	3
766	The importance of achieving additional drug benefits at a reasonable cost. A review of the fluoxetine years. 2000 , 17, 319-24	4
765	Effect of angiotensin inhibition on the coronary artery lower pressure limit in anesthetized dogs. 2000 , 78, 892-896	4
764	Better guidelines for better care: accounting for multimorbidity in clinical guidelines & structured examination of exemplar guidelines and health economic modelling. 2017 , 5, 1-150	10
763	Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. 2017 , 21, 1-150	17
762	Drug-Induced Cough. 2020 , 69, S81-S92	7
761	Are patients in heart failure trials representative of primary care populations? A systematic review. 2018 , 2, bjpgopen18X101337	5
760	Advances in systolic heart failure. 2010 , 2,	0
759	Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. 2020 , 2, 113	5
758	Angiotensin Receptor-Nepriylsin Inhibition (ARNI) in Heart Failure. 2020 , 2, 73	7
757	Paradigm Shifts of Heart Failure Therapy: Do We Need Another Paradigm?. 2020 , 2, 145	12
756	Past and present of cardiocirculatory assist devices: a comprehensive critical review. 2012 , 9, 389-400	10
755	Effect of renin-angiotensin-system blockers on contrast-medium-induced acute kidney injury after coronary angiography. 2014 , 29, 203-9	9
754	Angiotensin receptor-nepriylsin inhibitor for the treatment of heart failure: a review of recent evidence. 2020 , 35, 498-513	5

753	Current status of heart failure: global and Korea. 2020 , 35, 487-497	12
752	Treatment of Advanced Heart Failure: Beyond Medical Treatment. 2012 , 82, 658	2
751	Treatment of Heart Failure with Reduced Ejection Fraction: Current Update. 2015 , 88, 127	4
750	The heart in muscular dystrophy. 2005 , 34, 531-5	13
749	Dysfunction of the autonomic nervous system in atrial fibrillation. 2015 , 7, 193-8	21
748	Mechanical circulatory support devices as destination therapy-current evidence. 2014 , 3, 513-24	17
747	Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics. 2013 , 6, 751	12
746	[An elderly man with known heart failure admitted with cardiogenic shock]. 2010 , 130, 1352-4	1
745	The Correlation of Brain Natriuretic Peptide (BNP), Pulmonary Arterial Pressure, and St. George Respiratory Questionnaire (SGRQ) and Their Changes with a Trial of an Angiotensin Converting Enzyme Inhibitor. 2010 , 68, 273	1
744	Biventricular pacing and heterogeneity of ventricular repolarization in heart failure patients. 2006 , 2, 27	3
743	Sudden death prevention in heart failure: The case of CIBIS III. 2006 , 2, 73	5
742	Utilization of guideline-directed medical therapy in patients with de novo heart failure with reduced ejection fraction: A Veterans Affairs study. 2020 , 9, 3065-3069	3
741	Pulmonary artery denervation using catheter-based ultrasonic energy. 2019 , 15, 722-730	11
740	2014 ESC/EACTS guidelines on myocardial revascularization. 2015 , 10, 1024-94	195
739	Heart failure in subjects with chronic kidney disease: Best management practices. 2010 , 2, 112-7	4
738	Combined assessment of myocardial damage and electrical disturbance in chronic heart failure. 2017 , 9, 457-465	3
737	Is Entresto good for the brain?. 2017 , 9, 594-599	10
736	The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. 2015 , 6,	1

735	Update of treatment of heart failure with reduction of left ventricular ejection fraction. 2016 , 1, e106-e116	8
734	HEART FAILURE AND FIRST DOSE HYPOTENSION AFTER ANGIOTENSIN CONVERTING ENZYME INHIBITORS. 2004 , 148, 113-118	1
733	Nepriylsin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions. 2016 , 23, 591-598	8
732	Some characteristics of blood shed into the Solcotrans postoperative orthopaedic drainage/reinfusion system*. 1992 , 157, 95-96	10
731	Angiotensin-Converting enzyme inhibitors. 1994 , 160, 279-281	1
730	Critical Questions about PARADIGM-HF and the Future. 2016 , 32, 387-96	13
729	Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease. 2020 , 9,	3
728	Obesity paradox in patients with chronic total occlusion of coronary artery. 2021 , e13698	0
727	Hypertensive Heart Failure in Asia.. 2021 , 9, 47-56	2
726	Association Between the Angiotensin II/Angiotensin (1-7) Imbalance and Left Ventricular Hypertrophy in Patients with Heart Failure. 2021 , 48, 12-18	
725	Comparative efficacy of enalapril and valsartan in heart failure with mid-range ejection fraction. 2021 , 102, 614-620	
724	Akute kardiale Dyspnoe und Lungenödem. 2000 , 527-538	
723	The Heart Failure Syndrome: New Insights - From Receptors to Molecular Biology. 2000 , 1-18	
722	Koronare Herzkrankheit. 2000 , 503-510	
721	Heart Failure: Potential Benefit of Growth Hormone Therapy. 2000 , 175-181	
720	Geometrical considerations in (reverse) remodeling. 2000 , 67-82	2
719	Outpatient Therapy. 2000 , 149-200	
718	Pathophysiologie der chronischen Herzinsuffizienz. 2000 , 545-595	

717 Beneficial Effects of Angiotensin Blockade in Heart Failure Due to Myocardial Infarction. **2000**, 279-302

716 Neurohumoral modulation of metalloproteinases in cardiac failure: impact on remodeling. **2000**, 247-261

715 Myocardial infarction, infarct repair, and strategies for muscle regeneration. **2000**, 298-315

714 Medical Treatment of Coronary Artery Disease. **2000**, 267-286

713 Klinik und Symptomatologie der chronischen Herzinsuffizienz. **2000**, 597-610

712 β -Blocker treatment of chronic heart failure with special regard to Carvedilol. **2000**, 257-275

711 The Heart in Diabetes: Results of Trials. **2000**, 55-65

710 End stage heart failure-options for medical treatment and beyond. **2000**, 19-30

709 Human Heart Failure: A Mechanistic Assessment of Altered Ventricular Function. **2000**, 409-421

708 Oxidative Stress and Use of Antioxidants in Patients with Congestive Heart Failure. **2000**, 211-224

707 Definition und Epidemiologie der chronischen Herzinsuffizienz. **2000**, 539-543

706 Herzinsuffizienz, Kardiomyopathien, Herzklappenfehler. **2000**, 517-523

705 Beta-blocker treatment in heart failure. Role of heart rate reduction. **2000**, 239-250

704 ?????????(????1999????). **2000**, 8, 107-112

703 Angiotensin converting enzyme inhibitors for heart failure.

702 Pharmacotherapy of systolic heart failure: a review of recent literature and practical applications. **2000**, 14, 57-75

701 Generika und Analogpräparate. **2001**, 687-713

700 Behandlung der Herzinsuffizienz mit β -Blockern [Mechanismen und klinische Ergebnisse. **2001**, 24-38

- 699 Pharmaka mit Wirkung auf die NO-Signaltransduktion. **2001**, 21-35
- 698 Der NO/cGMP-Signaltransduktionsweg. **2001**, 5-7
- 697 The role of beta-blockers in the management of patients with heart failure. **2001**, 20, 24-9
- 696 Literatur. **2001**, 257-287
- 695 Nierenfunktion bei Herzinsuffizienz. **2001**, 57-69
- 694 Evaluative and epidemiological approaches of ACE therapy. **2001**, 47-70
- 693 Dilated Cardiomyopathy and Steps in the Treatment. **2001**, 135-148
- 692 Herzinsuffizienz: AT1-Rezeptor-Blocker als Ergänzung zur optimalen Standardtherapie?. **2001**, 117-124
- 691 Einleitung. **2001**, 1-3
- 690 Epidemiology and Problems with Diagnosis of Heart Failure. **2001**, 54-68
- 689 The Future of Heart Failure Management. **2001**, 131-143
- 688 The Future of the Diagnosis of Left Ventricular Dysfunction and Heart Failure. **2001**, 69-79
- 687 Hemmer des Renin-Angiotensin-Systems. **2001**, 320-341
- 686 Hintergrund der MERIT-HF-Studie. **2001**, 143-155
- 685 Körperliches Training und Endothelfunktion. **2001**, 17-19
- 684 Einsparpotentiale. **2001**, 729-769
- 683 ACE-Hemmer bei der Behandlung der Herzinsuffizienz Ein Update. **2001**, 11-23
- 682 Mechanismen potenziell vasoprotektiver Wirkungen von NO. **2001**, 9-16

- 681 Non-cardiac surgery in the heart failure patient. **2001**, 85, 505-507
- 680 Beneficial haemodynamic effects of insulin in chronic heart failure. **2001**, 85, 508-513 1
- 679 Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. **2001**, 86, 21-26 1
- 678 Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. **2001**, 86, 97-103
- 677 Is Skeletal Myoblast Transplantation Clinically Relevant in the Era of Angiotensin-Converting Enzyme Inhibitors?. **2001**, 104, 1
- 676 Assessment of Heart Failure. **2002**, 127-143
- 675 Prognostic Indicators and Assessment of Therapeutic Responses. **2002**, 145-159
- 674 3.????????????? EBM?????. **2002**, 91, 211-216
- 673 Besonderheiten der Herzinsuffizienz bei Frauen. **2002**, 192-207
- 672 Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade. **2002**, 193-209
- 671 Pharmaka zur Behandlung der Herzinsuffizienz. **2002**, 305-329
- 670 Atherosclerotic Lesions: Vulnerability. **2002**, 327-339
- 669 How Great Is the Arrhythmic Risk for Heart Failure Patients and Does Resynchronization Therapy Modify It?. **2002**, 151-156
- 668 How Many Patients Really Need Ventricular Resynchronization Therapy?. **2002**, 99-102
- 667 Pathophysiology and Management of Congestive Heart Failure in Patients with Diabetes Mellitus. **2002**, 211-229
- 666 Einsparpotentiale. **2003**, 784-831
- 665 Ischemia / Myocardial Infarction. **2003**, 139-155
- 664 Thoratec IVAD-System. **2003**, 135-139

663 Geneesmiddelen bij hart- en vaatziekten. **2003**, 74-95

662 Infarct Scar. Living Tissue. **2003**, 333-343

661 Effects of Angiotensin II Receptor Blockade and Angiotensin Converting Enzyme Inhibitor on Ventricular Remodeling After Myocardial Infarction: With Special References to Sarcoplasmic Reticulum and its mRNA. **2003**, 265-277

660 Dyslipidaemia: implications for cardiovascular risk in hypertensive diabetic subjects. **2003**, 77-96

659 Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after Myocarditis. **2003**, 77-82

1

658 Clinical Features and Treatment of Coronary Heart Disease in Diabetes.

657 Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure and high risk myocardial infarction. **2003**, 97-113

656 Omapatrilat. **2003**, 141-157

655 Falls, chronic diseases, and drug use in elderly women: lack of association may be explained. **2003**, 327, 1288; author reply 1288

654 Pharmacological Therapy in COMPANION Study: Compliance and Dosage. **2004**, 865-876

653 Inhibitors of the RAS: Evidence-Based Medicine. **2004**, 545-592

652 Treatment Strategies for Women With Stable Angina. **2004**, 197-214

651 1.?????????????. **2004**, 93, 43-47

650 Primary Prevention of Sudden Death in Post-Infarction Patients: When ICD Implantation is Really Cost-effective. **2004**, 497-504

649 Herz, Gefäß, Lunge. **2004**, 81-196

648 Heart Failure in Women. **2004**, 65-91

647 Diuretika. **2004**, 961-970

646 Smad Cofactors/Corepressors in the Fibrosed Post-MI Heart: Possible Therapeutic Targets. **2004**, 485-511

645 Evaluation of Cardiac Function. **2004**, 178-204

644 Congestive Heart Failure. **2004**, 247-248

643 Tissue Renin-Angiotensin-Aldosterone System. **2004**, 586-593

642 Herzinsuffizienz. **2004**, 323-366

641 The Influence of Gender on Cough Reflex Sensitivity. **2004**, 347-354

640 [Back to the future: pathophysiology and therapeutic strategies in heart failure]. **2004**, 71, 421-5

639 Einsparpotentiale. **2004**, 863-914

638 Heart failure: an epidemic of the 21st century. **2004**, 3, 194-204

9

637 ACE Genotyping. **2004**, 7-11

636 Inhibition of the Renin-Angiotensin-Aldosterone System. **2005**, 195-212

635 Assessment of Heart Failure. **2005**, 127-143

634 Pathophysiological characteristics and responsiveness to neurohormonal antagonism in idiopathic dilated cardiomyopathy patients with antihepatitis C virus antibody. **2005**, 46, 407-17

1

633 Cell Therapy for Heart Failure. **2006**, 59-69

632 Clinical Use of Natriuretic Peptides for the Diagnosis and Management of Heart Failure. **2006**, 387-408

631 Congestive Heart Failure. **2006**, 83-95

630 The Data Monitoring Experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program. **2006**, 166-175

629 Stopping a Trial for Futility: The Cooperative New Scandinavian Enalapril Survival Study II. **2006**, 302-311

628 Pharmacological interventions in reperfusion therapy for acute myocardial infarction. **2006**, 111-128

- 627 Pharmacologic Treatment of Heart Disease. **2006**, 237-275 1
- 626 Vasodilators in the Management of Heart Failure. **2006**, 99-112
- 625 Management of Ventricular Arrhythmias in Heart Failure. **2006**, 183-202
- 624 Acute Heart Failure. **2006**, 203-226
- 623 Oxidative stress in hypertension. **2006**, 336-349
- 622 Angiotensin receptor blockers for chronic heart failure. **2006**, 127-171
- 621 The Pharmaceutical Revolution. **2006**, 547-562
- 620 Arterial hypertension and endothelial dysfunction in chronic kidney diseases. **2006**, 12, 352-357 2
- 619 Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. **2006**, 525-544
- 618 Update in the approach to and management of heart failure. **2006**, 99, 1346-55; quiz 1356-7, 1384 3
- 617 Sudden cardiac death: the size of the problem. **2006**, 25-36
- 616 Sudden Death in Heart Failure: Risk Stratification and Treatment Strategies. **2007**, 1-20
- 615 Heart Failure. **2007**, 281-294
- 614 Heart Failure in Hypertension. **2007**, 340-350
- 613 Special Considerations in Research. **2007**, 275-350
- 612 Chronic Stable Angina. **2007**, 290-313
- 611 Pharmacologic Management of Heart Failure in the Ambulatory Setting. **2007**, 331-362
- 610 Aritmie en Asynchronie Bij Hartfalen: Geneesmiddelen en Implantaten. **2007**, 95-122

609 Behandeling terminaal hartfalen. **2007**, 139-156

608 The Medical Management of Heart Failure. **2007**, 1397-1416

607 Clinical usefulness of electrophysiologic study (EPS)-guided risk stratification for life-threatening arrhythmia in patients with heart failure. **2007**, 48, 155-63

1

606 Heart Disease. **2007**, 913-938

605 Cardiovascular Pharmacology. **2007**, 33-52

604 Sudden Cardiac Death. **2007**, 2039-2083

603 Cost-Effectiveness Issues. **2007**, 2771-2790

602 ACE Inhibition in Heart Failure and Ischaemic Heart Disease. **2007**, 21-54

601 Dilated Cardiomyopathy. **2007**, 1233-1259

1

600 Effect of Glycemic Control on the Progress of Left Ventricular Hypertrophy and Diastolic Dysfunction in Children with Type I Diabetes Mellitus. **2007**, 7, 783-789

599 Acute peripartum cardiomyopathy after cesarean section - A case report -. **2008**, 55, 634

598 Heart Transplantation and Treatment of End-Stage Heart Disease. **2008**, 173-193

597 Acute Heart Failure and Myocarditis. **2008**, 183-199

596 Heart failure: Back to basics for pharmacists. **2008**, 141, 48-57

595 Traitement de l'insuffisance cardiaque. **2008**, 101-125

594 Systemic Hypertension in the Elderly. **2008**, 137-158

593 Antihypertensive treatment in patients with heart failure. **2008**, 345-359

592 Pharmacologic Therapy. **2009**, 85-96

591 Unique Aspects of Vascular and Cardiac Ultrasound in Racial/Ethnic Groups. **2009**, 247-268

590 Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin. **2009**, 112-159

589 Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction. **2009**, 93-102 1

588 HEART FAILURE. **2009**, 389-399

587 2.???RCT??? Real World?????. **2009**, 40, 113S-114S 1

586 Respiratory failure due to myotonic dystrophy combined with peripartum cardiomyopathy: A case report. **2009**, 57, 376-380

585 Cardiac Failure. **2009**, 557-572

584 Management of Hypertension in Heart Failure. **2009**, 1-15

583 Case 22. Congestive Heart Failure. **2009**,

582 Effect of renin-angiotensin system inhibitors in diabetic dialysis patients with chronic heart failure. **2009**, 42, 151-157

581 Clinical burden and health service challenges of chronic heart failure. **2009**, 8, i1-i4 1

580 Pathophysiology of Heart Failure. **2010**, 1-27

579 Medical Therapy for Heart Failure. **2010**, 29-68

578 Cardiac Resynchronization Therapy. **2010**, 185-213

577 Pharmacogenomics. **2010**, 273-287

576 Dilated Cardiomyopathy. **2010**, 179-190

575 Principles of Treatment and Pharmacotherapy. **2010**, 255-275

574 Acute Decompensated Cardiac Failure. **2010**, 323-342

573 Heart Failure. **2010**, 320-340

572 SALICYLATES, PARACETAMOL, AND OTHER NON-OPIOID ANALGESICS. **2010**, 165-221

571 Heart Failure. **2010**, 131-166

570 The Future of Old Age. **2010**, 11-17

569 Pregnancy and the Systemic Right Ventricle. **2010**, 305-310

568 Patient Compliance. **2010**, 967-971

567 Significance of performing 123I-metaiodobenzylguanidine myocardial scintigraphy at different times for the long-term prediction of cardiac events in patients with dilated cardiomyopathy. **2010**, 31, 488-494 1

566 Unstable Angina and Non-ST Elevation Myocardial Infarction. **2011**, 195-225

565 Evidence-Based Management of the Patient with Congestive Heart Failure. **2011**, 497-518

564 Congestive Heart Failure. 684-697

563 Drug Therapy: Special Considerations in Diabetes. 410-423

562 Nonsustained Ventricular Tachycardia. **2011**, 225-241

561 ?3? ???. **2011**, 44, 369-374

560 4.?????????????????. **2011**, 31, 365-375

559 Pathophysiology of cardiac failure. **2011**, 88-95

558 Medicamenteuze behandeling van chronisch hartfalen. **2011**, 117-126

557 NHG-Standaard Hartfalen. **2011**, 459-496 3

556 Antagonism of the Renin-Angiotensin-Aldosterone System in Heart Failure. **2011**, 659-673

555 Acute Coronary Syndromes. **2011**, 548-558

554 New Approaches to the Surgical Treatment of End-Stage Heart Failure. **2011**, 814-835

553 ACE-inhibitors and angiotensin receptor blockers. **2011**, 247-252

552 Cardiovascular Pharmacology. **2011**, 235-295

1

551 Heart Failure as a Consequence of Congenital Heart Disease. **2011**, 455-464

550 Antihypertensive Drugs and Their Cardioprotective and Renoprotective Roles in the Prevention and Management of Cardiovascular Disease. **2011**, 161-181

549 Myocarditis and Acute Myopathies. **2011**, 613-624

548 Exercise. **2011**, 567-582

547 Hypertension. **2012**, 81-90

546 Congestive Heart Failure. **2012**, 281-324

545 Surgical Mechanical Circulatory Support. **2012**, 455-469

o

544 Recent Aspects of Angiotensin II Action in the Heart. Implications for Myocardial Ischemia and Heart Failure. **2012**, 367-378

543 Hyperkalemia Risk and Treatment of Heart Failure. **2012**, 81-99

542 Hyperkalemia Risk and Treatment of Heart Failure. **2012**, 23-41

541 Value of Orthostatic Hypotension as a Prognostic Bed-Side Test in Heart Failure. **2012**, 02, 132-140

540 Ventricular Fibrillation. **2012**, 681-706

539 Heart Failure. **2012**, 217-226.e4

538 Emergency Department Therapy of Acute Heart Failure. **2012**, 141-161

- 537 Does impaired glucose tolerance associate with heart failure?. **2012**, 18, 245-251
- 536 Treatment of Acute Heart Failure in Consideration of Long Term Prognosis - Increased How to Use ANP and Beta Blocker. **2012**, 32, 43-45
- 535 Heart Disease. **2012**, 825-850
- 534 Outpatient Medication Titration in Acute Heart Failure. **2012**, 217-227
- 533 Effects of transluminal balloon angioplasty and stenting on the clinical course of ischemic chronic heart failure with preserved or reduced left ventricular ejection fraction: radionuclide 4D tomoventriculography data. **2012**, 11, 73-78
- 532 Pregnancy in a patient with cancer and heart failure: challenges and complexities. **2012**, 3, 85-93 1
- 531 Heart Failure. 117-142
- 530 [Chronic heart failure with impaired left ventricular function (systolic heart failure)]. **2012**, 153, 2021-9
- 529 Medical Practice Variations in Heart Failure. **2013**, 1-28
- 528 Trends in the medical management of patients with heart failure. **2013**, 5, 194-204 9
- 527 Induction of tissue angiotensin II-forming activity in two-kidney, one-clip hypertensive hamster model. **2013**, 3, 9
- 526 The ACE2/Ang-(1 $\bar{7}$) Pathway in Cardiac Fibroblasts as a Potential Target for Cardiac Remodeling. **2013**, 547-557 1
- 525 Algorithm for Treatment of Advanced Heart Failure. **2013**, 9-34
- 524 Heart Transplantation. 813-826
- 523 Angiotensin converting enzyme inhibitors for heart failure.
- 522 Diagnosis and Management of Acute Heart Failure. **2014**, 238-254 0
- 521 Chronic and End-Stage Heart Failure. **2014**, 255-270
- 520 Congestive Heart Failure. **2014**, 2045-2062

519 Heart Failure and Pulmonary Hypertension in Women. **2014**, 155-173

518 Preventive Lessons from Hypertension and Myocardial Infarction: Treating Asymptomatic Individuals to Lower the Risk for Subsequent Cardiovascular Events. **2014**, 229-239

517 Myofibroblasts, Cytokines, and Persistent Atrial Fibrillation. **2014**, 459-467

516 The RAAS in Heart Failure: An Update on Clinical Trials and Opportunities for Therapy. **2014**, 165-182

515 Treatment of arterial hypertension in the light of new guidelines. **2014**, 33, 241-245

514 Applications of Molecular Small-Animal Imaging in Cardiology. **2014**, 547-584

513 Changes in blood-pressure control among patients with hypertension from 2008 through 2011: surveys of actual clinical practice. **2014**, 81, 258-63

1

512 Pharmacoeconomics. **2014**, 59-72

511 Pharmacological Treatment of Patients with Chronic Systolic Heart Failure. **2014**, 9, 43-48

0

510 Direct Prevention Against Progressive 201TL Perfusion Defects by Captopril Treatment in Patients with Mild to Moderate Heart Failure. **1992**, 189-191

509 Congestive Heart Failure. **1992**, 135-171

508 Therapie Vasodilatierende Substanzen. **1992**, 181-191

507 Effect of Lisinopril on Hemodynamics and Cardiac Hypertrophy in Rats with Aortocaval Fistula. **1992**, 159-161

506 Myocardial Oxygen Consumption in Patients with Idiopathic Dilated Cardiomyopathy: Effects of Vasodilating and Inotropic Agents. **1993**, 185-194

505 Idiopathic Dilated Cardiomyopathy: Current Concepts in Clinical Research. **1993**, 3-9

1

504 Pathophysiologie der Herzinsuffizienz und das Renin-Angiotensin-System. **1993**, 197-217

503 Econazol. **1993**, 1-163

502 ACE-Hemmer in der Behandlung der klinischen Herzinsuffizienz. **1993**, 219-226

- 501 Angiotensin-converting enzyme inhibitors in the treatment of clinical heart failure. **1993**, 88 Suppl 1, 203-9 1
- 500 Clinical approach to volume overload: predicting the vulnerable patient. **1993**, 105-116
- 499 Local Effects of Angiotensin-Converting Enzyme Inhibitors on the Vascular Wall. **1993**, 121-135
- 498 Wirkung der ACE-Hemmer auf das myokardiale Ischämie-/Reperfusionstrauma: Eine Übersicht. **1993**, 167-180
- 497 Heart Failure. **1993**, 91-120
- 496 Digitalistherapie. **1993**, 41-79
- 495 Digitalis for patients with heart failure in sinus rhythm. **1993**, 159, 647-9
- 494 The Diagnostic Evaluation of Patients with Heart Failure. **1994**, 597-621 2
- 493 Cardiology. **1994**, 160, 88-90
- 492 Angiotensin II Receptor Antagonism in an Ovine Model of Heart Failure Comparison with ACE and Renin Inhibition. **1994**, 287-308
- 491 Evolution of Concepts of Myocardial Function in the Treatment of Congestive Heart Failure in Man. **1994**, 3-8
- 490 Cardiac Transplantation. **1994**, 717-738
- 489 Abnormalities in Cardiac Relaxation and Other Forms of Diastolic Dysfunction. **1994**, 68-82
- 488 Heart Failure Secondary to Coronary Artery Disease. **1994**, 177-195
- 487 Angiotensin-Converting Enzyme Inhibitor Therapy for Congestive Heart Failure: Rationale, Results, and Current Recommendations. **1994**, 380-399
- 486 Congestive Heart Failure. **1994**, 626-633
- 485 Dynamic Cardiomyoplasty: The Management of Heart Failure Using Autologous Skeletal Muscle. **1995**, 323-336
- 484 Neuroendocrine Mechanisms in the Pathogenesis of Heart Failure. **1995**, 475-486

483 Therapeutische Ansätze und medikamentöse Therapie der Herzinsuffizienz. **1995**, 420-443

482 Prä- intra- und postoperative Herzinsuffizienz: Diagnostik, Behandlungsstrategien und Effektivitätskontrolle. **1995**, 61-75

481 Chronische Herzinsuffizienz. **1995**, 119-143

480 Pharmakologische Grundlagen der Behandlung der koronaren Herzkrankheit. **1995**, 38-59

479 ???????? : ?????????? : ?????? : ??????????(259????????????????????,????????????). **1995**, 3, 339-345

478 MANAGEMENT OF ACUTEMYOCARDIAL INFARCTION. **1995**, 13, 923-942

477 Plötzlicher Herztod. **1996**, 571-583

476 The role of electrophysiology and pharmacotherapy in prevention of factors triggering sudden cardiac death. **1996**, 347-366

475 Herzinsuffizienz. **1996**, 421-474

474 Diuretika. **1996**, 1398-1409

473 Calciumantagonisten bei chronischer Herzinsuffizienz. **1996**, 311-323

472 Skeletal Muscle Metabolism in Heart Failure. **1996**, 161-182

471 Prevention of cardiovascular disease. **1996**, 495-517

470 The cardiologist's dilemma: Drugs or ICDs in patients with severe ventricular dysfunction. **1996**, 317-327

469 Begleiterkrankungen bei arterieller Hypertonie im Alter. **1996**, 87-104

468 Secondary prevention of myocardial infarction: the roles of β -adrenergic blockers, calcium-channel blockers, angiotensin converting enzyme inhibitors, and aspirin. **1996**, 367-394

6

467 Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure. **1996**, 251-258

466 Training for the Enhancement of Exercise Tolerance in Patients with Left Ventricular Dysfunction. **1996**, 287-295

- 465 How may dilated cardiomyopathy benefit from cardiac pacing?. **1996**, 199-208
- 464 Positive Inotropic Therapy for Chronic Heart Failure: New Perspective on Therapeutic Strategies. **1996**, 209-218
- 463 Klinik der koronaren Herzerkrankung III: Der Herzinfarkt im chronischen Stadium. **1996**, 725-770
- 462 Therapie der Herzinsuffizienz. **1996**, 1157-1213
- 461 Responses of the Heart to Mechanical Stress. **1996**, 59-75
- 460 Klinische Erfahrungen mit dem Angiotensin-II-Rezeptor-Antagonisten Losartan bei der Behandlung der arteriellen Hypertonie. **1996**, 80-90
- 459 Klinischer Einsatz der ACE-Hemmer. **1996**, 123-165
- 458 Prospects for permanent mechanical circulatory support. **1997**, 185-189
- 457 Addendum zu Kapitel 5. **1997**, 138-139
- 456 The Diuretic-Magnesium Question in Heart Failure. **1997**, 179-187
- 455 Stufentherapie der Herzinsuffizienz. **1997**, 231-238
- 454 Cardiovascular Disease. **1997**, 357-374 1
- 453 Adrenocortical Response to Critical Illness. **1997**, 137-154
- 452 Pharmaka zur Behandlung der Herzinsuffizienz. **1997**, 291-317
- 451 Endothelin in Congestive Heart Failure: Pathophysiology and Therapeutic Implications. **1997**, 123-134
- 450 Cardiac Transplantation or Ventriculectomy?. **1997**, 695-708
- 449 ?????? : ??????????. **1997**, 5, 335-341
- 448 How to Treat High-Risk Post Myocardial Infarction Patients Based on MADIT and Other Recent Trials. **1998**, 245-250

447 Translating Clinical Guidelines For Management of Heart Failure and Hypertension Into Clinical Practice. **1998**, 105-113

446 Atherosclerosis: Implications of Angiotensin II and the AT-1 Receptor. **1998**, 233-243

445 β -Blocker Therapy in Severe Cardiac Heart Failure. **1998**, 243-248

444 β -Blocker Treatment of Chronic Heart Failure. **1998**, 177-205

443 The Role of β -Blockers in the Management of Heart Failure: Results of Controlled Trials. **1998**, 245-253

442 Comparison of Direct Angiotensin II Receptor Blockade with Converting Enzyme Inhibition in the Rat Model of Heart Failure. **1998**, 515-525

441 Evidence-based medicine and ACE inhibition. **1998**, 32 Suppl 2, S24-35

7

440 In Pursuit of Optimal Care and Outcomes for Patients with Congestive Heart Failure: Insights from the Past Decade. **1998**, 221-232

439 Cough Induced by Pharmacological Modulation of the Renin-Angiotensin-Aldosterone System. Angiotensin Converting Enzyme Inhibitors And Angiotensin II Receptor Antagonists. **1998**, 115-126

0

438 Hypertensive Patients and Diabetes. **1998**, 32, S1-S8

8

437 Heart Failure: Treatment with α -Adrenoceptor Antagonists. **1998**, 207-232

436 Cardiovascular Complications in Uremia and Dialysis. **1998**, 817-839

435 Treatment of Congestive Heart Failure in the Elderly. **1998**, 145-152

434 Sudden Cardiac Death in Heart Failure. **1998**, 357-367

433 Medical Treatment of Heart Failure: Problems in Dilated Cardiomyopathy. **1998**, 229-235

432 The Heart in Diabetes: Results of Trials. **1998**, 51-60

431 Moderatormanual Herzinsuffizienz. **1998**, 167-182

430 Klinische Evaluation des neuen ACE-Hemmers Moexipril in der Behandlung der arteriellen Hypertonie. **1998**, 25-35

- 429 Molekulare Grundlagen der Herzinsuffizienz. **1998**, 147-221 0
- 428 Controversial Issues on β -Blocker Treatment: Has Metoprolol an Additive Effect to Conventional Medical Treatment in Heart Failure Due to Dilated Cardiomyopathy?. **1998**, 254-261
- 427 Entzündliche Herzmuskelerkrankung. **1998**, 111-146 5
- 426 β -Blockers for Chronic Heart Failure. **1998**, 32, S52-S60 2
- 425 Medical Treatment in the Case of Severe Coronary Artery Disease. **1998**, 67-77
- 424 ?????????(????1997????). **1998**, 6, 81-92
- 423 ?????????(????????)(????????). **1998**, 6, 11-17
- 422 ?????????(K)????????(???? III ?????????????????????)(?62? ?????????????). **1998**, 6, 223-228
- 421 Angiotensin-Converting Enzyme Inhibitors in Acute Coronary Syndromes. **1999**, 357-382
- 420 Dilated Cardiomyopathy. **1999**, 278-293
- 419 Pathophysiology and Management of Heart Failure. **1999**, 249-266
- 418 Evidence Based Management of Acute Myocardial Infarction. **1999**, 57-91
- 417 Pharmaka zur Behandlung der Herzinsuffizienz. **1999**, 293-317
- 416 Lokales Renin-Angiotensin-System in der Gefäßwand. **1999**, 11-23
- 415 Hemodynamic and Cardiac Effects of Nisoldipine in Ischemic Left Ventricular Dysfunction. **1999**, 33-45
- 414 Placebos. **1999**, 1-6
- 413 The Renin-Angiotensin System and the Heart. **1999**, 53-67
- 412 Congestive Heart Failure. **1999**, 211-223

411 Pathophysiologische Erkenntnisse und Therapieempfehlungen bei ischämischer Kardiomyopathie. **1999**, 69-81

410 Angiotensin Converting Enzyme Inhibitors. **1999**, 228-235

409 Chronische Herzinsuffizienz. **1999**, 98-124

408 Growth Hormone in Heart Failure. **1999**, 309-323

407 Angiotensin II und koronare Herzerkrankung, Herzinsuffizienz und plötzlicher Herztod. **1999**, 173-184

406 New treatment strategies in patients with impaired left ventricular systolic function. Part II: Treatment of moderate to severe cardiac dysfunction. **1999**, 317, 312-7

405 The role of neurohormonal antagonists in hibernating myocardium. **1999**, 33 Suppl 3, S9-16

404 Different causes of heart failure need different treatment strategies. **1999**, 33 Suppl 3, S37-41

403 Ischemic and nonischemic heart failure do not require different treatment strategies. **1999**, 33 Suppl 3, S1-7

1

402 Different Causes of Heart Failure Need Different Treatment Strategies. **1999**, 33, S37-S41

2

401 Ischemic and Nonischemic Heart Failure do not Require Different Treatment Strategies. **1999**, 33, S1-S7

6

400 The Role of Neurohormonal Antagonists in Hibernating Myocardium. **1999**, 33, S9-S16

1

399 Dosing of ACE inhibitors in left ventricular dysfunction: does current clinical dosing provide optimal benefit?. **1999**, 34 Suppl 1, S13-7

398 Dosing of ACE Inhibitors in Left Ventricular Dysfunction: Does Current Clinical Dosing Provide Optimal Benefit?. **1999**, 34, S13-S17

2

397 Endothelial Dysfunction and the Promise of ACE Inhibitors. **1999**, 99, 44-50

396 ACE Inhibitor and Renin-Angiotensin System the Cornerstone of Therapy for Systolic Heart Failure. **2015**, 41-72

0

395 Target Organ Damage and RAAS Blockade. **2015**, 119-148

394 Heart Failure. **2015**, 369-421

- 393 Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. **2015**, 85-127
- 392 Renal Denervation for Congestive Heart Failure. **2015**, 163-173
- 391 Acute Decompensated Cardiac Failure. **2015**, 445-470
- 390 Neurohormonal Blockade in Heart Failure. **2015**, 77-111
- 389 Congestive Heart Failure in Nigerians: A Review. **2015**, 319-328
- 388 Cardiovascular System. **2015**, 93-110
- 387 Principles of Primary and Secondary Prevention of Cardiovascular Disease. **2015**, 1627-1664
- 386 Heart Failure. **2015**, 173-187
- 385 Risk for Sudden Cardiac Death in Heart Failure: Underlying Mechanisms and Therapeutic Modalities. **2015**, 129-149
- 384 Adding T1 Mapping and Extracellular Volume Fraction for Myocardial Fibrosis Assessment: Implications for Cardiovascular Risk Assessment. **2015**, 137-151
- 383 1. Clinical Pharmacology in Heart Failure. **2015**, 46, 83-88 1
- 382 Spezifische Aspekte der Arzneimitteltherapie in der Palliativmedizin. **2015**, 1-63
- 381 Epidemiology of Heart Failure. **2015**, 1-12
- 380 Heart Failure in South Asian Population. **2015**, 305-317
- 379 Elevated Heart Rate is Associated with Cardiac Denervation in Patients with Heart Failure: A 123-Iodine-MIBG Myocardial Scintigraphy Study. **2016**, 107, 455-459 1
- 378 Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study. **2016**, 106, 247-9 0
- 377 C-reactive protein as an indicator of risk of cardiovascular complications in patients with type 2 diabetes mellitus and its correction. **2016**, 94, 683-687 1
- 376 Outpatient Medication Titration in Acute Heart Failure. **2017**, 243-258

- 375 Heart Failure Prevention. **2017**, 267-284 2
- 374 Prognostic Factors in Severe Chagasic Heart Failure. **2017**, 108, 246-254 5
- 373 Correction of anemic syndrome in patients with chronic heart failure with intravenous iron-containing complex. **2017**, 98, 571-576
- 372 Inhibition of the Renin-Angiotensin-Aldosterone System. **2017**, 85-96
- 371 Tissue ACE/Angiotensin/AT1 Receptor Axis and Repair in the Heart. **2017**, 497-504
- 370 Emergency Department Therapy of Acute Heart Failure. **2017**, 165-183
- 369 Acute Decompensated Heart Failure: Treatment with Guideline Directed Medical Therapy and Discharge Planning. **2017**, 285-308
- 368 Neurohormonal Activation and the Management of Heart Failure. **2017**, 239-246
- 367 A Historical Overview of Cardiovascular Medicine and Heart Failure. **2017**, 3-19
- 366 Dual inhibition in the treatment of heart failure. **2017**, 19, 29-32
- 365 PharmacotherapyFirst: A Multimedia Learning Resource. **2017**,
- 364 Novelties in the treatment of heart failure. **2017**, 63, 255-264 2
- 363 Chronic Heart Failure. **2017**,
- 362 Koroner arter bypass cerrahisinde ramiprilin miyokardiyal hasar ve inflamatuvar yanıtaki etkisi üzerinde sitokin gen polimorfizmlerinin rolü **2017**, 42, 436-445
- 361 The Concept of Heart Failure: Chronic Diseases Accompanied by an Attack of Acute Exacerbation. **2018**, 1-15 1
- 360 Isolated Systolic Hypertension: In the Young and in the Elderly. **2018**, 613-637
- 359 OBSOLETE: Heart Failure in the Elderly. **2018**,
- 358 Inherited Cardiac Muscle Disorders: Hypertrophic and Restrictive Cardiomyopathies. **2018**, 259-317

- 357 Spezifische Aspekte der Arzneimitteltherapie in der Palliativmedizin. **2018**, 1-81
- 356 Management of Advanced Heart Failure: An Overview. **2018**, 1-14
- 355 Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. **2018**, 99-122.e3
- 354 Acute and Chronic Heart Failure. **2018**, 237-252
- 353 OBSOLETE: Echocardiography in Heart Failure. **2018**,
- 352 Optimal Strategies for Mitigating Sudden Cardiac Death Risk in At-risk Patients with Structural Heart Disease. **2018**, 9, 3025-3032
- 351 Sex-Based Differences in Risk Determinants and Management of Heart Failure. **2018**, 49-61
- 350 [A novel agent in the treatment of heart failure with depressed systolic function]. **2018**, 88, 287-297 1
- 349 Inhibition of Renal Fibrosis and Glomerular Injury by Sacubitril/Valsartan, a Combination Angiotensin Receptor Blocker and Neprilysin Inhibitor, in a Salt-Sensitive Hypertensive Model Using Angiotensin 1 Receptor Knockout Mice: The Contribution of Non-Angiotensin Blocking Effects to Renal Protection. **2018**, 5, 108-118
- 348 Current Management and Treatment. **2019**, 199-215
- 347 Recently Approved Pharmacologic Agents to Improve Outcomes in Heart Failure. **2019**, 105-115
- 346 Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. **2020**, 23, 160-168 2
- 345 Therapie der chronischen Herzinsuffizienz. **2019**, 40,
- 344 Enalapril attenuates endoplasmic reticulum stress and mitochondrial injury induced by myocardial infarction via activation of the TAK1/NFAT pathway in mice. **2020**, 19, 972-980 2
- 343 Triple neurohormonal blockade in de novo heart failure with reduced ejection fraction during index hospitalization. **2020**, 55, 79-85
- 342 Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications. **2020**, 33, 1-5
- 341 EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). **2020**, 6-76 3
- 340 Harnessing the Potential of Primary Care Pharmacists to Improve Heart Failure Management. **2021**, 48, 25-25

- 339 Exercise in Specific Diseases: Heart Failure with Reduced Ejection Fraction. **2020**, 957-976
- 338 Angiotensin-Converting Enzyme Inhibitors and Contrast-Associated Acute Kidney Injury After Coronary Angiography and Intervention. **2021**, 21, 487-497 0
- 337 Prevention of Heart Failure. **2021**, 489-512
- 336 Impaired renal gluconeogenesis is a major determinant of acute kidney injury associated mortality.
- 335 Skin Autofluorescence as a Predictor of First Heart Failure Hospitalization in Patients With Heart Failure With Preserved Ejection Fraction. **2020**, 11, 247-255 2
- 334 Cardiorenal syndrome. **2020**, 63, 20
- 333 Heart Failure. **2020**, 529-544
- 332 Chronic Heart Failure. **2020**, 137-154
- 331 Maternal Cardiomyopathy and Critical Care Medicine. **2020**, 135-148
- 330 Adherence to guideline-directed medical and device Therapy in outpatients with heart failure with reduced ejection fraction: The ATA study. **2020**, 24, 32-40 3
- 329 Traditional and Novel Invasive Hemodynamic Indices in the Evaluation of Congestive Heart Failure in Cardiorenal Syndrome. **2020**, 379-395
- 328 Implantable Cardioverter-defibrillator Utilization and Its Outcomes in Korea: Data from Korean Acute Heart Failure Registry. **2020**, 35, e397 0
- 327 Does left ventricular reverse remodeling influence long-term outcomes in patients with Chagas cardiomyopathy?. **2020**, 0
- 326 Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. **2021**, 1 1
- 325 Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction.. **2022**, 9, 712-720 2
- 324 Treatment Recommendations for Adults with Various Stages of Heart Failure. **2020**, 67, 12-20
- 323 Pulmonary hypertension, sleep-disordered breathing, and beta blockers in heart failure patients. **2002**, 6, 181-7 1
- 322 Use of Antioxidants in Patients with Congestive Heart Failure. **2006**, 451-476

- 321 Ventricular Remodeling In Ischemic Cardiomyopathy. **2006**, 3-22
- 320 Heart Failure. **2005**, 199-207
- 319 Therapie der chronischen Herzinsuffizienz. **2005**, 149-268
- 318 Chronische Herzinsuffizienz. **2006**, 217-335
- 317 Herzinsuffizienz. **2006**, 355-374
- 316 Kardiovaskuläre Pharmakologie. **2006**, 1-30
- 315 Value of Angiotensin-Converting Enzyme Inhibitors to Prevent Sudden Death. **2006**, 409-413
- 314 The Consequences of Cardiac Autonomic Dysfunction in Multiple Organ Dysfunction Syndrome. **2008**, 55-64
- 313 Selection and Management of the Potential Candidate for Cardiac Transplantation. **1999**, 61-91
- 312 Coronary Vascular Pharmacology. **1997**, 155-168
- 311 Selection and Management of the Potential Candidate for Cardiac Transplantation. **1996**, 161-176
- 310 Assessment of the Role of ACE Inhibitors in the Elderly. **2005**, 321-348
- 309 Treatment of Congestive Heart Failure. **2005**, 371-390
- 308 Heart Disease in the Elderly. **2005**, 705-727
- 307 Management of Hypertension. **2006**, 93-112
- 306 Diabetic Renal and Related Heart Disease. **2006**, 437-451
- 305 Management of Heart Failure. **2007**, 211-240
- 304 Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. **2007**, 43-61

303 Role of Neurohormones and Peripheral Vasculature. **2008**, 71-79

302 Diastolic Versus Systolic Heart Failure. **2008**, 119-133

301 Destination Therapy with Permanent Mechanical Circulatory Assist Devices. **2008**, 181-191

300 Arteriosklerose und Durchblutungsstörungen. **2007**, 299-322

299 Analogpräparate. **2007**, 105-181

298 Diagnosis and Management of Acute Heart Failure. **2021**, 497-515

297 Chronic and End-Stage Heart Failure. **2021**, 517-533

296 Type 2 Cardiorenal Syndrome. **2021**, 75-94

295 The impact of a run-in period on treatment effects in cardiovascular prevention randomised control trials: A protocol for a comprehensive review and meta-analysis. 3, 82

1

294 Prevalence and Patterns of Obstructive Sleep Apnea in Asian Indians With Congestive Heart Failure. **2020**, 12, e11438

293 Clinical pharmacology and clinical trials in Japan. **1996**, 74, 479-486

292 Management of congestive heart failure: how well are we doing?. **2001**, 165, 305-6

1

291 Congestive heart failure: what can we offer our patients?. **2001**, 165, 1053-5

1

290 Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. **2002**, 166, 737-45

35

289 Left ventricular dysfunction among elderly patients in general practice. Electrocardiograms are useful in these patients. **1999**, 318, 1483

288 Heart failure in primary care. **1996**, 46, 373-4

1

287 Open-access echocardiography to general practitioners for suspected heart failure. **1996**, 46, 475-6

18

286 The investigation and management of patients with heart failure. **1996**, 46, 551-2

- 285 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. **1999**, 161 Suppl 12, S1-17 38
- 284 Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension. **1999**, 161 Suppl 12, S18-22 2
- 283 Heart failure: Part I. First hospitalization and post-hospital care. **1999**, 170, 268-73 2
- 282 Diagnosis of patients with chronic heart failure in primary care: usefulness of history, examination, and investigations. **2000**, 50, 50-4 21
- 281 Medicare prescription coverage and congressional gridlock. **2001**, 16, 864-6
- 280 The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. **2006**, 56, 327-33 69
- 279 The Gordon Wilson Lecture: neurohormonal signaling pathways that link cardiac growth and death. **2007**, 118, 137-52
- 278 Prognostic value of 6-minute walk test in stable outpatients with heart failure. **2007**, 34, 166-9 53
- 277 Moexipril and left ventricular hypertrophy. **2007**, 3, 23-30 1
- 276 Macro- and micronutrients in patients with congestive heart failure, particularly African-Americans. **2007**, 3, 743-7 3
- 275 Bisoprolol in the treatment of chronic heart failure. **2007**, 3, 431-9 6
- 274 Cardiovascular high-risk patients--treat to protect, but whom?. **2008**, 10 Suppl, S2 2
- 273 Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. **2007**, 3, 937-45 20
- 272 Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action?. **1996**, 107, 57-66; discussion 66-7
- 271 Physical training in patients with chronic heart failure: An elaboration of the statements from the Committee on Cardiac Rehabilitation of the Netherlands Society of Cardiology and the Netherlands Heart Foundation and review of studies on physical training in chronic heart failure. **2004**, 12, 279-286
- 270 Heart failure: chapter 8. Treatment of end-stage heart failure. **2004**, 12, 548-554 2
- 269 Left ventricular assist device as bridge to transplantation in patients with end-stage heart failure: Eight-year experience with the implantable HeartMate LVAS. **2002**, 10, 267-271 12
- 268 Cardio-renal anemia syndrome. **2008**, 12, 11-6 9

267	Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptors. 2009 , 5, 73-8	44
266	Results of the ONTARGET and TRANSCEND studies: an update and discussion. 2009 , 5, 21-9	15
265	Angiotensin-converting enzyme and angiotensinogen gene polymorphism in hypertrophic cardiomyopathy. 2003 , 8, 155-9	9
264	The possible role of peroxisome proliferator-activated receptor gamma in heart failure. 2004 , 9, 169-73	2
263	The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. 2009 , 14, e62-7	8
262	Role of the angiotensin II receptor blocker valsartan in heart failure. 2001 , 6, 215-21	3
261	Heart failure. 2010 , 2010,	1
260	DEFEAT - Heart Failure: a guide to management of geriatric heart failure by generalist physicians. 2009 , 100, 39-50	11
259	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. 2010 , 6, 449-55	6
258	Congestive heart failure in Indians: how do we improve diagnosis & management?. 2010 , 132, 549-60	8
257	Clinical and Therapeutic Profiles of Heart Failure Patients admitted to a Tertiary Hospital, Aseer Region, Saudi Arabia. 2011 , 11, 230-5	5
256	Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. 2011 , 52, 1219-25	7
255	Dilated cardiomyopathy in childhood. 2000 , 2, 3-10	7
254	Pharmacological management of chronic heart failure in adults: a review of the literature. 2004 , 16, 22-6	
253	Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. 2012 , 31, 24-30	31
252	Efficacy of Carvedilol in Patients with Dilated Cardiomyopathy due to Beta-thalassemia major; a Double-blind Randomized Controlled Trial. 2010 , 20, 277-83	5
251	Diagnostic utility of specific electrocardiographical parameters in predicting left ventricular function. 2012 , 17, 210-4	5
250	A review of ethical considerations for ventricular assist device placement in older adults. 2013 , 4, 100-12	5

249	Heart failure with preserved ejection fraction. 2013 , 10, 369-76	14
248	A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. 2008 , 19, 292-6	11
247	Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry. 2008 , 19, 188-93	11
246	The G-308A polymorphism of the TNF-alpha gene does not predict changes in cardiac function in response to medical therapy for idiopathic dilated cardiomyopathy. 2008 , 19, 254-8	3
245	The Relationship between Left Atrial Volume and Ventricular Arrhythmias in the Patients with Dilated Cardiomyopathy. 2014 , 8, 18-23	3
244	A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention. 2013 , 6, 88-99	15
243	Managing hypertension in the elderly: a common chronic disease with increasing age. 2012 , 5, 146-53	9
242	Management of Patients Admitted with Acute Decompensated Heart Failure. 2015 , 15, 284-9	3
241	PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?. 2015 , 12, 470-3	3
240	Renin Angiotenin Blocker Pre-treatment and Recurrence After Pulmonary Vein Isolation in Patients with Paroxysmal and Persistent Atrial Fibrillation. 2013 , 6, 898	0
239	Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation. 2012 , 4, 438	
238	Atrial Fibrillation Complicating Acute Coronary Syndromes. 2012 , 5, 611	2
237	One-Year Outcomes of Acute Decompensated Systolic Heart Failure in Taiwan: Lessons from TSOC-HFrEF Registry. 2017 , 33, 127-138	21
236	A unifying hypothesis of body fluid volume regulation. The Lilly Lecture 1992. 1992 , 26, 295-306	4
235	Heart failure in a district general hospital. 1992 , 26, 139-42	30
234	Atrial Remodeling And Atrial Fibrillation: Mechanistic Interactions And Clinical Implications. 2009 , 2, 125	4
233	Heart Failure: A Class Review of Pharmacotherapy. 2017 , 42, 464-472	6
232	Pharmacist- or Nurse Practitioner-Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. 2020 , 73, 186-192	1

231	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. 2020 , 7, L1-L4	1
230	Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?. 2020 , 17, 782-786	1
229	Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy. 2021 , 145, 112463	1
228	Beneficial Extracardiac Effects of Cardiovascular Medications. 2021 ,	1
227	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. 2021 , 1	0
226	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. 2021 ,	0
225	Langzeitsicherheit von Blutdrucksenkern. 2021 , 25, 366-370	
224	When Heart Failure Collides with Diabetes and Chronic Kidney Disease: Challenges and Opportunities. 2021 ,	1
223	Transcatheter mitral valve interventions. 2021 , 69, 84-84	
222	Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with acute decompensated heart failure: a systematic review and meta-analysis. 2021 , 1-7	0
221	Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. 2021 , 42, 1	0
220	Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTEMI-ACS). 2021 , 6-59	1
219	Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy.. 2022 , 9,	0
218	Cardiovascular therapeutics: A new potential for anxiety treatment?. 2022 ,	0
217	OUP accepted manuscript.	0
216	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. 2020 , 7, L1-L4	1
215	ACEi to ARNi: "The Switch" An Evidence Based Review. 2020 , 288-292	
214	Endpoints in Heart Failure Drug Development.. 2022 , 8, e01	0

213	Heart Failure. 2022 , 103-155	
212	Cardiac MRI predictors of adverse outcomes in adults with a systemic right ventricle.. 2022 ,	3
211	JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. 2022 , 86,	3
210	QGC606, a best-in-class orally active centrally acting aminopeptidase A inhibitor prodrug, for treating heart failure following myocardial infarction.. 2022 ,	0
209	Myocardial strain to identify benefit from beta-blockers in patients with heart failure with reduced ejection fraction.. 2022 ,	1
208	Racial Differences in Trends and Prognosis of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study.. 2022 ,	
207	Targeting mitochondrial dysfunction with elamipretide.. 2022 , 1	1
206	Characterizing a Clinical Trial - Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction.. 2022 , 14, 39-49	1
205	Anti-Remodeling Cardiac Therapy in Patients With Duchenne Muscular Dystrophy, Meta-Analysis Study.. 2021 , 12, 769896	0
204	Treatment of heart failure with reduced ejection fraction. 2022 , 65, 9-17	
203	Coronary blood flow in heart failure: cause, consequence and bystander.. 2022 , 117, 1	3
202	Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.. 2022 , 1	
201	Drug Treatment of Heart Failure in Children: Gaps and Opportunities.. 2022 , 24, 121	0
200	Heart failure: a 70 year Odyssey. 2022 ,	1
199	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. 2022 , 24, 4-131	50
198	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction.. 2022 , 82, 375	2
197	Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, and vericiguat for congestive heart failure therapy.. 2022 ,	0
196	The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin-converting enzyme inhibitor in dilated cardiomyopathy.. 2022 ,	2

195	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning.. 2022 , 1	1
194	Drug therapy for HFrEF: What is the "right" dose?. 2022 ,	2
193	CPAP telemonitoring can track Cheyne-Stokes respiration and detect serious cardiac events: The AlertApnè Study. 2021 ,	0
192	Quinapril inhibits progression of heart failure and fibrosis in rats with dilated cardiomyopathy after myocarditis. 2003 , 251, 77-82	1
191	Clinical trials report. The sweet secret of dark chocolate. 2004 , 6, 45-6	
190	Valsartan in acute myocardial infarction trial. 2004 , 6, 159-60	2
189	Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors. 2022 , 53, 51-76	1
188	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.. 2022 , 52, 173-197	2
187	Predictive Analysis of Clinical Outcomes Using an Enhanced Random Survival Forest for Heart Failure Patients. 2022 , 683-691	
186	Capillaries as a Therapeutic Target for Heart Failure.. 2022 ,	1
185	Spezifische Aspekte der Arzneimitteltherapie in der Palliativmedizin. 2022 , 1-108	
184	Influence of Hospital Formularies on Outpatient Prescribing Practices: Analysis of the Introduction of a Local Formulary: A Single-Center, 2-Year Follow-Up, Retrospective Cohort Study of a Local Formulary in Japan.. 2022 , 59, 469580221087876	
183	Management of heart failure in older people. 2022 , 52, 72-79	
182	Classifying Heart Failure Based on Ejection Fraction: Imperfect but Enduring.. 2022 ,	2
181	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.. 2022 , 145, 693-712	6
180	Opportunistic screening for asymptomatic left ventricular dysfunction in type 2 diabetes mellitus.. 2022 ,	
179	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure.. 2022 ,	2
178	Association Between Dosing And Combination Use Of Medications And Outcomes In Heart Failure With Reduced Ejection Fraction: Data From The Swedish Heart Failure Registry.. 2022 ,	1

177	LVAD Patients in Non-Cardiac Surgery: Implications for Anesthetic Management. 1	
176	Sex Differences in Therapies for Heart Failure.. 2022,	
175	Optimizing Foundational Therapies in Patients With HFrEF. 2022,	6
174	Optimal effectiveness of heart failure management - an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure.. 2022, 1	2
173	Generalizability of Cardiovascular Disease Clinical Prediction Models: 158 Independent External Validations of 104 Unique Models.. 2022, 101161CIRCOOUTCOMES121008487	1
172	Effects of mokuboito, a Japanese Kampo medicine, on long-term clinical outcomes in patients with heart failure. 2022, 9, 49-56	
171	The interaction among OSA, CPAP, and medications in patients with comorbid OSA and cardiovascular/cerebrovascular disease: a randomized controlled trial.. 2022, 22, 99	0
170	Impact of Antihypertensive Drug Class on Outcomes in the SPRINT.. 2022, HYPERTENSIONAHA12118369	1
169	Are There Any Differences in the Prognostic Value of Left Ventricular Ejection Fraction in Coronary Artery Disease Patients With or Without Moderate and Severe Mitral Regurgitation?. 2022, 9, 799253	
168	Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.. 2022, 1-8	0
167	[SEMERGEN positioning on approaching chronic heart failure in primary care].. 2021,	0
166	The Cardiovascular Pharmaceutical Cornucopia: A Conundrum of Riches.. 2022, 79, 1138-1140	
165	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,	1
164	Clinical Phenotypes of Cardiovascular and Heart Failure Diseases Can Be Reversed? The Holistic Principle of Systems Biology in Multifaceted Heart Diseases. 2022, 12, 142-169	
163	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction.. 2022,	2
162	Acute but not Chronic Heart Failure is Associated with Higher Mortality among Patients Hospitalized with Pneumonia: An Analysis of a Nationwide Database. 2022, 100013	
161	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,	15
160	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022, 101161CIR0000000000001063	35

159	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022 , 101161CIR0000000000001062	6
158	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022 ,	49
157	The Proportional Mean Residual Life Regression Model with Cure Fraction and Auxiliary Covariate. 2022 , 38, 312-323	
156	Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.. 2022 , 108185	0
155	A fixed-dose combination as an opportunity to reduce the morbidity and mortality in patients with coronary artery disease. 2021 , 20, 140-143	
154	Heart failure and its treatment from the perspective of sympathetic nerve activity.. 2021 ,	1
153	Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy.. 2021 , 13, e20295	
152	Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: A 2021 heart failure expert consensus paper.. 2021 , 40, 975-983	
151	Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go.. 2021 , 13, e20359	0
150	The Effect of Mokubito in the Puerperium Lung Edema. 2020 , 71, 352-361	
149	Clinical and Economic Effectiveness of the Drug Sakubitril/ Valsartan in Treatment of Patients with Chronic Heart Failure with the Reduced Ejection Fraction in Conditions of Healthcare System of the Republic of Belarus. 2020 , 439-448	
148	Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study.. 2022 ,	0
147	Accelerated and personalized therapy for heart failure with reduced ejection fraction.. 2022 ,	3
146	SGLT2 Inhibitors and Sacubitril-Valsartan: How Trial Results will Revolutionize the Treatment of Heart Failure with Mildly Reduced Ejection Fraction. 2022 , 2, 67-71	
145	Sequencing of Pharmacotherapy for Heart Failure with Reduced Ejection Fraction: A Clinical Profile-Based Approach. 2022 , 2, 36-40	
144	Heart Failure in Older Adults: Medical Management and Advanced Therapies.. 2022 , 7,	
143	Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials.. 2022 ,	
142	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. 2022 ,	1

- 141 Gu# ESC 2021 sobre la prevenci# de la enfermedad cardiovascular en la pr#ctica cl#nica. **2022**, 1
- 140 Sex and Gender-Related Issues in Heart Failure.. **2022**, 40, 259-268
- 139 Cardiovascular Diseases in Pet Birds: Therapeutic Options and Challenges.. **2022**, 25, 469-501
- 138 Remodelling of the heart is not a proven clinical concept. **1997**, 92 Suppl 2, 62-4
- 137 Endothelin in congestive heart failure. **1996**, 91 Suppl 1, 21-9 6
- 136 Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.. **2022**, 0
- 135 Signaling cascades in the failing heart and emerging therapeutic strategies.. **2022**, 7, 134 1
- 134 The promise and problems of metabolic-based therapies for heart failure.. **2021**, 13, 415-424
- 133 Abordaje terap#utico del paciente con insuficiencia cardiaca y fracci# de eyecci# reducida. Papel del vericiguat. **2022**, 22, 23-29
- 132 Retos en el abordaje de pacientes con insuficiencia cardiaca y fracci# de eyecci# reducida. **2022**, 22, 1-7
- 131 Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction.. **2022**, 8, e16 1
- 130 Cardiac Remodelling Part 2: Clinical, Imaging and Laboratory Findings A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.. **2022**, 2
- 129 Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction.. **2022**, 22, 217 0
- 128 Sacubitril/Valsartan vs. ACEi/ARB at Hospital Discharge and 5-Year Survival in Older Patients with Heart Failure with Reduced Ejection Fraction: A Decision Analysis Approach.. **2022**, 250, 23-23 0
- 127 Daily Ambulatory Remote Monitoring System for Drug Escalation in Chronic Heart Failure with Reduced Ejection Fraction: Pilot Phase of DAVID-HF Study. 0
- 126 New Clinical Guidelines for the Diagnosis and Treatment of Heart Failure: Snatching Life from the Jaws of Death.. **2022**,
- 125 Circulatory Assistance With a Permanent Implantable IABP: Initial Human Experience. **2002**, 106, 6
- 124 Inhibitors of the renin-angiotensin-aldosterone system. **2013**, 119-168 6

- 123 Quantitative Evaluation of Left Ventricular Structure, Wall Stress, and Systolic Function. **2017**, 107-127 1
- 122 Heart Disease in Pregnancy. **2017**, 803-827.e1
- 121 Chronische Herzinsuffizienz: Der Langzeitverlauf in der allgemeinärztlichen Praxis. **2022**, 03, 157-175
- 120 Paradigm change in the treatment of chronic heart failure according to ESC Guide 2021: New innovative drugs in focus. **2022**, 47, 40-47 0
- 119 Potassium and disease-modifying therapy for heart failure with reduced ejection fraction: The beginning of a beautiful friendship?. **2022**,
- 118 Special Issue: Sudden Cardiac Death: Clinical Updates and Perspectives. **2022**, 11, 3120 1
- 117 Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults. **2022**, 21, 0
- 116 Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction. **2022**, 101, e29452
- 115 Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy. 0
- 114 LVAD as a Bridge to Remission from Advanced Heart Failure: Current Data and Opportunities for Improvement. **2022**, 11, 3542 1
- 113 Polypharmacy in Older Heart Failure Patients: a Multidisciplinary Approach. 0
- 112 Association of Age with Optimal Medical Therapy in Patients with Chronic Heart Failure. **2022**, 2, 138-145
- 111 Neurohormonal Connections with Mitochondria in Cardiomyopathy and Other Diseases. 0
- 110 Heart failure medication: moving from evidence generation to implementation. **2022**, 43, 2588-2590 0
- 109 Insights into foundational therapies for heart failure with reduced ejection fraction. **2022**, 45, 0
- 108 Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. 1
- 107 Positionspapier Herzinsuffizienz und Diabetes. 0
- 106 A medium-chain triglyceride containing ketogenic diet exacerbates cardiomyopathy in a CRISPR/Cas9 gene-edited rat model with Duchenne muscular dystrophy. **2022**, 12, 0

- 105 Cardiorenal Interactions: A review. **2022**, 0
- 104 A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis. 1
- 103 Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes. 0
- 102 Optimizing Therapies in Heart Failure: The Role of Potassium Binders. **2022**, 10, 1721 1
- 101 Positionspapier Herzinsuffizienz und Diabetes.
- 100 Are There Benefits for Patients Attending A Heart Failure Clinic? A Five Year Review. **2000**, 30, 298-301
- 99 Frühe Implementierung der Antastatic four bei Herzinsuffizienz mit reduzierter Ejektionsfraktion. **2022**, 147, 931-938
- 98 Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis. **2022**, 21, 0
- 97 Prognostic Value of Pericardial Effusion Size in Patients with Acute Heart Failure. **2022**, 20,
- 96 Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review. 9, 0
- 95 Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan. 9, 0
- 94 Management of Heart Failure in Patients with Chronic Kidney Disease. 17, 0
- 93 Cost-effectiveness of a centrifugal-flow pump for patients with advanced heart failure in Argentina. **2022**, 17, e0271519
- 92 Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. 1
- 91 Pragmatism in clinical trials: essential, not optional.
- 90 Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66). **2022**,
- 89 Survival Predictors in Patients with a Left Ventricular Ejection Fraction of 10-30% Receiving a Coronary Bypass: Analysis of Preoperative Variables. **1993**, 1, 558-562 2
- 88 Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling. **2022**, 15, 1711-1722 1

87	Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology. 2022 , 133-198	0
86	Prevalence, risk factors, and survival associated with pulmonary hypertension and heart failure among patients with underlying coronary artery disease: a national prospective, multicenter registry study in China. 2022 , 135, 1837-1845	0
85	The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: An observational study using the MIMIC database. 13,	0
84	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction.	1
83	Midterm Outcome of Hybrid Transcatheter and Minimally Invasive Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure. 2022 , 100081	1
82	Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Unstable Angina with Preserved Left Ventricular Systolic Function. 000331972211237 ^o	0
81	The complex pathophysiology of cardiac cachexia: Review of current pathophysiology and implications for clinical practice. 2022 ,	0
80	Edema formation in congestive heart failure and the underlying mechanisms. 9,	1
79	(Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into Clinical Care? Translation of the document prepared by the Czech Society of Cardiology). 2022 , 64, 441-454	0
78	How Do I Optimize Heart Failure Medications for Patients with Hypotension or Chronic Kidney Disease?. 2022 , 1,	0
77	Heart Failure and Cardiomyopathies: CT and MR from Basics to Advanced Imaging. 2022 , 12, 2298	0
76	Left Ventricular Systolic Dysfunction in Aortic Stenosis: Pathophysiology, Diagnosis, Management, and Future Directions. 2022 , 100089	0
75	Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure.	0
74	Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. 2022 , 23, 11336	1
73	Therapie der chronischen Herzinsuffizienz State of the Art nach den europäischen Leitlinien von 2021.	0
72	The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials.	0
71	Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients.	1
70	Practical Asymmetric Synthesis of a Bicyclic Pyrrolidinol.	0

69	Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender.	0
68	Randomization-Based Test for Censored Outcomes: A New Look at the Logrank Test. 2022 , -1,	0
67	Soluble Guanylate Cyclase Stimulators in Patients with Heart Failure with Reduced Ejection Fraction Across the Risk Spectrum.	3
66	The association between beta-blockers and outcomes in patients with heart failure and concurrent Alzheimer's disease and related dementias.	0
65	Effect of a Run-In Period on Estimated Treatment Effects in Cardiovascular Randomized Clinical Trials: A Meta-Analytic Review. 2022 , 11,	0
64	History of clinical care and research in cardiac sarcoidosis. 2022 , 42, 1-7	0
63	Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists. 2022 , 100082	0
62	CURRENT TRENDS IN THE MANAGEMENT OF HEART FAILURE. 2000 , 35, 855-875	1
61	Optimising Renin-Angiotensin-Aldosterone System Inhibitor Therapy in Heart Failure and Resistant Hypertension: Challenges and Solutions. 19-26	0
60	Hypertension management in patients with cardiovascular comorbidities.	0
59	Sequencing of medical therapy in heart failure with a reduced ejection fraction. heartjnl-2022-321497	0
58	Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. 2022 , 101509	1
57	Network Meta-Analysis Comparing Angiotensin Receptor-Nepriylsin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. 2023 , 187, 84-92	0
56	Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction. 2023 , 188, 52-60	0
55	Current trends in the use of the renin-angiotensin system blocking drugs in renovascular arterial hypertension. 2022 , 19, 49-54	0
54	C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. 9,	0
53	Incident stroke events in clinical trials of antihypertensive drugs in cardiovascular disease patients: A network meta-analysis of randomized controlled trials. 2022 , 101551	0
52	Hyperkalemia: Prevalence, Predictors and Emerging Treatments.	0

51	Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come. 2022 , 24, L2-L9	0
50	Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis. 106002802211405	0
49	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. 2022 , 24, L10-L19	0
48	Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest. 2023 , 12, 693	1
47	Use of Guideline-Directed Medical Therapy in Patients Aged 80 Years or Older with Heart Failure with Reduced Ejection Fraction. 2023 ,	0
46	Pathophysiology of cough with angiotensin-converting enzyme inhibitors: How to explain within-class differences?. 2023 ,	0
45	Renin Angiotensin System Inhibitors in Heart Failure with Reduced Ejection Fraction: Clinical Evidence and Considerations for Use. 2023 , 331-347	0
44	Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.	0
43	Renin-Angiotensin-Aldosterone System as an Old New Target in Heart Failure Therapy. 2023 , 307-330	0
42	Outcomes in Patients with Cardiometabolic Disease Who Develop Hyperkalemia While Treated with a RAAS Inhibitor. 2023 ,	0
41	Therapeutic Potential of Metformin in Diabetes Mellitus-Related Cardiovascular Complications.	0
40	Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan. 2022 ,	0
39	Medications for When the Heart Fails. 2023 ,	0
38	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. 2023 , 47, 10-26	0
37	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. 2023 , 5, 1	2
36	COMPARISON OF THERAPIES WITH TORASEMIDE OR FUROSEMIDE IN PATIENTS WITH CONGESTIVE HEART FAILURE FROM A PHARMACOECONOMIC VIEWPOINT. 1998 , 52, 467-471	1
35	Pharmacology of angiotensin in renovascular diseases. 2023 , 151-178	0
34	Bioinformatics Study on Renin Angiotensin in Lung, and Liver Cancer Using Plant-Based Extracts. 2023 , 155-177	0

- 33 Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. ○
- 32 A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction. **2023**, 100289 ○
- 31 Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Nepriylsin Inhibitor: Requirement for Additional Evidence of Kidney Protection. ○
- 30 Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan. **2023**, 12, 1086 ○
- 29 Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction: Technique Principles, Current Evidence, and Future Perspectives. Publish Ahead of Print, ○
- 28 The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure. **2023**, 10, 1314-1325 ○
- 27 Medication-Attributable Adverse Events in Heart Failure Trials. **2023**, 11, 425-436 ○
- 26 Adult Congenital Heart Disease. **2023**, 999-1054 ○
- 25 Influence of angiotensin receptor-nepriylsin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial. **2023**, 26, 100264 ○
- 24 Renal denervation in management of heart failure with reduced ejection fraction: A systematic review and meta-analysis. **2023**, 81, 513-521 ○
- 23 Consistency Breeds Confidence: The Continuing Story of SGLT2 Inhibitors. **2023**, 147, 635-637 ○
- 22 The interaction between physical frailty and prognostic impact of heart failure medication in elderly patients. ○
- 21 Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?. **2023**, 147, 759-767 ○
- 20 Prognosis after discontinuing renin angiotensin aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction. **2023**, 13, ○
- 19 Sex and gender differences in myocarditis and dilated cardiomyopathy: An update. 10, ○
- 18 Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With PreHeart Failure With Preserved Ejection Fraction. **2023**, 8, 366 ○
- 17 Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. **2023**, 10, 114 ○
- 16 Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction. **2023**, 23, ○

- 15 Renin Angiotensin System (RAS): The Common Thread Between Cancer and Heart Failure. **2023**, 429-449 ○
- 14 Relationship Between Medical Therapy, Long-Term Care Insurance, and Comorbidity in Elderly Patients With Heart Failure With Systolic Dysfunction. **2023**, ○
- 13 Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure. ○
- 12 Beyond Stage C: Considerations in the Management of Patients with Heart Failure Progression and Gaps in Evidence. **2023**, ○
- 11 The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. **2023**, 15, 1092 ○
- 10 Event Adjudication Is Unnecessary in Blinded Trials and May Be Detrimental. **2023**, 11, 422-424 ○
- 9 Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease. **2023**, ○
- 8 Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study. **2023**, 18, ○
- 7 Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. **2023**, ○
- 6 Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure. **2023**, 12, ○
- 5 ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKADE: A NEW DEVELOPMENT IN CARDIOVASCULAR PHARMACOLOGY. **1998**, 52, 475-481 ○
- 4 Updates in Cardiorenal Syndrome. **2023**, ○
- 3 Therapeutic Innovations for Heart Failure. **2023**, 337-353 ○
- 2 Coronary Artery Disease and Prognosis of Heart Failure with Reduced Ejection Fraction. **2023**, 12, 3028 ○
- 1 Hallmarks of cardiovascular ageing. ○